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Background: People with traumatic brain injuries (TBIs) commonly report memory impairments. These are
persistent, debilitating and reduce quality of life, but patients do not routinely receive memory rehabilitation
after discharge from hospital.
Objective: To assess the clinical effectiveness and cost-effectiveness of a group memory rehabilitation
programme for people with TBI.
Design: Multicentre, pragmatic, cluster randomised controlled trial. Qualitative and health economic
evaluations were also undertaken.
Setting: Community settings in nine sites in England.
Participants: Participants were aged 18–69 years, had undergone a TBI > 3 months prior to recruitment,
reported memory problems, were able to travel to a site to attend group sessions, could communicate in
English and gave informed consent.
Randomisation and blinding: Clusters of four to six participants were randomised to the memory
rehabilitation arm or the usual-care arm on a 1 : 1 ratio. Randomisation was based on a computer-generated
pseudo-random code using random permuted blocks of randomly varying size, stratified by study site.
Participants and therapists were aware of the treatment allocation whereas outcome assessors were blinded.
Interventions: In the memory rehabilitation arm 10 weekly sessions of a manualised memory
rehabilitation programme were provided in addition to usual care. Participants were taught restitution
strategies to retrain impaired memory functions and compensation strategies to enable them to cope with
memory problems. The usual-care arm received usual care only.
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Main outcome measures: Outcomes were assessed at 6 and 12 months after randomisation. Primary
outcome: patient-completed Everyday Memory Questionnaire – patient version (EMQ-p) at 6 months’
follow-up. Secondary outcomes: Rivermead Behavioural Memory Test – third edition (RBMT-3), General
Health Questionnaire 30-item version, European Brain Injury Questionnaire, Everyday Memory
Questionnaire – relative version and individual goal attainment. Costs (based on a UK NHS and Personal
Social Services perspective) were collected using a service use questionnaire, with the EuroQol-5
Dimensions, five-level version, used to derive quality-adjusted life-years (QALYs). A Markov model was
developed to explore cost-effectiveness at 5 and 10 years, with a 3.5% discount applied.
Results: We randomised 328 participants (memory rehabilitation, n= 171; usual care, n= 157), with 129 in
the memory rehabilitation arm and 122 in the usual-care arm included in the primary analysis. We found no
clinically important difference on the EMQ-p between the two arms at 6 months’ follow-up (adjusted
difference in mean scores –2.1, 95% confidence interval –6.7 to 2.5; p= 0.37). For secondary outcomes,
differences favouring the memory rehabilitation arm were observed at 6 months’ follow-up for the RBMT-3
and goal attainment, but remained only for goal attainment at 12 months’ follow-up. There were no
differences between arms in mood or quality of life. The qualitative results suggested positive experiences of
participating in the trial and of attending the groups. Participants reported that memory rehabilitation was not
routinely accessible in usual care. The primary health economics outcome at 12 months found memory
rehabilitation to be £26.89 cheaper than usual care but less effective, with an incremental QALY loss of 0.007.
Differences in costs and effects were not statistically significant and non-parametric bootstrapping
demonstrated considerable uncertainty in these findings. No safety concerns were raised and no deaths
were reported.
Limitations: As a pragmatic trial, we had broad inclusion criteria and, therefore, there was considerable
heterogeneity within the sample. The study was not powered to perform further subgroup analyses.
Participants and therapists could not be blinded to treatment allocation.
Conclusions: The group memory rehabilitation delivered in this trial is very unlikely to lead to clinical
benefits or to be a cost-effective treatment for people with TBI in the community. Future studies should
examine the selection of participants who may benefit most from memory rehabilitation.
Trial registration: Current Controlled Trials ISRCTN65792154.
Funding: This project was funded by the National Institute for Health Research (NIHR) Health Technology
Assessment programme and will be published in full in Health Technology Assessment; Vol. 23, No. 16.
See the NIHR Journals Library website for further project information.
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MICE multiple imputation using
chained equations
NART National Adult Reading Test
NBS non-invasive brain stimulation
NCTU Nottingham Clinical Trials Unit
NICE National Institute for Health and
Care Excellence
NIHR National Institute for Health
Research
NMB net monetary benefit
ONS Office for National Statistics
PIC participant identification centre
QALY quality-adjusted life-year
R&D research and development
RA research assistant
RBMT-3 Rivermead Behavioural Memory
Test – third edition
RCT randomised controlled trial
SAP statistical analysis plan
SD standard deviation
SE standard error
SIGN Scottish Intercollegiate Guidelines
Network
SMART specific, measurable, assignable,
realistic and time related
SMR standardised mortality ratio
SOP standard operating procedure
SST Sheffield Screening Test for
Acquired Language Disorders
SUQ service use questionnaire
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Plain English summary
People with brain injuries often report memory problems. These difficulties can continue long after theinjury, causing complications in daily life. Many people do not receive specific help for these memory
problems after leaving hospital.
Our study explored whether receiving ‘memory rehabilitation’ (a group treatment to help people deal
with memory difficulties) was better than the treatment that people usually receive to help reduce the
frequency of forgetting in daily life.
We recruited 328 people who had memory problems following brain injury. About half were allocated
at random to receive memory rehabilitation and half did not have any extra memory treatments, but
everyone continued to receive their usual care. Those who had memory rehabilitation were offered
10 group sessions at which strategies were taught to help them cope with memory problems. We asked
all participants to complete memory tests and questionnaires at the start of the study and again 6 and
12 months afterwards to find out whether the memory rehabilitation had any effect. Some participants
were also interviewed about the study.
At the 6- and 12-month assessments, there were no differences between those who received memory
rehabilitation and those who did not in terms of how often participants reported memory problems in
their daily lives or how well they performed on memory tests. We also did not find any differences in
participants’ mood or quality of life. However, individual goals set by the participants at the start of the
study were a little better met by those who received memory rehabilitation than by those who did not.
The memory rehabilitation did not represent value for money. In interviews, participants reported positive
experiences of taking part in the study and of attending the group sessions.
This group memory rehabilitation programme is unlikely to help people with memory problems following
a brain injury more than the usual treatment that people receive. Some people may benefit more from
memory rehabilitation than others, but this needs further investigation.
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Scientific summary
Background
Traumatic brain injury (TBI) is a major cause of mortality and morbidity. The most common cause of TBI is
road traffic accidents, which tend to produce diffuse injuries. Impairments of memory are commonly
reported by people with TBIs. They are persistent, debilitating and reduce quality of life. Many people with
memory impairment do not routinely receive memory rehabilitation after discharge from hospital, yet they
continue to have problems in daily life. Cognitive rehabilitation is a structured set of therapeutic activities
designed to retrain an individual’s memory and other cognitive functions. A narrative review found cognitive
rehabilitation to be beneficial for treating cognitive deficits following brain damage. Some randomised
controlled trials (RCTs) have demonstrated the effectiveness of cognitive rehabilitation following TBI, focusing
mainly on attention, executive functions and visual neglect; however, memory rehabilitation has not been
sufficiently researched. Most evidence for the effectiveness of memory rehabilitation comes from single case
experimental design studies and controlled clinical trials. The few RCTs and quasi-RCTs in this area have offered
some support for the effectiveness of memory rehabilitation, but many trials have had methodological limitations.
We conducted a small-scale RCT (REMIND; n= 72) to evaluate a group memory rehabilitation programme.
Patients with memory problems were randomly allocated to one of three group treatment programmes:
compensation strategy training, restitution or a self-help attention placebo control. The results showed that
there were no statistically significant differences in outcome between the groups. However, the qualitatively
analysed participant feedback interviews indicated that the interventions seemed worthy of further evaluation.
Objectives
The primary objective of the ReMemBrIn trial was to determine whether attending a group memory
rehabilitation programme was associated with subjective reports of reduced frequency of forgetting in
daily life when compared with a usual-care control. The secondary objectives were to assess whether the
intervention was associated with improvements in objectively assessed memory abilities, participants’ ability
to achieve individually set goals, mood, health-related quality of life and cognitive, emotional and social
well-being. The cost-effectiveness of the intervention was also investigated. A qualitative evaluation sought
to explore participants’ experiences of the trial and the intervention.
Methods
We conducted a multicentre, pragmatic, cluster RCT with follow-up at 6 and 12 months after randomisation.
A subset of participants took part in a qualitative study that explored the perceived benefits of the intervention
and experiences of being involved in the trial. A health economic evaluation was also conducted.
Participants were recruited from community settings in nine sites in England. We included participants who
had sustained a TBI > 3 months prior to recruitment, who had participant-reported or objectively assessed
memory problems, who were aged 18–69 years, who were able to travel to one of our sites and attend
group sessions and who spoke English and gave informed consent. We excluded those who were considered
unable or unsuitable to engage in group treatment if allocated, who were involved in other psychological
intervention studies or who had a language impairment.
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Once four to six participants had been recruited at a site, all of whom could notionally attend the intervention
sessions at the same time, they were randomly allocated as a cluster to memory rehabilitation or usual care
on a 1 : 1 ratio. The randomisation was based on a computer-generated pseudo-random code using
random permuted blocks of randomly varying size and stratified by study site.
Those allocated to the intervention received 10 weekly sessions of a manualised group memory rehabilitation
programme in addition to their usual care. Participants were taught restitution strategies to retrain impaired
memory functions and compensation strategies to enable them to cope with their memory problems. Some
sessions were video recorded to check the fidelity of the intervention.
Outcomes were assessed 6 and 12 months after randomisation. The primary outcome was the Everyday
Memory Questionnaire – patient version (EMQ-p) at the 6-month follow-up. Secondary outcomes included the
Rivermead Behavioural Memory Test – third edition (RBMT-3) to objectively assess memory ability, the General
Health Questionnaire 30-item version (GHQ-30) to assess mood, the European Brain Injury Questionnaire
(EBIQ) to assess cognitive, emotional and social well-being, the Everyday Memory Questionnaire – relative
version (EMQ-r) and individual goal attainment, with the Euro-Qol-5 Dimensions, five-level version (EQ-5D-5L)
and a service use questionnaire used to inform the economic evaluation.
A sample size of 312 was required to detect a minimum clinically relevant difference in mean scores of
12 points on the EMQ-p with a type 1 error of 0.05 and 90% power assuming a standard deviation (SD)
of 21.9 and accounting for 20% loss to follow-up and the potential for clustering as a result of the
group intervention.
The main approach to analysis was a modified intention-to-treat approach, that is, analysis according to
randomised arm regardless of adherence to allocation and including only participants who provided
outcome data at follow-up. We estimated the difference in mean outcome scores between the two arms
using a multilevel linear model, with site and baseline score (if measured) as covariates and a random
effect for cluster in the memory rehabilitation arm and by allowing the participant-level variance to differ
between arms. A planned exploratory subgroup analysis on the primary outcome was performed on the
basis of memory impairment at baseline.
We undertook a within-trial analysis consisting of a cost–utility [incremental cost per quality-adjusted life-year
(QALY) gain] analysis at 12 months and secondary analysis at 6 months. Incremental cost-effectiveness
analyses were also conducted based on the EMQ-p and GHQ-30 at these time horizons. A UK NHS and
personal social services perspective was adopted. An exploratory model-based analysis considered
longer-term cost-effectiveness at 5 years, with 3.5% discounting applied.
A subset of participants was interviewed from each arm and different participating sites. The purposive
selection strategy was designed to include participants with varying levels of memory impairment and
with varying social situations. The interviews were conducted by a researcher who was not involved in
the participants’ assessment or treatment.
Results
In total, 4023 people with TBI were invited to participate between February 2013 and December 2015.
Of these, 1710 (43%) did not respond to the invitation, 1129 (28%) were not eligible, 718 (18%) were
not enrolled for other reasons and 466 (12%) gave consent. Of those who gave consent, 328 (70%)
were randomised. The main reasons participants were not randomised after consent were non-eligibility
and recruitment being closed at the site. In total, 171 participants were randomised to the memory
rehabilitation arm and 157 to the usual-care arm.
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The mean age of participants was 45 years (SD 12 years), 239 (73%) were men and 314 (96%) were
white. The median time since TBI was just over 4 years. The mean EMQ-p score at baseline was 48.7
(SD 22.8). Characteristics assessed at baseline were well balanced between the arms.
Attendance at the memory rehabilitation groups was good. Participants attended a mean of 6.3 sessions
(SD 3.5 sessions) and 131 (77%) participants attended four or more sessions. At the 6-month follow-up,
260 (79%) participants returned the questionnaire booklet and 276 (84%) completed the assessment visit.
Questionnaire booklet return and visit completion were similar in the two arms. At the 12-month follow-up,
238 participants (73%) returned the questionnaire booklet and 256 (78%) completed the assessment visit;
completion was again similar in the two arms. In total, 122 (78%) participants in the usual-care arm and
129 (75%) in the memory rehabilitation arm were included in the primary analysis.
There was no clinically important difference on the EMQ-p between the two arms at the 6-month follow-up
[adjusted difference in mean scores –2.1, 95% confidence interval (CI) –6.7 to 2.5; p = 0.37]. There was no
evidence of a difference in the effect of the group memory rehabilitation sessions across subgroups based
on baseline RBMT-3 score; the p-value for the interaction effect was 0.12. Although the difference in mean
EMQ-p score in the subgroup of those with borderline/moderate memory impairment favoured the memory
rehabilitation arm (adjusted difference in mean scores –7.1, 95% CI –13.9 to –0.3; n = 102), there was no
statistical evidence of any overall subgroup effect.
Memory ability on the RBMT-3 favoured the memory rehabilitation arm at 6 months; however, there was
no evidence of a difference at the 12-month follow-up (adjusted difference in mean scores: 6 months 2.5,
95% CI 0.1 to 4.8; 12 months 0.5, 95% CI –2.6 to 3.6). There was no evidence of a difference in mood
between the arms based on the GHQ-30 at 6 months (adjusted difference in mean scores: –1.6, 95% CI
–5.3 to 2.1) or 12 months (adjusted difference in mean scores: –0.2, 95% CI –4.5 to 4.1). Scores from all
subscales of the EBIQ for both the participant and the relative/friend versions were similar in the two arms
at both 6 and 12 months’ follow-up. Goal attainment scores favoured the memory rehabilitation arm at
both the 6-month follow-up (adjusted difference in mean scores: short-term goal 0.6, 95% CI 0.3 to 0.9;
long-term goal 0.5, 95% CI 0.2 to 0.7) and the 12-month follow-up (adjusted difference in mean scores:
short-term goal 0.3, 95% CI 0.0 to 0.5; long-term goal 0.4, 95% CI 0.1 to 0.6). No safety concerns were
raised and no deaths were reported.
The cost of the memory rehabilitation programme was estimated at £167 per participant. The base-case
analysis (incremental cost per QALY gained at 12 months) showed the intervention to be slightly less
effective but less costly than usual care, with a reported incremental cost-effectiveness ratio of £2445.
At 6 months, the intervention was slightly less costly and slightly more effective, with numerically small,
statistically non-significant differences in costs and QALY gains. The health economic analyses showed
uncertainty, with results changing depending on the outcomes, time horizon and imputation method
used. Overall, it was unlikely that memory rehabilitation, as provided by the trial, could be considered
cost-effective compared with usual care. Exploration of the longer-term cost-effectiveness at 5 and
10 years did not change the conclusions.
Thirty-two participants from both arms of the trial were interviewed. Four main themes were identified:
feedback on the trial, experience of the rehabilitation group, strategy use and usual care. Participants were
positive about their experiences of taking part in the trial. Those who received the intervention found it
helpful, and the format and content of the intervention were appropriate, with specific benefits identified
from being part of a group. Participants reported little systematic training in strategy use before the
intervention and had developed memory coping strategies themselves. Participants reported that there was
a lack of support or specific training for those with memory problems provided as part of their usual care.
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Conclusions
Implications for practice
l People who have had a TBI continue to report memory problems following discharge from hospital or
rehabilitation services.
l This trial did not show any benefit of this group memory rehabilitation intervention for people with a
TBI, late after their injury.
l However, participant feedback based on interviews was positive, with some participants reporting
benefits of attending memory rehabilitation.
l Clinicians need to identify what interventions may be useful at this late stage after TBI.
Recommendations for research
l There needs to be more small-scale efficacy studies to establish appropriate selection criteria for group
memory rehabilitation programmes so that interventions are tailored to those who may benefit most.
l Further research may also need to consider the required ‘dose’ of the intervention to effect changes.
l There needs to be more information on the usual care that people with memory problems following
TBI receive so that group memory rehabilitation can be evaluated in those who have not already been
taught the strategies covered in the group programme.
Trial registration
This trial is registered as ISRCTN65792154.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Introduction
Parts of this chapter have been reproduced with permission from das Nair et al.1 This is an Open Accessarticle distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0)
license, which permits others to distribute, remix, adapt and build upon this work, for commercial use,
provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/.
Background
Traumatic brain injuries (TBIs) are defined as an alteration in brain function, or other evidence of brain
pathology, caused by an external force.2 In 2013–14, the total number of people who were admitted for
a TBI in the UK was 162,544 (254 per 100,000 population).3 As well as TBIs sustained by civilians in daily
life, TBIs among military personnel have also been a major contributor to mortality and morbidity.4,5 The
epidemiological variations seen in TBIs observed in the armed forces are the result of different approaches
to screening, definitions of TBI and methods of reporting.6
The costs of morbidity from TBIs are incurred by the health-care system and those outside it (in terms of loss
of productivity as a result of short-term sick leave and early retirement), as well as through non-medical costs
(e.g. transformation of the house or work environment). In addition, informal care by family or friends also
adds to the costs of care for affected individuals. For TBI, the direct medical costs and indirect costs were
estimated at US$60B in the USA in 2000.7 The full costs of dealing with memory problems caused by TBI
in the UK are not known. Care costs escalate when interventions are provided on an inpatient basis, but
Salazar et al.8 have demonstrated that the benefits of inpatient and home cognitive rehabilitation programmes
for TBI, in terms of return to duty (for military personnel) or employment, were similar.
Impairment of memory is one of the most common cognitive deficits reported by people with TBIs,
affecting 40–60% of patients.9,10 These memory problems are not only persistent, but also debilitating
and difficult to treat.11 Memory deficits may also affect the extent to which patients engage with other
interventions and rehabilitation. The safety of such patients can also be compromised, making them
vulnerable citizens in the home (e.g. forgetting to turn the stove off), community (e.g. forgetting road
rules) and work (e.g. forgetting important documents) settings. Memory problems consequently have a
devastating effect on the psychological well-being of the individuals and others around them.12
Cognitive rehabilitation is a structured set of therapeutic activities designed to retrain an individual’s cognitive
functions. Memory rehabilitation is a domain-specific type of cognitive rehabilitation that focuses on improving
memory and helping people deal with the consequences of memory problems. In the UK, memory rehabilitation
is offered by some services as a means to help people cope with their cognitive problems.
Research evidence
Individual studies
Some randomised controlled trials (RCTs) have demonstrated the effectiveness of cognitive rehabilitation
following brain injuries. These have mainly focused on attention, executive functions and visual neglect,
but memory rehabilitation specifically has not been sufficiently researched.13 Most evidence for memory
rehabilitation comes from single case experimental design studies and controlled clinical trials, with the
few RCTs and quasi-RCTs in this area offering some support for the effectiveness of intervention.
Wilson et al.14 examined a paging system used as an external memory aid. This enabled participants to achieve
more memory-related goals than when NeuroPage was not available. Doornhein and de Haan15 reported
that patients who received a memory training programme performed significantly better than those in a
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pseudo-treatment control group on trained memory tasks, but no differences were observed in subjective
ratings of everyday memory functions. Kaschel et al.16 reported that imagery mnemonics significantly improved
delayed recall of verbal material and reduced observer-rated reports of memory failures. However, systematic
reviews of memory rehabilitation have not found evidence to support or refute the effectiveness of such
programmes.17,18 This lack of evidence is partly because of a lack of well-designed trials, which has led one
of the largest meta-analyses to conclude that ‘the results for memory rehabilitation are mixed and weak’
(p. 33).13 The authors of this review suggested that ‘researchers need to reduce reliance on single-subject
and single group designs’ (p. 34) and recommended more RCT evidence, a view supported by others.19
At a symposium on disorders of memory, Wilson20 called for ‘better evaluation of memory rehabilitation
programmes’ (p. e4–5). This is a conclusion that more recent systematic reviews of memory rehabilitation
following TBI,18 stroke21 and multiple sclerosis22 also reached. This conclusion has been attributed mainly to the
dearth of high-quality RCTs, but may also reflect the lack of common outcomes measures that are responsive
to the effects of memory rehabilitation.
In a small-scale RCT (n = 72) to evaluate a group memory rehabilitation programme,23 patients with
memory problems were randomly allocated to one of three group treatment programmes: compensation
strategy training, restitution or a self-help attention placebo control. Although the results showed no
statistically significant differences in outcomes, they indicated that the interventions seemed worthy of
further evaluation. This was supported by the qualitatively analysed participant feedback interviews,24
which suggested improvements in knowledge and skills with regard to memory aid use, among other
improvements. This small trial provided feasibility and pilot data for the current trial.
Literature reviews
A narrative review25 found cognitive rehabilitation to be beneficial for treating cognitive deficits following
brain damage. Cernich et al.26 reviewed evidence for cognitive rehabilitation in TBI and recommended that,
although RCTs had demonstrated the utility of specific rehabilitation approaches to attention retraining
and retraining of executive functioning skills, further research was needed on rehabilitation techniques in
other domains of cognition (such as memory). They also suggested that training in the use of supportive
devices to improve an individual’s daily activities was central to their ability to function independently.
Systematic reviews, such as that by Cicerone et al.,27 published in 2000, concluded that there was strong
evidence of the effectiveness of treatments for memory problems after a TBI. The updated review,25
published in 2005, continued to endorse this view. These reviews included both RCTs and single case
studies. However, Rohling et al.’s13 more stringent meta-analytic re-examination of both reviews by
Cicerone et al.25,27 included 115 studies of cognitive rehabilitation trials and found mixed, or at best, only
weak, support for memory treatment. It is worth noting that, of all of the included studies (of TBI and
stroke), only 30 (26.1%) were classified as being in ‘class I’ (i.e. well-designed, prospective RCTs) and
only 14 specifically focused on memory. Also of note was that these studies were small, with an average
of 16.9 and 18.5 participants in the treatment and control arms, respectively.
Bergquist et al.28 found that people with TBI not only were willing to use the internet to receive cognitive
rehabilitation, but also were satisfied with the treatment. Encouraged by results from imaging studies that
have shown neuroplasticity, Spreij et al.29 conducted a systematic review that offered novel insights into
remediation-oriented approaches for the rehabilitation of memory deficits following acquired brain injuries
(ABIs). They classified the 15 studies that they included in their review as falling within the rubric of
(1) virtual reality (VR) training, (2) computer-based cognitive retraining (CBCR) and (3) non-invasive brain
stimulation (NBS). They concluded that CBCR was the most promising of these interventions, with all
seven of the CBCR studies they included showing positive effects. However, closer inspection of these
studies (and the other VR and NBS studies) showed that they were not methodologically robust (some
were not RCTs) and the outcomes included were mainly impairment-level measures. Furthermore, most of
these studies included mixed diagnosis samples and, therefore, it was not possible to extract what the
specific effects of these interventions would be on people with a TBI. More robust mixed-methods RCTs
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are therefore still required to evaluate the effectiveness of these newer forms of cognitive rehabilitation for
people with TBIs.
Another review30 that focused specifically on computerised cognitive training (CCT) in ABI and on
outcomes classified within the framework of the International Classification of Functioning, Disability and
Health (ICF)31 included 96 primary studies that evaluated CCT. The authors noted that only 15% of these
studies represented ‘level 1′ evidence (i.e. good-quality RCTs). Interestingly, the authors also reported that,
although the population with TBI was the most studied population, only two of the 31 TBI studies were
considered to offer ‘level 1′ evidence. Overall, their findings suggest that CCT has limited positive impacts
on outcomes that relate to activity or participation, although only 43% of the studies included an outcome
measure that assessed activity or participation.
Clinical guidelines
There are recommendations for the provision of cognitive rehabilitation for people with ABIs. Older national
and international guidelines for TBI rehabilitation, such as the Brain Injury Interdisciplinary Special Interest Group
of the American Congress of Rehabilitation Medicine’s published practice guidelines for rehabilitation after
TBI and stroke,32 the European Federation of Neurological Societies Task Force on Cognitive Rehabilitation’s
guidelines for stroke and TBI33,34 and the national clinical guidelines for rehabilitation following ABIs from the
Royal College of Physicians and the British Society of Rehabilitation Medicine,35 found limited high-quality
evidence supporting some forms of cognitive rehabilitation, specifically, treatments for memory problems after
TBI. This was mainly because of a lack of RCTs, with most evaluations being uncontrolled trials or single case
experimental designs.
The national clinical guidelines for rehabilitation following ABIs from the Royal College of Physicians and the
British Society of Rehabilitation Medicine35 recommend that patients with persistent cognitive deficits following
ABI should be offered cognitive rehabilitation, which may include compensatory strategies, including the use
of memory aids, to help manage memory problems in daily life and support independence. They further state
that ‘trial-and-error’ learning should be avoided. Again, the level of recommendation is low because of the low
quality of the evidence. Therefore, it is perhaps unsurprising that most previous recommendations have been
qualified by the need for more research.
The national clinical guidelines for brain injury rehabilitation in adults from the Scottish Intercollegiate
Guidelines Network (SIGN)36 recommend training in the use of compensatory strategies for people with
memory problems following TBI, focusing on improving the management of memory problems in daily life
rather than underlying memory impairment. Recommendations differ depending on the severity of memory
problems, with both internal and external strategies advised for those with mild to moderate impairment,
whereas the focus for those with severe memory impairment should be on improving functional abilities
through external aids.
However, this is a ‘grade D’ recommendation, based on level 3 (non-analytical studies) and level 4 (expert
opinion) evidence and on extrapolating level 2 evidence (well-conducted case–control or cohort studies).
This SIGN guideline forms the basis of the National Institute for Health and Care Excellence (NICE)
guidance on head injury.37
More recently, recommendations for the management of memory problems following TBI by an international
team of researchers and clinicians38 concluded that there is ‘good evidence for the integration of internal and
external compensatory memory strategies that are implemented using instructional procedures for rehabilitation
for memory impairments’ but that the ‘evidence for the efficacy of restorative strategies currently remains weak’
(p. 369). However, this conclusion was arrived at on the basis of few RCTs, many of which had a small sample
size and a large number of outcomes, did not report power analyses and did not consider the longer-term
effects of the intervention.
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On the basis of the foregoing discussion, and in response to a commissioned call by the National Institute
for Health Research Health Technology Assessment (HTA) programme,39 we designed the ReMemBrIn trial
to address the concerns raised by authors of individual studies, systematic reviews and clinical guidelines.
The trial, funded by the HTA programme, was designed to assess the effectiveness of a group memory
rehabilitation programme, on the basis of recent research suggestions from researchers and clinicians,19
our own pilot study23 and current clinical guidelines40,41 and clinical practice in the UK. Furthermore, in line
with the Better Value in the NHS report,42 we designed this project to deliver value for money through
innovative changes to current clinical practice leading to improved patient outcomes.
Rationale
Currently, patients with TBI experiencing memory problems do not routinely receive cognitive rehabilitation
after the outpatient rehabilitation phase, even though their abilities and needs may change once they are
discharged from clinical services. This is in part because of the current lack of evidence for the clinical
effectiveness and cost-effectiveness of memory rehabilitation and because of resource limitations.
This study sought to address these issues.
Research question
What is the clinical effectiveness and cost-effectiveness of memory rehabilitation for people with memory
problems following TBI?
Objectives
Primary objective
The primary objective was to determine whether attending a group-based memory rehabilitation
programme (the intervention) was associated with improved subjective reports of the management of
memory problems in daily life, as measured using the Everyday Memory Questionnaire – patient version
(EMQ-p),43 compared with a usual-care control.
Secondary objectives
The secondary objectives were to assess:
l whether the intervention was associated with improvements in participants’:
¢ objectively assessed memory abilities
¢ ability to achieve individually set goals
¢ health-related quality of life (HRQoL)
¢ cognitive, emotional, and social well-being.
l the cost-effectiveness of the intervention.
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Chapter 2 Methods
Parts of this chapter have been reproduced with permission from das Nair et al.1 This is an Open Accessarticle distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0)
license, which permits others to distribute, remix, adapt and build upon this work, for commercial use,
provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/.
Design
The ReMemBrIn study was a multicentre, two-arm, parallel-group randomised controlled superiority trial of
a group-based memory rehabilitation programme, provided in addition to usual care, compared with usual
care alone. Participants were randomised in clusters of between four and six. Clusters were allocated to
memory rehabilitation or usual care in a ratio of 1 : 1.
An economic analysis was conducted to determine the costs and cost-effectiveness of group memory
rehabilitation compared with usual care (see Chapter 4). In addition, a nested qualitative substudy sought
to explore participants’ experiences of the group memory rehabilitation and usual care (see Chapter 5).
Study setting and participants
Sites
The trial was conducted in nine sites in the UK (see Appendix 1). Each site was a NHS trust providing
rehabilitation services for people with TBI.
We initially intended to recruit from four sites, but we activated new sites owing to old ones shutting
down because of their participant pools being exhausted. The original four sites were opened to
recruitment between February and April 2013. Because of staff turnover and staff recruitment difficulties,
two of these sites were subsequently closed to recruitment and were replaced by two new sites that
opened in March and November 2014, respectively. To address delays in recruitment, three additional sites
were also opened between March and June 2015.
Identification of participants
Participants were identified through NHS services at the participating sites. This included searching hospital
databases and departmental records for people with head injuries from rehabilitation medicine, neurosurgery
and clinical psychology and neuropsychology departments. In-clinic recruitment also took place from
rehabilitation consultant-led clinics and outpatient TBI rehabilitation clinics. Participants were also identified
from similar sources at other NHS trusts acting as participant identification centres (PICs). In addition, posters
were displayed in clinic areas in the hospitals. Participants were also identified by self-referral as a result of
publicity by local and national charities and patient groups (e.g. head injury charities) and advertising to the
general public through the study website, on various support group websites and newsletters and through
features on television and radio programmes. In order to include military personnel, participants were sought
from a military rehabilitation centre and a NHS surgical centre treating personnel from the armed forces.
Clinical teams sent an invitation letter to individuals who were identified as potential participants. This
letter included a participant information sheet, a consent form, a contact details slip and a prepaid reply
envelope. If potential participants were interested in taking part, they were asked to complete the contact
slip and return it in the envelope directly to the assistant psychologist (AP) at their nearest site.
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Informed consent
Written consent was obtained by the AP and participants were given a copy of the consent form for their
records. Participant information sheets and consent forms were based on those developed for the pilot
study,23 and these had been checked for clarity and readability by a service user representative. Potential
participants had the opportunity to read about the study and discuss it with other clinical staff members,
family and friends and the research team before they decided whether or not to take part. They had a
minimum of 24 hours to do this. Potential participants also had the opportunity to read the participant
information sheet and consent forms with the AP at their first assessment.
Eligibility criteria
Eligible participants were those who:
l Were admitted to hospital with a TBI sustained > 3 months prior to recruitment.
l Had memory problems, defined as a score or ≥ 24 on the EMQ-p and/or a score below the 25th
percentile on the Rivermead Behavioural Memory Test – third edition (RBMT-3),44 as assessed at the
initial screening assessment. A score of ≥ 24 on the EMQ-p is two standard deviations (SDs) below the
mean for healthy participants (Professor Nadina B Lincoln, University of Nottingham, 2017, personal
communication). The 25th percentile cut-off for the RBMT-3 indicates below average objectively
assessed memory ability.44
l Were aged 18–69 years. The upper age limit was applied in order not to include those with age-related
memory problems.
l Were able to travel to one of the study sites and attend group sessions. Participants had to live within
the geographical area covered by the sites and be able to travel to sites. We offered travel expenses to
all participants who requested it. Participants also needed to be willing to receive treatment in a group
if allocated to the intervention.
l Gave informed consent.
Potential participants were excluded if they:
l Were unable to engage in group treatment if allocated. This was assessed by the clinicians at the
recruitment sites, with reasons for exclusion including severe aural sensory problems. Those who
had behavioural problems that would interfere with group treatment were not considered.
l Were participating in other psychological intervention studies, assessed by self-report.
l Had impairment of language that would make them unable to take part in the rehabilitation group
activities, defined as a score of < 17 on the Sheffield Screening Test for Acquired Language Disorders
(SST)45 completed at the initial screening assessment. In accordance with the test manual, participants
who scored < 17 on the SST were considered to have impairment of language that would limit their
ability to complete the intervention.
Study procedures
We expected participants to be involved in the study for approximately 13 months from the initial screening
assessment to the final follow-up visit 12 months from randomisation. The data collected at each time point
are shown in Appendix 2 and are detailed below. Data were collected through a combination of self-report
questionnaires completed by participants and their relatives/friends and face-to-face assessments with
participants, completed by a research assistant (RA) during study visits. Visits took place at participants’
homes whenever possible. However, if there were concerns about the suitability of the home environment
or if a participant preferred, assessments were conducted at NHS sites or community venues.
METHODS
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Initial screening visit
At the initial screening visit, the AP first explained the study and made clear that the initial assessments
were required to check that the participant met the inclusion criteria, to obtain demographic and clinical
data and to conduct baseline assessments for those who were eligible. The AP responded to queries and
obtained informed consent prior to conducting the following initial assessments, questionnaire completion
and demographic data collection:
l EMQ-p:43 this is a subjective, patient-centred outcome measure with good ecological and face
validity46,47 and has been previously used in cognitive rehabilitation studies.23,48 The EMQ-p comprises
28 items asking about the frequency of memory failures in everyday life over the past month. Each
item is rated on a five-point Likert scale (from ‘once or less in the last month/never’ to ‘once or more a
day’). Total scores range from 0 to 112, with higher scores indicating more frequent memory problems.
l RBMT-3:44 this is a standardised objective measure of memory, with adequate psychometric properties.
This was chosen as an objective measure that closely reflected daily life memory ability. It has also been
used as an outcome measure in other studies of memory rehabilitation.16,23,49–52 A General Memory
Index (GMI) score was derived to provide an assessment of overall memory abilities. GMI values range
between 52 and 174 and are standardised on a representative sample from the UK44 to have a mean
of 100 (SD 15). Lower scores indicate more significant memory impairment.
l National Adult Reading Test (NART):53 the premorbid level of intellectual functioning, required to
interpret RBMT-3 scores, was estimated using the NART.
l SST:45 this was used to assess eligibility for the trial on the basis of language ability.
l General Health Questionnaire 30-item version (GHQ-30):54 this is a 30-item questionnaire that was
designed to detect psychological distress in the general population. It assesses participants’ mood over
the past few weeks compared with their usual mood. The GHQ-30 was chosen as it is suitable for
postal administration and is easy to complete. The General Health Questionnaire (GHQ) (12-, 28- or
30-item versions) has also been shown to be responsive to the effects of psychological interventions
in people with neurological conditions48,55–57 and has been used in previous TBI and rehabilitation
studies.23 Likert scoring was used for the GHQ-30 for the clinical outcome, with scores ranging from
0 to 90 and higher scores indicating more psychological distress. The alternative GHQ scoring
methodology (0–0–1–1) was applied for the health economic evaluation.
In addition, we collected demographic information from participants at the screening assessment. This
included gender, date of birth, ethnicity, date of TBI (self-reported by participants), duration of the initial
hospital stay for the TBI, current employment status, living arrangements, military status and highest
educational achievement.
The following clinical information on participants’ brain injury was collected from medical notes when
these could be accessed at the recruiting site:
l severity of injury assessed by the Glasgow Coma Scale (GCS)58 score closest to admission and the worst
total score
l date of TBI (verified from medical notes)
l type of brain injury (open or closed)
l other neurological conditions.
Scores from the EMQ-p, RBMT-3 and SST completed at the initial screening visit were used to confirm
eligibility for the trial. Patients who did not meet the eligibility criteria following the initial screening visit
were notified by letter to thank them for their interest in the study and a brief report of their test results
was provided if requested. Those who met the inclusion criteria were invited to continue in the trial, if they
were happy to do so, and proceeded to the second assessment visit.
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Participants continuing in the trial were asked to nominate a relative/friend who knew about their memory
problems in daily life, although this was not a mandatory requirement of trial participation. A questionnaire
booklet for the relative/friend was sent to eligible participants following the initial screening visit. Participants
were asked to pass this on to their relative/friend and return completed questionnaires at the second
assessment visit.
Second assessment visit
The following questionnaires were completed at the second visit, conducted 2 weeks (±1 week) after the
initial screening visit:
l EuroQol-5 Dimensions, five-level version (EQ-5D-5L):59 this is a validated, generalised health profile
questionnaire used to assess HRQoL. EQ-5D-5L scores are used to derive utilities, which can be used to
calculate quality-adjusted life-years (QALYs).
l Service use questionnaire (SUQ): we used a bespoke self-report SUQ to assess NHS health-care
utilisation. The data collected included use of community-based services, such as contacts with general
practitioners (GPs), practice nurses, other community-based professionals and community-based social
care services and medication. Use of hospital services [including outpatient appointments, accident and
emergency department attendance, day-care services and hospitalisation] was also captured. We asked
participants to report services used for their memory problems and for other reasons separately. The
period covered by the questionnaire was the previous 3 months. This was considered long enough for
people to have received a range of services but not so long that they would have forgotten what they
had received. The SUQ was adapted from a questionnaire used in previous studies.60,61
In addition, the participants’ nominated relative/friend completed the following questionnaire prior to the
visit, which was collected by the AP:
l Everyday Memory Questionnaire – relative version (EMQ-r):43 this is a parallel version of the EMQ-p that
offers an independent rating by a relative/friend of the memory problems that a person experiences.
The EMQ-r was included to identify any effect of treatment on daily life problems as observed by
another person, which might not have been detected by the participants themselves. EMQ-r scores
range from 0 to 112, with higher scores indicating more frequent memory problems.
Participants were also asked to set the short- and long-term goals that they would like to achieve by the
end of the study. With the assistance of the AP, each participant set between one and five personal
short- and long-term goals. The AP also checked participants’ availability to attend for treatment in the
event that they were assigned to the memory rehabilitation group, in order to form clusters of participants
for randomisation.
Randomisation
Eligible patients were randomised following screening and baseline data collection.
Formation of clusters
Clusters of four to six participants were formed by the AP at each site prior to randomisation. This cluster
size was selected as we considered this the optimal number of participants for the memory rehabilitation
group sessions based on our previous experience of delivering the intervention. Furthermore, if the cluster
sizes were larger participants may have needed to wait longer after the baseline assessments for a group
to be formed. Clusters were based on participants’ availability to attend for treatment at the same time
and same venue, should they be allocated to the memory rehabilitation arm. In the period while waiting
for group allocation, the AP remained in regular contact with the participants to inform them when it was
likely that there would be sufficient participants to form a group and to maintain their interest in the trial.
METHODS
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Participants who were awaiting randomisation at the time that their site closed to recruitment were sent a
letter informing them that the AP had not been able to recruit enough people to create a group at a time
and place that was convenient for them and that their participation in the trial was therefore at an end.
Randomisation
Participants were randomised in clusters of four to six to the memory rehabilitation arm or a usual-care
control using a 1 : 1 ratio. The randomisation was based on a computer-generated pseudo-random code
using random permuted blocks of randomly varying size, created by the Nottingham Clinical Trials Unit
(NCTU) in accordance with its standard operating procedure (SOP) and held on a secure server. The
randomisation was stratified by study site. Access to the sequence was limited to the NCTU information
technology manager. The AP at the site accessed the allocation for each cluster by means of a remote,
internet-based randomisation system developed and maintained by the NCTU. The sequence of treatment
allocations was concealed from the study statistician until all participants were assigned and recruitment and
data collection and all other study-related assessments were complete.
Intervention
Participants were randomised to group memory rehabilitation in addition to usual care or usual care alone.
Usual care
All participants received their usual clinical care during the trial. Based on our knowledge of the recruiting
sites, we expected that the majority of participants would no longer be receiving any formal rehabilitation
but that they may be attending employment rehabilitation services or self-help groups or receiving support
from specialist charities, such as Headway. Any additional interventions that people received were noted in
the SUQ completed at the follow-up assessments.
Memory rehabilitation
The intervention was offered in groups of between four and six participants. Each group was led by an AP
trained to deliver the intervention. Sessions were held at NHS sites or community venues. Participants were
offered 10 group memory rehabilitation sessions, lasting approximately 1.5 hours each, which were planned
to take place once a week for 10 weeks. However, sessions could be rearranged if necessary (e.g. because
of staff or participant absence). The sessions followed a treatment manual.18 The intervention included
restitution strategies to retrain memory functions, including attention retraining (such as letter cancellation),
and strategies to improve encoding and retrieval (such as deep-level processing). Compensation strategies
were taught, including mnemonics (such as chunking, use of first letter cues, rhymes), use of external devices
(such as diaries, mobile phones and calendars) and ways of coping with memory problems. The importance
of ‘errorless learning’ (not making errors while learning new material and, therefore, preventing learning the
errors)62 was also taught. The emphasis was on identifying the most appropriate strategies to help individuals
overcome their memory problems and on providing participants with a range of memory techniques that
they could adapt and use depending on their needs. This intervention provided an opportunity for revision of
strategies taught during inpatient rehabilitation and discussion of their application in a community setting.
Treatment fidelity
The fidelity of the group rehabilitation programme was assured in a number of ways:
l Manualised treatment. The group memory rehabilitation programme followed a manual (see Report
Supplementary Material 1) that was developed and tested in the pilot study. A detailed description of
the manual has been published.18,23 The manual was accompanied by facilitator notes to guide delivery
of the sessions (see Report Supplementary Material 2).
l Training and supervision. Staff delivering the intervention (APs) were psychology graduates with clinical
experience. A clinical psychologist provided study-specific training on conducting baseline assessments
and the delivery of the intervention. In addition, monthly teleconferences between all APs, a clinical
psychologist and NCTU staff provided an opportunity for peer group supervision. Furthermore, additional
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monthly one-to-one supervision with a clinical psychologist allowed for discussion of specific challenges
relating to treatment or assessment. To ensure continuity and consistency, when staff changes occurred,
old staff completed a ‘handover’ document for new staff, who were trained by the same trainers.
l Fidelity assessment. Formal fidelity assessment of the group memory rehabilitation was undertaken
through analysis of video recordings of treatment sessions. Intervention sessions were video recorded
by APs facilitating the groups. APs were asked to video record all treatment groups, unless it was the
first group run by the AP or participants had not given consent to be recorded. Practices for video
recording drew on guidance on minimising the intrusiveness of the recording.63,64
Sessions were selected for analysis in order to include sessions from the start, middle and end of the
10-week course and from each site. As far as possible, only recordings that covered a complete session
were analysed. A coding schedule was developed based on the components of treatment described in the
manual, listing possible activities for both the APs and participants (see Appendix 3).
A distinction was made between non-rehabilitation activities (e.g. social chat, information about sessions,
preparing tasks or materials) and rehabilitation activities (e.g. discussing educational material, recap of previous
session). An independent researcher coded the videos using a time sampling procedure. Observations were
made on the minute, every minute, throughout the video recording. For each observation, the activities of the
AP and participants were given the appropriate activity code. A sample of coding was checked by another
observer and discrepancies were resolved by discussion. Data from coding sheets were entered into the SPSS
statistics programme for analysis (version 21; IBM Corporation, Armonk, NY, USA).
Requirements for usual care were not specified and so no measures of fidelity were applied.
Blinding
Blinding of participants and the APs delivering the intervention to treatment allocation was not possible.
RAs collecting outcome data at the 6- and 12-month follow-up visits were blind to treatment allocation.
RAs were not involved in the delivery of the intervention. To prevent unblinding, at the start of each
follow-up visit, the RAs reminded participants of the importance of the RAs remaining blind to treatment
allocation and asked that participants did not discuss any aspects of their involvement in the study. At the
beginning of each follow-up visit, the RAs recorded whether they had been unblinded prior to the visit and
recorded their opinion of each participant’s treatment allocation using the following categories: definitely
control, probably control, probably intervention or definitely intervention. At the end of each visit, the RAs
recorded whether they had been unblinded during the visit and again recorded their opinion of each
participant’s treatment allocation.
Follow-up
Outcomes were assessed at 6 and 12 months after randomisation to assess the immediate and longer-term
effects of the intervention. The primary time point of interest was 6 months after randomisation. This time
point was chosen to allow time to complete the 10 group sessions, while still allowing for one group session to
be rescheduled if it had to be cancelled through illness or for other unforeseen circumstances. The 12-month
assessment was carried out to determine whether or not any treatment gains had been maintained over time.
All reasonable attempts were made to contact any participant lost to follow-up during the course of the
study in order to complete assessments. Participants were contacted by telephone in the first instance when
follow-up visits were due. If telephone contact could not be made, a letter was sent to the participant’s last
known address, so that the participant could contact the outcome assessor to arrange the appointment or
provide updated contact details.
METHODS
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The following assessments were completed at the follow-up visits:
l RBMT-3.
l Assessment of individual goal attainment: each participant’s individual goals were evaluated in terms of
the degree to which each goal had been met on a four-point Likert scale: ‘not met at all’, ‘met a little’,
‘mostly met’ and ‘fully met’. The participant and researcher discussed the extent to which goals were
met and jointly determined the goal attainment. The average goal attainment score was used as the
secondary outcome (with attainment coded as 0 for ‘not met at all’ and 3 for ‘fully met’). Goal
attainment scaling (GAS) has been used in memory rehabilitation studies and has been recommended
as an outcome measure of choice for cognitive rehabilitation.65
In addition, a questionnaire pack was posted to participants before their 6- and 12-month appointments.
Participants were asked to complete this questionnaire pack at home and return it by post to the trial
co-ordinating centre in the prepaid envelope provided as soon as possible. If questionnaires had not been
returned by the time of the follow-up visit they were collected by the RA at the follow-up visit.
The questionnaire pack included the following questionnaires for completion by participants:
l EMQ-p.
l GHQ-30.
l EQ-5D-5L.
l SUQ.
l European Brain Injury Questionnaire – patient version (EBIQ-p):66,67 this contains 63 items that assess
the subjective experience of cognitive, emotional and social difficulties experienced by people with
brain injury; there are an additional three items that ask about the impact of the participant’s brain
injury on their relative/friend. Each item is rated on a three-point Likert scale, ‘not at all’, ‘a little’ or
‘a lot’, depending on how much each has been experienced over the past month. The EBIQ-p is a
clinically reliable measure that is used to determine the subjective well-being of people with brain injury
and to assess change in subjective concerns over time.67,68 It is used in rehabilitation centres as an
outcome measure.68 We used the modified subscales proposed by Bateman et al.69 In this model, EBIQ-p
scores range between 1 and 3 on each of seven subscales, with higher scores indicating greater
difficulties. The seven subscales are:
¢ somatic (seven items)
¢ cognitive (12 items)
¢ impulsivity (10 items)
¢ depression (five items)
¢ social interaction (five items)
¢ fatigue (eight items)
¢ communication (four items).
In addition, the following questionnaires, for completion by the participants’ nominated relative/friend,
were included in the questionnaire pack sent to participants. Participants were asked to pass these on
to their relative/friend for completion:
l EMQ-r.
l European Brain Injury Questionnaire – relative version (EBIQ-r).67 This is a parallel version of the EBIQ-p,
completed by the participant’s relative/friend to assess the cognitive, emotional and social difficulties
experienced by people with brain injury.
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Originally, all questionnaires were intended to be returned by post only; however, the procedure was
changed after a HTA programme monitoring visit in December 2014 so that follow-up questionnaires were
collected at the follow-up visit by the outcome assessor if these had not been posted back. This was in
response to a poor return rate because of the previous reliance on postal returns.
The returned questionnaire packs were checked for completeness and participants were telephoned if items
were missing or we needed clarification about their responses (e.g. unclear marking on questionnaires).
Participants were also telephoned if their questionnaire packs were not received before the follow-up visit.
Qualitative feedback interviews
A sample of participants was invited to take part in qualitative feedback interviews, conducted within
2 months of the 6-month follow-up appointment. The interviews were intended to provide feedback on
the participants’ experience of being involved in the trial, their experience of usual care and, for those in
the intervention groups, their experience of receiving group memory rehabilitation. The qualitative analysis
is described in detail in Chapter 5.
End of the study
Participants left the study when they had completed the 12-month follow-up. The end of the study was
defined as the time of the last participant’s 12-month follow-up appointment, although questionnaires
were accepted after completion of the final visit to allow for any delays in return.
Premature discontinuation from the intervention or withdrawal from follow-up was reported and reasons
for withdrawal (if given) were documented. If a participant discontinued treatment but agreed to remain
in the trial, outcome data collection continued in accordance with the protocol1 [the protocol is also
available at www.journalslibrary.nihr.ac.uk/programmes/hta/105724/#/ (accessed 1 August 2018)].
Participants were informed at the start of the study that data collected up to the point of withdrawal
would be retained and used in the final analysis. We did not replace participants who withdrew.
Outcome measures
All measures were selected on the basis of their clinical utility, relevant psychometric properties and ease of use
for participants. Furthermore, the measures reflect the three levels of the ICF31 domains – impairment, activity
limitations and participation restrictions – thereby embracing the aims and spirit of cognitive rehabilitation.70,71
Primary outcome
l Frequency of memory failures in daily life assessed using the EMQ-p at 6 months’ follow-up.
Secondary outcomes
l Objective measure of memory problems assessed by the RBMT-3.
l Mood assessed with the GHQ-30.
l Individual goal attainment.
l Subjective experience of brain injury assessed with the EBIQ-p.
l Subjective report of frequency of memory problems in daily life in the longer term assessed using the
EMQ-p.
l Subjective report of the importance of memory problems in daily life. To assess this, we added to the
EMQ-p a measure of how important each item was. The rationale was that, even if some items were
forgotten less frequently than others, these may be more significant if participants viewed these
items as being more important than other items. The 28 EMQ-p items were therefore also rated for
importance on a five-point Likert scale (from ‘not at all important’ to ‘very important’). Importance
scores ranged from 0 to 112, with higher scores indicating more important memory problems.
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Relative/friend-completed outcomes
l Relative/friend report of the frequency of participants’ memory problems in daily life assessed using
the EMQ-r.
l Relative/friend report of the experience of brain injury assessed using the EBIQ-r.
Health economic outcomes
l Quality of life assessed using the EQ-5D-5L.
l Service use assessed using the bespoke SUQ.
Research governance
The study was conducted in accordance with the recommendations for clinicians involved in research on
human subjects adopted by the 18th World Medical Assembly (Helsinki, 1964)72 and later revisions, the
NHS Research Governance Framework for Health and Social Care (second edition)73 and the principles of
the International Conference of Harmonisation Good Clinical Practice guidelines.74
Trial registration
The study was prospectively registered as ISRCTN65792154 on 17 October 2012.
Ethics
The National Research Ethics Service – East Midlands (Nottingham 1) gave ethics approval for the study for
NHS participants (reference 12/EM/0324) and the Ministry of Defence Research Ethics Committee gave
approval for recruiting military participants (reference 374/PPE/12).
Site initiation and training
Prior to the commencement of the study, members of the central research team (chief investigator and/or
co-chief investigator and NCTU staff) met with study collaborators from each site to discuss implementation
and training issues to ensure that all staff members were familiar with all aspects of the study. New staff
were trained before starting work on the trial. A clinical psychologist and the NCTU staff provided
study-specific training on the trial documentation and database.
Protocol deviations
A protocol deviation was defined as an unanticipated or unintentional divergence or departure from the
expected conduct of the study inconsistent with the protocol, consent document or other study procedures.
Protocol deviations were recorded on the electronic case report form by APs and RAs. Protocol violations
were defined as deviations that affected eligibility or outcome measures, as assessed by the Trial
Management Group (TMG).
Oversight
We convened a number of oversight groups to monitor study progress and conduct throughout the trial.
The general roles and responsibilities of these groups were outlined in the protocol, with specific charters
also developed for the independent Trial Steering Committee (TSC) and Data Monitoring Committee (DMC).
Trial Management Group
The TMG comprised the co-chief investigators and members of the NCTU responsible for the running of
the trial, who met regularly throughout the trial. This group was responsible for the day-to-day running
of the trial.
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Trial Steering Committee
The TSC was responsible for overseeing the conduct of the study. The TSC had an independent
chairperson and five independent members. Independent members were rehabilitation professionals and
patient/carer representatives who were not otherwise involved in the trial. Members of the study team,
including the chief investigator, co-chief investigator, service user co-applicant and trial manager, were also
part of the TSC. The TSC advised on recruitment strategies, monitored the progress of recruitment and
checked adherence to the study protocol. Observers from the funder and the sponsor were invited to
TSC meetings.
Data Monitoring Committee
The DMC was an independent group, the members had no other involvement with the study. Members of
this committee included two rehabilitation professionals and an experienced study statistician. The role of
the DMC was to safeguard the interests of trial participants, with particular reference to the safety of the
intervention, monitor the overall progress and conduct of the trial and assist and advise the investigators to
protect the validity and credibility of the trial.
The TSC and the DMC met independently of each other, with the DMC providing reports to the TSC.
Safety monitoring
The risks of the study were assessed during protocol development. The assessment of memory may have
made participants aware of memory problems that they did not know that they had. As a result, the main
risk associated with this trial was considered to be distress caused by this realisation. However, such
distress was considered unlikely and any distress caused was deemed likely to be mild. Overall, therefore,
the risk of the trial was assessed as negligible. As a result, data on adverse events or serious adverse events
were not collected in this study. The independent DMC instead was provided with a report detailing
hospital and GP visits (either related to TBI or otherwise), recorded from participant-reported SUQs for all
participants, and any deaths. This was agreed by the sponsor, the Research Ethics Committee, the DMC
and the TSC.
‘Notable events’ occurring during both assessments and treatment were recorded throughout the trial.
Notable events were those that were assessed by the APs or RAs as being out of the ordinary, such as
problems arising during group sessions or issues that might pose a risk to participants or researchers.
These were reviewed by the study team on an ongoing basis and were reported to the DMC/TSC during
routine meetings.
Patient and public involvement
During protocol development, service user and carer representatives with experience of TBI and/or
rehabilitation in NHS services advised on recruitment and dissemination options and contributed
to the development of the intervention manual and the lay summary of the project. One service user
representative had experience of NHS rehabilitation services following his head injury and participated in
our pilot study, so was able to provided first-hand experience of the intervention. He told us what he
and the peers in his group enjoyed and found useful and what they did not find useful. This information
enabled us to make some changes to the manual and content of the intervention. We also recruited a
carer representative who had caring responsibilities for a person with TBI. The service user co-applicant and
a carer helped us advertise the study by being part of a video about our study and by taking part in a radio
and television interview about brain injury and our study. The service user co-applicant was involved in
project management decisions, project approval through the Integrated Research Application System and
recruitment and consent (by contributing to the development of participant information sheets).
A service user and carer and representatives from relevant charities (e.g. Headway and Combat Stress)
were members of the TSC and DMC. Their involvement in these committees enabled us to check with
them when any amendments to the protocol were required.
METHODS
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We developed participant and public newsletters to keep participants and the public informed about the
progress of our study. These were sent to participants, clinicians and local head injury charities so that they
could be cascaded to interested members of the public. We sent the final plain English summary of our
findings to our carer representative to assess its readability and we made changes where these were
required. All service user involvement was resourced appropriately.
Payments to participants
Participants were not paid to take part in the trial but reasonable travel expenses for attendance at trial
assessments and intervention sessions were reimbursed.
Statistical methods
Sample size
The sample size calculation was based on the primary outcome measure (EMQ-p) at 6 months post
randomisation. The main study aim was to detect a minimum clinically relevant difference in mean EMQ-p
score of 12 points between the memory rehabilitation arm and the usual-care arm. In the absence of
any agreed and published minimum clinical relevant differences on the EMQ-p, we deemed a 12-point
difference on this measure to be a clinically significant change, based on our pilot data18 and clinical
interviews. A common SD of 21.9 from the pilot study gave us an effect size of 0.55. For the sample size
calculation, a two-sided type 1 error of 0.05 and power of 90% and a fixed-effects model at the level of
the four original planned sites were used, with 10% of the total variation due to between-site variation.
The participants were cluster randomised and a cluster size of six was used for the sample size calculation,
with an intracluster correlation coefficient (ICC) of 0.1. Using the Optimal Design software (version 3.01;
William T. Grant Foundation, New York, NY, USA) with these parameters, the calculation gave 10 clusters
(five clusters for each allocation) per site (40 in total). Data from the pilot study, and taking account of the
fact that the control arm received only usual care, suggested a possible dropout rate of 20%. Therefore, we
needed 26 clusters for each allocation (52 in total), which amounted to 312 participants randomised in total.
Statistical analysis
Statistical analyses are detailed in the statistical analysis plan (SAP) [URL: www.journalslibrary.nihr.ac.uk/
programmes/hta/105724/#/ (accessed 17 August 2018)], which was finalised prior to database lock and
release of the treatment allocation codes for analysis. All analyses were carried out using Stata®/SE 13.1
(StataCorp LP, College Station, TX, USA).
Preliminary analysis
We used descriptive statistics of demographic and clinical measures to examine balance between the two
arms. The internal consistency of the EMQ-p, EMQ-r and GHQ-30 was also evaluated using Cronbach’s alpha.
Analysis populations
The main approach used in the analysis was to analyse participants as randomised regardless of the number
of memory rehabilitation sessions attended [intention to treat (ITT)], for all primary and secondary outcomes.
Data used at each time point were as follows:
l the outcomes at 6 months were questionnaires/visits completed within 9 months of randomisation
(i.e. within 275 nights of randomisation)
l the outcomes at 12 months were questionnaires/visits completed within 15 months of randomisation
(i.e. within 456 nights of randomisation).
Outcomes completed outside these time periods were not used, other than in a sensitivity analysis for the
primary outcome. The main analyses were based on participants with available data, with no imputation
for participants with missing outcomes.
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Descriptive analyses
We described the adherence to the intervention by tabulating the attendance at each session and
summarising the number of sessions that each participant attended. The reasons for non-attendance at
sessions were also described and summarised.
The numbers of participants returning the questionnaire booklet and completing the 6- and 12-month
follow-up visits were summarised in the two arms along with the number of days between randomisation
and completion. The pattern of missing outcome data was explored, overall and in the two arms, and
baseline characteristics were compared between participants with and without primary outcome data.
Missing data in questionnaires
We imputed missing items in questionnaires using the mean of the completed items if < 10% of the items in the
questionnaire were not completed. Scores were therefore calculable when ≥ 25 of the 28 items were completed
on the EMQ-p and EMQ-r, ≥ 27 of the 30 items were completed on the GHQ-30, ≥ 11 of the 12 items were
completed on the EBIQ-p and EBIQ-r cognitive subscale and ≥ 9 of the 10 items were completed on the EBIQ-p
and EBIQ-r impulsivity subscale. Scores for all other EBIQ-p and EBIQ-r subscales were calculable only if all items
in the subscale were completed. If > 10% of items were missed, outcomes were treated as missing.
If scores from the questionnaires remained missing at baseline after the process outlined above (or other
baseline information was missing), in order to be able to include all participants in the regression analysis
of the outcome score, we imputed these baseline data using the mean score at each site. These simple
imputation methods are superior to more complicated imputation methods when baseline variables
are included in an adjusted analysis to improve the precision of the treatment effect.75 Note that this
imputation was carried out only for the regression analyses and not for summarising the baseline scores.
Primary outcome
For the primary analysis we estimated the difference in mean EMQ-p score between the two arms at
the 6-month follow-up using a multilevel linear model, with baseline EMQ-p score and site as covariates.
Although participants were randomly allocated in clusters, individuals in the usual-care arm had no
contact with each other and outcomes in this arm were therefore assumed to be independent. However,
participants in the intervention arm attended group memory rehabilitation sessions, which needed to be
accounted for in the analysis. We therefore used a fully heteroscedastic model, as suggested by Roberts
and Roberts,76 for the analysis of trials comparing group-based treatments with individual-based treatment
as usual, when, as is the case here, there is adjustment for individual-level covariates. This model estimates
group-level residual variance in the intervention arm and also permits individual-level residual variance to
differ between the intervention arm and the control arm.76,77 Assumptions made in the multilevel linear
model were checked using diagnostic plots. The ICC in the intervention arm was estimated using the
estimates of the group-level residual variance and individual residual variance in the intervention arm.77
Sensitivity analyses for the primary outcome
We conducted the following sensitivity analyses:
l Including all 6-month questionnaires. We repeated the analysis described above including participants
whose 6-month questionnaires were returned after the 9-month post-randomisation window.
l Additional adjustment for baseline variables with an observed imbalance. We included baseline
variables with an observed imbalance (based on comparison of summary statistics only, not statistical
testing) as additional covariates in the multilevel model for the 6-month EMQ-p score.
l Multiple imputation of missing primary outcome data. We performed multiple imputation using
chained equations (MICE) separately for each arm, under the assumption that missing data were
missing at random.78 Variables included in the imputation model were site, age and gender, baseline
variables identified as predictive of dropout (by examination only), prognostic baseline variables
(EMQ-p, RBMT-3 GMI and GHQ-30), RBMT-3 GMI at the 6- and 12-month visit and 12-month EMQ-p
score. In addition, for the intervention arm, the number of intervention sessions attended was included.
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Forty data sets were imputed and the results of the analyses on the imputed data sets were combined
using Rubin’s rules.78
l Estimation of the complier average causal effect. We used instrumental variable regression to estimate
the effect of the intervention for participants who would comply with the allocated treatment whichever
arm they were randomised to.79,80 Participants in the intervention arm were classified as adherent if they
attended at least four memory rehabilitation sessions. The instrumental variable regression model included
baseline EMQ-p score and recruiting site and used a clustered sandwich estimator to estimate the variance
to allow for correlation between randomisation clusters (vce cluster option in Stata). We estimated the
complier average causal effect using both the observed data and the multiply imputed data.
We performed a prespecified exploratory subgroup analysis for the primary outcome according to memory
impairment at baseline (using the RBMT-3 GMI score, an objective measure of memory) by including an
interaction term in the model for the primary analysis. The RBMT-3 GMI score at baseline was categorised
into three groups on the basis of classifications provided by the test publisher:81 significant memory
impairment (scores of ≤ 69), borderline/moderate memory impairment (scores of 70–84) and average and
above average range (scores of ≥ 85).
During the trial, a Rasch analysis of the EMQ-p was performed using an independent data set of patients
with TBI (Rachel Johnson, Roshan das Nair and Nadina B Lincoln, University of Nottingham, 2017, personal
communication). We performed an exploratory analysis using this Rasch conversion of the EMQ-p scores
and compared scores between the two arms using the multilevel model described above.
After the planned analyses were conducted, at two meetings with collaborators and investigators, time
since TBI was raised as a potentially important factor with regard to whether or not patients could benefit
from the intervention. We therefore conducted a post hoc subgroup analysis of time since TBI, using the
methods described above.
Secondary outcomes at 6 and 12 months
We analysed the secondary outcomes using the multilevel model described for the primary outcome.
Estimates of the intervention effect are presented as difference in means with 95% confidence intervals
(CIs). For the goal attainment outcome, the number of goals set was additionally included as a covariate.
Estimates of the ICC in the memory rehabilitation arm for each outcome, calculated from the multilevel
models, are provided in Appendix 4.
Of the seven subscales of the EBIQ-p (and EBIQ-r), the cognitive, depression, communication and difficulties
in social interaction subscales were used in a formal comparison between arms, as the content of the group
memory intervention was most likely to have an impact on these subscales. The other subscales (impulsivity,
somatic and fatigue) were summarised using descriptive statistics only.
Sensitivity analyses for goal attainment secondary outcomes
Participants set at least one short- and one long-term goal but could set up to five. An interaction term
between the number of goals set (one or more than one) and treatment arm was included in the model
for the goal attainment score to explore whether there was evidence of any differential effect of the
intervention according to the number of goals set at baseline. We hypothesised that it could be harder for
participants who set more than one goal to meet all of their goals than for participants who set, and who
therefore focused on, one individual goal.
Goals set at the start of the trial should have been SMART (specific, measurable, assignable, realistic and
time-related) goals so that they could be assessed at the 6- and 12-month follow-up visits as being met
or not being met. During the trial it became apparent that not all goals set by the APs at baseline were
measurable. As a sensitivity analysis, each goal was classified as SMART or not by one of the trial APs and
a sample was independently checked by the chief investigator. We then repeated the analysis for goal
attainment including only SMART goals.
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Chapter 3 Results
Recruitment
Recruitment commenced in February 2013 and continued until December 2015 when the recruitment
target was met (see Appendix 5). The original planned recruitment period was extended by 8 months
because recruitment rates were lower than expected. This was in part because of staff turnover and delays
in recruiting new staff, resulting in a number of sites being inactive during the recruitment period.
Between February 2013 and December 2015, we screened 4023 people and consented 466. Of the 3557
people screened but not consented, the main reason was not replying to the letter of invitation (n = 1710,
43%); 1129 (28%) people were not eligible for the trial and 718 (18%) were not enrolled for other
reasons (Figure 1). Further details are provided in Appendix 6.
Of the 466 people who gave consent, 328 (70%) were randomised. Non-randomisation after consent was
the result of non-eligibility, recruitment being closed at the site (because of the site closing either during
the trial or at the end of recruitment in December 2015) and participants withdrawing consent or no
longer being contactable (see Figure 1).
Of the 328 participants randomised, 157 (48%) were randomised to usual care and 171 (52%) to memory
rehabilitation in addition to usual care (see Figure 1). The mean size of the cluster randomised was five.
The randomisation target of 312 was exceeded because of the requirement to randomise clusters of
participants who could attend the intervention sessions at the same time, if allocated to the intervention,
at the five sites remaining open at the end of recruitment.
Participants were randomised in clusters of four to six and the randomisation was stratified by site. The
number of clusters randomised to each arm within each site was well balanced (see Appendix 7). More
participants were randomised to the memory rehabilitation arm.
Participants waited a median of 18 days between the second assessment and randomisation (see Appendix 7).
However, a small number of participants (n = 23) waited for ≥ 6 months to be randomised; this was
because they had to wait both for other participants who could attend the intervention sessions at the
same time and for the AP to be available within the site to deliver the intervention.
Baseline data
The mean age of participants was 45 years (SD 12 years), 239 (73%) were men and almost all (96%) were
white (Table 1). We randomised 31 participants (9%) who were serving or who had served in the military,
including participants from the Territorial Army and reservists (see Table 1). There was a wide variation in
the time since the TBI at randomisation, from 3 months to almost 49 years. The median time since TBI was
just over 4 years (see Table 1).
Characteristics assessed at baseline were well balanced, although a greater proportion of participants in
the memory rehabilitation arm than in the usual-care arm had a degree or higher degree and the median
time since TBI was slightly longer in the memory rehabilitation arm (approximately 4 years in the usual-care
arm and approximately 5 years in the memory rehabilitation arm).
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Screened
(n = 4023)
Consented
(n = 466)
Randomised
(n = 328; 66 groups)
Usual care
(n = 157; 31 groups)
Memory rehabilitation
(n = 171; 35 groups)
• Did not attend any group sessions,
   n = 25
Not enrolled
(n = 3557)
Not randomised
(n = 138)
• No reply, n = 1710
• Not eligible, n = 1129
• Other, n = 718
• Not eligible, n = 67
   • TBI < 3 months, n = 1
   • SST score of < 17, n = 21
   • Failed EMQ-p and RBMT, n = 37
   • Unable to travel to study centre, n = 2
   • Unable to attend unsuitable for 
      group treatment, n = 3
   • ABI not TBI, n = 1
   • Principal investigator discretion, n = 2
• Withdrawn, n = 12
• Lost to follow-up, n = 1
• Recruitment closed at site, n = 58
12-month questionnaire not completed, n = 45
• Withdrawal of consent, n = 12
• Lost to follow-up, n = 19
• Not done, n = 14
12-month questionnaire completed
(n = 126; 74%)
6-month questionnaire not completed, n = 32
• Withdrawal of consent, n = 9
• Lost to follow-up, n = 8
• Not done, n = 15
6-month questionnaire not completed, n = 36
• Withdrawal of consent, n = 11
• Lost to follow-up, n = 10
• Not done, n = 15
6-month questionnaire completed
(n = 125; 80%)
Not included in primary analysis, n = 35
• Questionnaire completed > 9 months after
   randomisation, n = 2
• Questionnaire returned, EMQ-p not scoreable,
   n = 1
• Questionnaire not completed, n = 32
6-month assessment visit completed
(n = 133; 85%)
Included in primary analysis
(n = 122; 78%)
6-month questionnaire completed
(n = 135; 79%)
Not included in primary analysis, n = 42
• Questionnaire completed > 9 months after
   randomisation, n = 4
• Questionnaire returned, EMQ-p not scoreable,
   n = 2
• Questionnaire not completed, n = 36
6-month assessment visit completed
(n = 143; 84%)
Included in primary analysis
(n = 129; 75%)
12-month questionnaire completed
(n = 112; 71%)
12-month assessment visit completed
(n = 124; 79%)
12-month assessment visit completed
(n = 132; 77%)
      
12-month questionnaire not completed, n = 45
• Withdrawal of consent, n = 14
• Lost to follow-up, n = 19
• Not done, n = 12
FIGURE 1 Participant flow chart. Reproduced from das Nair et al.82 This is an Open Access article distributed in
accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to
distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited.
See: http://creativecommons.org/licenses/by/4.0/.
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TABLE 1 Participant baseline characteristics
Characteristic
Trial arm
Total
(N= 328)Usual care (N= 157)
Memory rehabilitation
(N= 171)
Age (years)
Mean (SD) 45.1 (12.5) 45.8 (11.5) 45.4 (12)
Median (25th, 75th centile) 45 (36, 55) 47 (38, 54) 46 (36, 54)
Min., max. 19, 69 20, 68 19, 69
Gender, n (%)
Men 116 (74) 123 (72) 239 (73)
Women 41 (26) 48 (28) 89 (27)
Ethnicity, n (%)
White 147 (94) 167 (98) 314 (96)
Black 6 (4) 2 (1) 8 (2)
Mixed race 3 (2) 1 (1) 4 (1)
Other 1 (1) 1 (1) 2 (1)
Residential status, n (%)
Lives alone 44 (28) 43 (25) 87 (27)
Lives with others 106 (68) 120 (70) 226 (69)
Living with informal carer 2 (1) 1 (1) 3 (1)
Living with formal carer 2 (1) 0 2 (1)
Living in care home 3 (2) 7 (4) 10 (3)
Highest educational attainment, n (%)
Below GCSE 26 (17) 29 (17) 55 (17)
GCSE 54 (34) 49 (29) 103 (31)
A level 42 (27) 34 (20) 76 (23)
Degree 24 (15) 41 (24) 65 (20)
Higher degree 10 (6) 17 (10) 27 (8)
Not known 1 (1) 1 (1) 2 (1)
Employment status at screening (not mutually exclusive), n (%)
Not employed 80 (51) 85 (50) 165 (50)
Employed full time 25 (16) 38 (22) 63 (19)
In education full time 2 (1) 1 (1) 3 (1)
Voluntary full time 1 (1) – 1 (< 0.5)
Retired 17 (11) 15 (9) 32 (10)
Employed part time 25 (16) 19 (11) 44 (13)
Voluntary part time 9 (6) 17 (10) 26 (8)
Current military service,a n (%)
Military 4 (3) 0 4 (1)
TA/reservist 0 2 (1) 2 (1)
Non-military 153 (97) 169 (99) 322 (98)
continued
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Data from the memory, mood and quality-of-life assessments completed prior to randomisation are shown
in Table 2. Scores were well balanced between arms; however, when the RBMT-3 GMI was categorised
into levels of memory impairment a smaller percentage of participants in the memory rehabilitation arm
than in the usual-care arm were classified as having a significant impairment (39% in the usual-care arm
vs. 29% in the memory rehabilitation arm; see Table 2).
The internal consistency of the EMQ-p and GHQ-30 at baseline using Cronbach’s alpha was 0.93 for the
EMQ-p and 0.95 for the GHQ-30.
Relative/friend participation in the trial
In total, 210 relatives or friends of participants agreed to take part in the trial by returning a questionnaire
at baseline or follow-up (64% in each arm). The scores from the EMQ-r were similar in the two arms at
baseline (see Table 2). The internal consistency of the EMQ-r using Cronbach’s alpha was 0.96.
TABLE 1 Participant baseline characteristics (continued )
Characteristic
Trial arm
Total
(N= 328)Usual care (N= 157)
Memory rehabilitation
(N= 171)
Previous military service, n (%)
Military 14 (9) 11 (6) 25 (8)
TA/reservist 2 (1) 4 (2) 6 (2)
Non-military 141 (90) 156 (91) 297 (91)
TBI during service 3 (2) 1 (1) 4 (1)
Time since TBI (months)b
Mean (SD) 99 (114.8) 102.6 (113.4) 100.9 (113.9)
Median (25th, 75th centile) 46 (23, 116) 58 (24, 148) 52 (24, 129.5)
Min., max. 4, 520 3, 587 3, 587
Length of initial hospital stay for TBI (days)c
Mean (SD) 81.8 (108.6) 86.5 (143.5) 84.2 (127.7)
Median (25th, 75th centile) 35 (7, 120) 35.5 (10, 93.5) 35 (9, 116)
Min., max.d 0, 468 0, 999 0, 999
n 148 160 308
Length of hospital stay unknown, n (%) 9 (6) 11 (6) 20 (6)
A level, Advanced level; GCSE, General Certificate of Secondary Education; max., maximum; min., minimum;
TA, territorial army.
a All participants reporting current military service also indicated that they had previous military service.
b Based on participant-reported date on TBI for 108 participants in the usual-care arm and 132 participants in the memory
rehabilitation arm and clinical notes for 49 participants in the usual-care arm and 39 participants in the memory
rehabilitation arm.
c Estimated for 84 participants in the usual-care arm and 105 participants in the memory rehabilitation arm.
d Maximum truncated at 999.
Notes
The other clinical information collected at baseline is not shown here because of large amounts of missing data. It is
reported in full in Appendix 8.
Reproduced from das Nair et al.82 This is an Open Access article distributed in accordance with the terms of the Creative
Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work,
for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/.
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TABLE 2 Assessments completed prior to randomisation
Assessment
Trial arm
Total
(N= 328)Usual care (N= 157)
Memory rehabilitation
(N= 171)
EMQ-p – frequency of problems
Mean (SD) 50.1 (24.6) 47.4 (21) 48.7 (22.8)
Median (25th, 75th centile) 50 (33, 65.2) 47.7 (30, 63) 48 (32, 64)
Min., max. 0, 105 5, 102 0, 105
na 156 171 327
EMQ-p – importance of problems
Mean (SD) 70.6 (22.4) 65.7 (23.5) 68 (23)
Median (25th, 75th centile) 72 (56, 87) 69 (51, 83) 70.5 (54, 84)
Min., max. 2, 112 0, 112 0, 112
n 152 170 322
RBMT-3 GMI
Mean (SD) 76.3 (14.5) 77.7 (13.6) 77 (14)
Median (25th, 75th centile) 75 (65, 85) 77 (67, 85) 76 (66.5, 85)
Min., max. 53, 114 53, 127 53, 127
n 157 171 328
Level of memory impairment based on the RBMT-3, n (%)
Significant memory impairment (score of ≤ 69) 61 (39) 50 (29) 111 (34)
Borderline/moderate memory impairment
(score 70–84)
54 (34) 77 (45) 131 (40)
Average or above average (score of ≥ 85) 42 (27) 44 (26) 86 (26)
GHQ-30
Mean (SD) 35.3 (16.3) 36.1 (15.4) 35.8 (15.8)
Median (25th, 75th centile) 33 (21, 47) 34 (25, 45) 33 (24, 45.3)
Min., max. 6, 90 6, 84 6, 90
n 154 170 324
Estimated premorbid IQ from the NART
Mean (SD) 106.5 (10) 108.1 (10.2) 107.4 (10.1)
Median (25th, 75th centile) 103 (99, 116) 109.5 (100, 117) 105 (100, 117)
Min., max. 86, 126 87, 128 86, 128
n 155 170 325
SST
Mean (SD) 19.3 (0.9) 19.4 (0.9) 19.4 (0.9)
Median (25th, 75th centile) 20 (19, 20) 20 (19, 20) 20 (19, 20)
Min., max. 17, 20 17, 20 17, 20
n 157 171 328
continued
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Group memory rehabilitation sessions
Attendance at group sessions
Participants attended a mean of 6.3 sessions (SD 3.5 sessions), with 131 (77%) participants attending four
or more sessions (Table 3). There were several reasons that participants did not attend sessions; these are
shown in Table 3.
Attendance at sessions decreased over time. Some groups were well attended throughout. In one group,
the final four sessions were not attended by any participants (see Appendix 9).
In total, 17 APs delivered group sessions during the trial. The number of sessions that each AP ran ranged
between 1 and 47, with a median of 20 (25th, 75th centile = 10, 28).
Analysis of treatment fidelity
The number of video recordings retrieved from each site are shown in Appendix 10 (see Table 35). No
videos were retrieved from three sites. Sites 2 and 4 recruited only one intervention group each and,
therefore, the sessions were not recorded as it was the first group conducted by the APs at those sites. At
site 7, two intervention groups were recruited, one of which was the first for the AP; for the second group
the recordings were not available for analysis. At two sites (sites 5 and 6) there were very few recordings
retrieved as the APs did not understand that all sessions needed to be recorded. For 25 sessions the
recording stopped partway through the session because of technical problems (e.g. the recorder battery
being completely discharged). Overall, there were some recordings from six of the nine sites.
TABLE 2 Assessments completed prior to randomisation (continued )
Assessment
Trial arm
Total
(N= 328)Usual care (N= 157)
Memory rehabilitation
(N= 171)
EMQ-r – frequency of problems
Mean (SD) 46.4 (24.4) 42 (28.4) 44.1 (26.6)
Median (25th, 75th centile) 46.7 (27, 65) 35.3 (18.7, 64) 38.5 (22, 64.5)
Min., max. 0, 107 0, 108 0, 108
n 95 105 200
EMQ-r – importance of problems
Mean (SD) 71.5 (24.5) 71.8 (21) 71.7 (22.7)
Median (25th, 75th centile) 76 (64, 87) 72 (60, 88) 75 (60, 87)
Min., max. 0, 112 4, 112 0, 112
n 90 101 191
IQ, intelligence quotient; max., maximum; min., minimum.
a One participant did not complete five items on the EMQ-p; the 23 items completed summed to a total of 27.
Notes
EMQ scores range from 0 to 112, with higher scores indicating more frequent/important memory problems.
RBMT-3 GMI scores range between 52 and 174; it has been standardised to have a mean score of 100 and a SD of 15 on
a demographically representative sample from the UK.
GHQ-30 scores range from 0 to 90, with higher scores indicating increased psychological distress.
A total SST score of ≥ 17 was required to participate in the trial (maximum score 20).
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A selection of all recordings of complete sessions was analysed; seven recordings of complete sessions
were not included because sufficient recordings from the site or the session had already been included in
the analysis. In addition, as there were no complete recordings of session 1, two recordings that were
almost complete were analysed for session 1. A summary of the video recordings analysed is provided in
Appendix 10 (see Table 36). Between two and five recordings of each session were analysed. A total of
31 sessions were included in the fidelity analysis, approximately 9% of the 350 memory rehabilitation
sessions delivered during the trial.
The frequency and percentage of each activity code were calculated for each session; these are provided in
Table 4 for APs and Table 5 for participants.
The main non-rehabilitation activity of APs was providing information about sessions, which occurred in just
under 5% of AP observations. The main rehabilitation activities of APs were discussing the educational
material (31.5%) and discussing memory strategies (35.8%). The main rehabilitation skills of APs were
facilitating discussion and providing encouragement. Overall, APs spent 88.9% of the time on rehabilitation
skills and activities. The pattern across time showed that the initial session included more non-rehabilitation
activities (50.9%), whereas all subsequent sessions included more rehabilitation activities (78.0–95.9%).
TABLE 3 Summary of attendance at group memory rehabilitation sessions
Summary Memory rehabilitation (N= 171)
Number of sessions attended
Mean (SD) 6.3 (3.5)
Median (25th, 75th centile) 8 (4, 9)
Min., max. 0, 10
0–2, n (%) 36 (21)
3–7, n (%) 44 (26)
8–10, n (%) 91 (53)
At least four, n (%) 131 (77)
Total number of sessions missed 627
Reason for missing sessions – number of sessions (number of participants)a
Did not want to continue 122 (16)
Withdrew from study 52 (7)
Lost to follow-up (unable to contact) 70 (7)
Forgot to attend 11 (10)
Unwell 83 (40)
Holiday 59 (36)
Work/family commitments 114 (34)
No reason given 94 (23)
Otherb 22 (16)
max., maximum; min., minimum.
a Reasons for missing sessions not mutually exclusive.
b Other reasons given for participants missing group rehabilitation sessions were prior engagements (n= 5), transport/
traffic problems (n= 4) and moved away (n= 1) (note: reasons are not mutually exclusive). There were also seven
participants included in the ‘other’ category for whom the reason for missing sessions is not known.
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Total7 8 9 10
n % n % n % n % n %
1 1.6 0 0 1 0.7 0 0 5 0.4
0 0 9 4.2 8 5.8 5 4.1 38 3.2
0 0 2 0.9 4 2.9 8 6.5 23 2.0
1 1.6 4 1.9 1 0.7 13 10.6 56 4.8
0 0 0 0 0 0 0 0 2 0.2
1 1.6 0 0 1 0.7 1 0.8 8 0.7
0 0 4 1.9 4 2.9 7 5.7 41 3.5
0 0 5 2.3 5 3.6 4 3.3 28 2.4
1 1.6 6 2.8 3 2.2 3 2.4 37 3.2
0 0 1 0.5 1 0.7 0 0 3 0.3
1 1.6 3 1.4 1 0.7 0 0 22 1.9
9 12 19.7 57 26.8 31 22.6 41 33.3 369 31.5
4 44 72.1 102 47.9 60 43.8 16 13.0 420 35.8
0 0 3 1.4 2 1.5 3 2.4 42 3.6
0 0 17 8.0 15 10.9 22 17.9 79 6.7
61 100 213 100 137 100 123 100 1173 100
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26TABLE 4 Assistant psychologists’ skills and activities observed within a session
Category
Session
1 2 3 4 5 6
n % n % n % n % n % n %
Non-rehabilitation
Introductions 1 1.8 0 0 0 0 1 0.7 1 1.0 0 0
Social chat 3 5.5 2 1.3 2 4.5 2 1.4 4 3.9 3 2.1
Preparing materials, tasks 2 3.6 5 3.3 0 0 1 0.7 0 0 1 0.7
Information about sessions, venue, group 20 36.4 3 2.0 2 4.5 4 2.9 6 5.8 2 1.4
Hospital visit discussion 1 1.8 0 0 0 0 0 0 1 1.0 0 0
Describing emotions and coping
strategies
1 1.8 3 2.0 0 0 1 0.7 0 0 0 0
Rehabilitation skills
Facilitating discussion (non-specific
prompts)
5 9.1 3 2.0 0 0 13 9.4 0 0 5 3.4
Providing feedback not directly related
to manual
1 1.8 5 3.3 0 0 3 2.2 5 4.9 0 0
Providing encouragement/reassurance 4 7.3 6 3.9 0 0 6 4.3 4 3.9 4 2.7
Summarising 0 0 1 0.7 0 0 0 0 0 0 0 0
Paraphrasing 1 1.8 8 5.2 0 0 4 2.9 2 1.9 2 1.4
Rehabilitation activities
Presenting/discussing educational material 13 23.6 81 52.9 21 47.7 41 29.7 24 23.3 48 32
Presenting/discussing strategies 1 1.8 2 1.3 18 40.9 53 38.4 49 47.6 75 51
Providing general information on
memory not related to manual
2 3.6 25 16.3 1 2.3 2 1.4 2 1.9 2 1.4
Recap of previous session 0 0 9 5.9 0 0 7 5.1 5 4.9 4 2.7
Total 55 100 153 100 44 100 138 100 103 100 146 10
%, percentage of observations; n, number of observations..
.
0
TABLE 5 Participant activities observed within sessions
Category
Session
Total1 2 3 4 5 6 7 8 9 10
n % n % n % n % n % n % n % n % n % n % n %
Non-rehabilitation
Introductions 5 6.2 0 0 0 0 3 2.0 0 0 0 0 0 0 0 0 1 0.6 0 0 9 0.8
Social chat 14 17.3 6 8.7 5 21.7 13 8.8 22 14.8 10 8.1 2 5.9 40 22.7 46 26.1 27 13.8 185 15.8
Preparing materials, tasks 2 2.5 2 2.9 0 0 0 0 0 0 0 0 0 0 1 0.6 0 0 1 0.5 6 0.5
Information about sessions,
venue, group
3 3.7 0 0 1 4.3 3 2.0 1 0.7 2 1.6 0 0 1 0.6 2 1.1 5 2.6 18 1.5
Hospital visit discussion 8 9.9 0 0 0 0 2 1.4 1 0.7 0 0 0 0 0 0 0 0 0 0 11 0.9
Describing emotions and
coping strategies
13 16.0 10 14.5 0 0 6 4.1 2 1.3 0 0 1 2.9 4 2.3 10 5.7 28 14.4 74 6.3
Rehabilitation activities
Discussing/filling in
educational material
13 16.0 17 24.6 11 47.8 63 42.9 51 34.2 32 26.0 19 55.9 12 6.8 11 6.3 53 27.2 282 24.0
Discussing strategies 6 7.4 8 11.6 5 21.7 28 19.0 51 34.2 62 50.4 6 17.6 76 43.2 95 54.0 45 23.1 382 32.6
Asking for information 0 0 6 8.7 1 4.3 4 2.7 2 1.3 0 0 2 5.9 3 1.7 0 0 3 1.5 21 1.8
Feedback on home activities 0 0 5 7.2 0 0 4 2.7 13 8.7 4 3.3 3 8.8 14 8.0 6 3.4 20 10.3 69 5.9
Describing problems related
to memory
17 21.0 15 21.7 0 0 21 14.3 6 4.0 13 10.6 1 2.9 25 14.2 5 2.8 13 6.7 116 9.9
Total 81 100 69 100 23 100 147 100 149 100 123 100 34 100 176 100 176 100 195 100 1173 100
%, percentage of observations; n, number of observations.
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For participants, the main non-rehabilitation activity was social chat, which occurred in about 16% of
observations. The main rehabilitation activities were discussing the educational material (24.0%) and discussing
memory strategies (32.6%). Overall, participants spent 74.2% of the sessions on rehabilitation activities. The
pattern of activities across time showed that the initial session included more non-rehabilitation activities
(55.6%), whereas all subsequent sessions included more rehabilitation activities (62.1–91.1%).
Overall, the results indicate that the APs followed the guidelines in the manual by providing and discussing
rehabilitation strategies and this was mirrored by participants, who also discussed the educational materials
and strategies. Most sessions included summarising and paraphrasing by the AP and the provision of
general information on memory not related to the manual. Most sessions included descriptions of
problems related to memory.
To examine the consistency between sites, we compared the distribution of observations at each site.
The results are shown in Appendix 10 (see Tables 37 and 38).
The distribution of AP activities was similar across the sites. The AP at site 5 spent more time organising
sessions, for example discussing the venue and the time of the groups (20.9%), and more time facilitating
discussion (16.4%) than the APs at the other sites. Most variation between sites occurred in the time spent
presenting and discussing strategies, which varied from 16.4% (site 5) to 65.6% (site 9). Providing a recap
of the previous session was more frequent at site 3 (17.2%) than at the other sites.
From the participants’ perspective, those at site 5 spent more time discussing information about the
sessions (4.4%) and hospital visits (11.1%). Participant rehabilitation activities were similar between the
sites. Site 3 participants spent the most time discussing the educational materials (35.6%) and participants
at sites 5 and 9 spent the highest proportion of time discussing strategies (42.5% and 41.8%, respectively).
Site 6 participants spent the highest proportion of time describing problems related to memory (20.9%).
Overall, the results of the fidelity analysis indicate that the components of therapy described in the manual
were delivered to participants. Each session included the essential components of therapy. The distribution
of time was as expected, with session 1 being introductory and providing an opportunity for participants to
get to know each other and later sessions focusing on the rehabilitation content. This suggests that the
outcomes reflect the effect of the intervention, as described in the manual.
Follow-up
Follow-up assessments were completed between October 2013 and December 2016. At the 6-month
follow-up, 260 (79%) participants returned the questionnaire booklet and 276 (84%) participants
completed the assessment visit (Table 6). Questionnaire booklet return and visit completion were similar
in the two arms.
At the 12-month follow-up, 238 (73%) of the participants returned the questionnaire booklet and 256
(78%) completed the assessment visit; completion rates were again similar in the two arms (see Table 6).
Most visits (n = 275, 84% at 6 months; n = 256, 78% at 12 months) and questionnaires (n = 254, 77%
at 6 months; n = 237, 72% at 12 months) were completed within 3 months of the scheduled time point.
A total of 64 (20%) participants did not complete any of the 12-month follow-up, either because they
withdrew consent (8%) or they were lost to follow-up (12%). Numbers lost to follow-up and withdrawing
consent were similar in each arm. Twenty-six participants (8%) withdrew from the trial: 12 in the usual-
care arm and 14 in the memory rehabilitation arm (see Table 6). The main reasons for withdrawal were
RESULTS
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Inclusion in primary analysis of the primary outcome
In total, 122 (78%) participants in the usual-care arm and 129 (75%) in the memory rehabilitation arm
were included in the primary analysis of the EMQ-p at the 6-month follow-up. Three participants in the
usual-care arm and six in the memory rehabilitation arm who returned questionnaires were not included,
because of either completing the questionnaire > 9 months from randomisation or not completing enough
items on the EMQ-p for it to be scored (see Figure 1).
Participants with no primary outcome data tended to have a slightly lower level of educational attainment
and slightly more memory problems at baseline based on both patient and relative/friend report. There
were no important differences in other baseline characteristics (see Appendix 11).
Unblinding at follow-up visits
Research assistants reported being unblinded more often in the memory rehabilitation arm than in the
usual-care arm, both prior to and during the visits (see Appendix 12). The percentage of participants
assessed correctly as ‘definitely’ in their allocated arm was higher in the memory rehabilitation arm than
the usual-care arm. The most frequent assessment of allocation at each time point was ‘probably control’.
The Kappa statistic was used to assess the agreement between a participant’s actual treatment allocation
and the RA’s opinion of treatment allocation (collapsing ‘probably’ and ‘definitely’ into one category).
Kappa values of ≤ 0.20 are considered to indicate no or poor agreement, 0.21–0.40 indicate fair
agreement, 0.41–0.6 indicate moderate agreement, 0.61–0.8 indicate substantial agreement and ≥ 0.81
indicate near perfect agreement. Kappa values were fair before goal assessment and moderate after goal
assessment (see Appendix 12).
Relative/friend questionnaire follow-up
Of the 210 relatives/friends who agreed to participate in the trial, the questionnaire booklet was returned
by 144 (69%) at the 6-month follow-up and 131 (62%) at the 12-month follow-up (see Appendix 13).
A slightly higher percentage of relatives/friends in the usual-care arm returned the questionnaire booklet
at the 6-month follow-up; however, the percentage returning the booklet at the 12-month follow-up was
similar in the two arms.
Primary outcome (EMQ-p) at the 6-month follow-up
Primary analysis
The mean EMQ-p score was lower in both arms at the 6-month follow-up than at baseline; however, there
was no clinically important difference between the two arms (Table 7).
TABLE 7 The EMQ-p score at the 6-month follow-up
Trial arm
Time point, mean (SD) score
Adjusted difference
in mean scores (95% CI) p-valueBaseline 6-month follow-up
Usual care (n= 122) 48.9 (23.9) 44.1 (24.6)
Memory rehabilitation (n= 129) 45.9 (21.0) 38.8 (26.1) –2.1 (–6.7 to 2.5) 0.37
Notes
EMQ-p scores range from 0 to 112, with higher scores indicating more frequent memory problems. The difference in mean
scores at the 6-month follow-up (memory rehabilitation vs. usual care) was estimated using a multilevel linear model with a
random effect for cluster in the memory rehabilitation arm, allowing the participant-level variance to vary between arms,
and baseline EMQ-p score and site included as covariates.
Reproduced from das Nair et al.82 This is an Open Access article distributed in accordance with the terms of the Creative
Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work,
for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/.
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The mean number of participants in each cluster with EMQ-P data at follow-up was 3.9 in the usual-care
arm and 3.7 in the memory rehabilitation arm. Diagnostic plots were used to check the assumptions in the
model, with no strong evidence that these were not met. The estimated ICC for the participant EMQ-p
was 0.05 in the memory rehabilitation arm.
Sensitivity analyses for the primary outcome
The estimates of the difference in EMQ-p scores between the two arms at the 6-month follow-up, after
additional adjustment for baseline variables, multiple imputation (assuming that missing outcomes were
missing at random) and the complier average causal effect estimate, were slightly greater than in the primary
analysis (Table 8 and see Appendix 14, Figure 15). However, the lower limit of the 95% CI for all of these
sensitivity analyses was greater than –12, the minimum clinically relevant difference specified in the sample
size calculation.
We conducted a further sensitivity analysis to explore the robustness of the results if missing EMQ-p data
at the 6-month follow-up were not missing at random. Under the extreme assumption of scores in the
usual-care arm being 12 points worse than as imputed under the missing at random assumption, the
lower limit of the 95% CI was –9.8.
The analysis after Rasch conversion of the EMQ-p scores gave similar results to using the standard EMQ-p
total scores (see Appendix 14).
Subgroup analysis for the primary outcome
We conducted a prespecified subgroup analysis based on the baseline level of memory impairment, as
assessed on the RBMT-3. The difference in mean EMQ-p score for those with borderline/moderate memory
impairment favoured the memory rehabilitation arm but there was no evidence of a difference in the
effect of the group memory rehabilitation sessions across the subgroups (p-value for interaction = 0.12)
(see Table 9 and Appendix 15).
The results of the post hoc subgroup analysis conducted on time since TBI are shown in Appendix 16.
There was no evidence of a difference in the intervention effect on the basis of time since TBI based on
this analysis (p-value for interaction effect = 0.48).
TABLE 8 Sensitivity analyses for the primary outcome
Analysis type n
Adjusted difference in
mean scores (95% CI)
Additional adjustment for educational attainment and time since TBI (log-transformed)
because of slight imbalance at baseline
251 –2.8 (–7.2 to 1.7)
Including participants completing the 6 month questionnaire booklet > 9 months after
randomisation
257 –2.0 (–6.5 to 2.5)
After multiple imputation of missing outcome dataa 328 –2.4 (–7.1 to 2.3)
Complier average causal effect using observed data at 6 months 251 –2.6 (–7.9 to 2.7)
Complier average causal effect at 6 months after multiple imputation of missing
outcome data
328 –3.2 (–9.3 to 2.9)
a Multiple imputation using chained equations separately for each arm and assuming that missing data are missing at
random. The imputation model included age, site, gender, baseline EMQ-p score, baseline GHQ-30 score, baseline
RBMT-3 GMI score, highest educational attainment (predictive of dropout) and log-transformed time since TBI. The
following outcomes were imputed: EMQ-p score at the 6- and 12-month follow-ups and RBMT-3 GMI score at the
6- and 12-month follow-ups. In addition, for the memory rehabilitation arm, the number of sessions attended was
included. Forty data sets were imputed and estimates were combined using Rubin’s rules.
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Secondary outcomes
EMQ-p at the 12-month follow-up
There was no clinically important difference in EMQ-p scores between the two arms at the 12-month
follow-up (Table 10). The EMQ-p importance scores at the 6- and 12-month follow-ups are reported in
Appendix 17. The importance scale was originally added to be able to investigate the effect of memory
rehabilitation on memory problems weighted for their importance. However, analysis of data from a
subsequent independent study83 showed no effect of weighting items by their importance and, therefore,
this was not included in the main analyses.
Objectively assessed memory ability
The GMI scores from the RBMT-3 were slightly higher at the 6-month follow-up in the memory
rehabilitation arm than in the usual-care arm. However, by the 12-month follow-up there was no evidence
of a difference between the arms (see Table 10).
Goal attainment
Participants set on average 2.5 (SD 1.2) short-term goals and 2.4 (SD 1.2) long-term goals at the second
assessment. These included goals such as better recall of names and dates, remembering forthcoming
tasks or appointments and improved memory of past events. We were unable to set goals for three
participants (two randomised to the usual-care arm and one randomised to the memory rehabilitation
arm); two participants did not wish to set any goals and one participant was not able to as they were
preoccupied with other non-memory issues.
For short- and long-term goals, the goal attainment scores favoured the memory rehabilitation arm at both
the 6-month follow-up and the 12-month follow-up (Table 11). There was no evidence of a difference in
the effect of the intervention on the basis of the number of goals set (p-values for the interaction effect
between treatment arm and one goal set or more than one goal set: 0.67 and 0.59 for short-term goals
and 0.07 and 0.67 for long-term goals at 6 and 12 months, respectively).
TABLE 9 Subgroup analysis of EMQ-p score on the basis of memory impairment at baseline
Subgroup
Time point, mean (SD) score Adjusted difference
in mean scores
(95% CI)
Adjusted interaction
effect (95% CI)Baseline 6-month follow-up
RBMT-3 GMI score of ≥ 85 (average and above average range)
Usual care (n = 34) 43.4 (15.0) 36.0 (20.5)
Memory rehabilitation
(n= 35)
42.7 (16.9) 34.4 (21.9) –0.1 (–8.3 to 8.1)
RBMT-3 GMI score of 70–84 (borderline/moderate memory impairment)
Usual care (n = 43) 45.7 (25.0) 43.9 (25.6)
Memory rehabilitation
(n= 59)
43.5 (20.8) 34.0 (23.9) –7.1 (–13.9 to –0.3) –7.0 (–17.5 to 3.4)
RBMT-3 GMI score of ≤ 69 (significant memory impairment)
Usual care (n = 45) 56.3 (26.9) 50.4 (25.1)
Memory rehabilitation
(n= 35)
53.2 (23.7) 51.3 (29.8) 3.3 (–4.4 to 11.0) 3.4 (–7.7 to 14.6)
Note
EMQ-p scores range from 0 to 112, with higher scores indicating more frequent memory problems.
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Of the 819 short-term goals set, 692 (84%) were classified as SMART. Of the 775 long-term goals set, 679
(88%) were classified as SMART. Thirty participants (9%) set no SMART short-term goals and 35 participants
(11%) set no SMART long-term goals. The results from the analysis of goal attainment including only SMART
goals were similar to the results from the analysis including all goals (see Appendix 18).
TABLE 10 Secondary outcomes for memory and mood at the 6- and 12-month follow-ups
Outcome
Time point, mean (SD) score Adjusted difference
in mean scores
(95% CI)Baseline Follow-up
EMQ-p – frequency of problems
12-month follow-up
Usual care (n= 107) 47.5 (24.6) 43.0 (26.7)
Memory rehabilitation (n = 124) 46.7 (20.4) 38.0 (25.0) –4.8 (–9.6 to 0.0)
GMI scores from the RBMT-3
6-month follow-upa
Usual care (n= 133) 77.1 (14.5) 79.1 (15)
Memory rehabilitation (n = 141) 78.9 (13.7) 82.7 (14) 2.5 (0.1 to 4.8)
12-month follow-upb
Usual care (n= 124) 76.2 (14.0) 84.0 (18.4)
Memory rehabilitation (n = 131) 79.5 (12.8) 87.2 (15.7) 0.5 (–2.6 to 3.6)
GHQ-30
6-month follow-up
Usual care (n= 110) 33.9 (15.7) 34.1 (16.8)
Memory rehabilitation (n = 124) 36.2 (15.4) 33.6 (16.3) –1.6 (–5.3 to 2.1)
12-month follow-up
Usual care (n= 103) 33.4 (15.8) 32.5 (18.8)
Memory rehabilitation (n = 119) 35.7 (15.3) 33.1 (18.5) –0.2 (–4.5 to 4.1)
EMQ-r – frequency of problems
6-month follow-up
Usual care (n= 66) 43.2 (23.1) 40.9 (25.9)
Memory rehabilitation (n = 68) 39.4 (26.3) 31.8 (24.5) –4.2 (–10.1 to 1.7)
12-month follow-up
Usual care (n= 57) 42.9 (23.5) 37.6 (26.6)
Memory rehabilitation (n = 67) 40.0 (26.7) 32.2 (26.2) –5.3 (–12.0 to 1.4)
a RBMT-3 not done for one participant who completed the 6-month follow-up visit in the memory rehabilitation arm
because the visit was done over the telephone as the participant had moved out of the area.
b One participant in the memory rehabilitation arm refused to complete the RBMT-3 at the 12-month follow-up visit.
Notes
The GMI from the RBMT-3 ranges between 52 and 174 and has been standardised to have a mean of 100 and a SD of 15
on a demographically representative sample from the UK.
GHQ-30 scores range from 0 to 90 (Likert scoring), with higher scores indicating increased psychological distress.
EMQ scores range from 0 to 112, with higher scores indicating more frequent memory problems.
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TABLE 11 Goal attainment and EBIQ-p subscale scores at the 6- and 12-month follow-ups
Outcome
Follow up time point
6 monthsa 12 monthsb
n
Mean (SD)
score
Adjusted difference
in mean scores
(95% CI) n
Mean (SD)
score
Adjusted difference
in mean scores
(95% CI)
Goal attainmentc
Short-term goal attainment average score
Usual care 131 1.2 (1.0) 123 1.5 (1.1)
Memory rehabilitation 141 1.8 (1.0) 0.6 (0.3 to 0.9) 131 1.8 (0.9) 0.3 (0.0 to 0.5)
Long term goal attainment average score
Usual care 131 1.0 (0.9) 123 1.3 (1.0)
Memory rehabilitation 141 1.5 (1.0) 0.5 (0.2 to 0.7) 131 1.6 (1.0) 0.4 (0.1 to 0.6)
EBIQ-p subscale scoresd
Cognitive subscale
Usual care 109 1.97 (0.43) 99 1.94 (0.47)
Memory rehabilitation 121 1.89 (0.45) –0.05 (–0.17 to 0.06) 117 1.88 (0.46) –0.05 (–0.17 to 0.08)
Depression subscale
Usual care 109 1.68 (0.62) 97 1.63 (0.63)
Memory rehabilitation 118 1.76 (0.62) 0.06 (–0.10 to 0.23) 118 1.77 (0.64) 0.16 (–0.01 to 0.34)
Communication subscale
Usual care 110 1.86 (0.53) 99 1.90 (0.57)
Memory rehabilitation 120 1.92 (0.57) 0.06 (–0.10 to 0.21) 115 1.85 (0.57) –0.05 (–0.21 to 0.11)
Difficulties with social interaction subscale
Usual care 110 1.71 (0.48) 97 1.71 (0.45)
Memory rehabilitation 120 1.82 (0.50) 0.09 (–0.04 to 0.22) 118 1.77 (0.48) 0.05 (–0.08 to 0.18)
Impulsivity subscale
Usual care 108 1.7 (0.50) 97 1.64 (0.48)
Memory rehabilitation 121 1.8 (0.51) NAe 118 1.76 (0.50) NAe
Somatic subscale
Usual care 110 1.94 (0.52) 96 1.91 (0.51)
Memory rehabilitation 120 1.95 (0.52) NAe 115 1.89 (0.50) NAe
Fatigue subscale
Usual care 107 2.01 (0.47) 99 1.99 (0.55)
Memory rehabilitation 120 2.00 (0.50) NAe 117 1.97 (0.51) NAe
NA, not applicable.
a Of those completing the 6-month follow-up, two participants in the usual-care arm and one participant in the memory
rehabilitation arm had not set any goals.
b Of those completing the 12-month follow-up, one participant in the usual-care arm and one participant in the memory
rehabilitation arm had not set any goals.
c Goal attainment was assessed on a four-point Likert scale: ‘not met’ (0), ‘met a little’ (1), ‘mostly met’ (2), and ‘fully met’ (3).
The average attainment score across the goals set was calculated for each participant. The number of goals set was included
in the analysis model.
d EBIQ-p subscale scores range between 1 and 3, with higher scores indicating increased difficulties.
e Impulsivity, somatic and fatigue subscales summarised using descriptive statistics only, as per the SAP.
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Mood
The GHQ-30 scores were similar in the two arms at both time points (see Table 10).
Cognitive, emotional and social well-being
Scores from all subscales of the EBIQ-p were similar in the two arms at both the 6-month follow-up and
the 12-month follow-up (see Table 11).
Relative/friend secondary outcomes
The differences between the two arms at follow-up based on the relative/friend assessment (Table 12)
were consistent with the results of the participant-completed questionnaires (see Table 10), indicating that
there was no clinically important difference between the two arms on the EMQ-r, even though this
outcome was completed for only a subgroup of participants. The EMQ-r importance scores at the 6- and
12-month follow-ups are reported in Appendix 19.
TABLE 12 The EBIQ-r subscale scores
EBIQ-r subscale
Follow up time point
6 months 12 months
n
Mean (SD)
score
Adjusted difference
in mean scores
(95% CI) n
Mean (SD)
score
Adjusted difference
in mean scores
(95% CI)
Cognitive subscale
Usual care 72 1.98 (0.50) 60 1.88 (0.52)
Memory rehabilitation 69 1.89 (0.52) –0.06 (–0.23 to 0.12) 68 1.91 (0.53) 0.00 (–0.18 to 0.19)
Depression subscale
Usual care 67 1.67 (0.65) 59 1.64 (0.61)
Memory rehabilitation 68 1.71 (0.59) 0.10 (–0.11 to 0.31) 69 1.77 (0.57) 0.13 (–0.08 to 0.34)
Communication subscale
Usual care 71 1.76 (0.65) 59 1.72 (0.59)
Memory rehabilitation 70 1.75 (0.58) 0.00 (–0.20 to 0.21) 69 1.80 (0.59) 0.04 (–0.17 to 0.26)
Difficulties with social interaction subscale
Usual care 71 1.95 (0.57) 59 1.85 (0.52)
Memory rehabilitation 67 1.97 (0.51) 0.05 (–0.13 to 0.23) 63 1.97 (0.56) 0.11 (–0.08 to 0.30)
Impulsivity subscale
Usual care 72 1.92 (0.61) 60 1.83 (0.56)
Memory rehabilitation 69 1.93 (0.55) NAa 68 1.97 (0.59) NAa
Somatic subscale
Usual care 69 1.95 (0.50) 56 1.79 (0.47)
Memory rehabilitation 68 1.97 (0.51) NAa 66 1.92 (0.54) NAa
Fatigue subscale
Usual care 70 2.01 (0.50) 59 1.92 (0.51)
Memory rehabilitation 68 1.97 (0.54) NAa 66 2.02 (0.55) NAa
NA, not applicable.
a Impulsivity, somatic and fatigue subscales summarised using descriptive statistics only, as per the SAP.
Note
EBIQ-r subscale scores range between 1 and 3, with higher scores indicating increased difficulties.
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Notable events
There were 11 notable events recorded during the trial: two occurred during contact with potential
participants before consent, four occurred during memory rehabilitation groups and five were reported
during follow-up visits.
The events reported during memory rehabilitation groups included issues with group dynamics, such as
disagreements between participants, which were addressed within the group sessions. The events reported
during follow-up included inappropriate behaviour exhibited by some participants towards the RA.
Protocol deviations
All reported protocol deviations were reviewed by the TMG prior to data lock. None was considered to
constitute a violation of the protocol.
RESULTS
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Chapter 4 Health economics
Introduction and aim
This chapter reports the methods and results of the economic evaluation conducted alongside the trial.
The aim was to assess the cost-effectiveness of the group-based memory rehabilitation programme
(the intervention) in addition to usual care compared with usual care alone. In line with NICE guidelines,84
a UK NHS and personal social services perspective was taken.
Methods
We took two approaches to the economic evaluation:
1. a within-trial evaluation to assess the cost-effectiveness of the group-based memory rehabilitation
programme compared with usual care based on the time horizon of the trial (12 months)
2. a decision-analytic model to estimate the cost-effectiveness of the group-based memory rehabilitation
programme compared with usual care over longer time periods.
A summary of the health economic analyses was set out in the trial protocol, with an agreed analysis plan
in place prior to data lock and commencement of the analysis.
Within-trial economic evaluation
The primary economic analysis was a cost–utility analysis (incremental cost per QALY gained) at 12 months
based on area under the curve (AUC) analysis. To present a comparable time point of interest with the clinical
analyses, we undertook additional analyses of the 6-month follow-up data. Secondary cost-effectiveness
analyses were undertaken to assess the incremental cost per point improvement based on the primary clinical
outcome (EMQ-p) and assessment of mood (GHQ-30) at the 6-month follow-up in order to reflect the primary
time point of interest, with additional consideration at the 12-month follow-up to reflect a comparison of
costs over potential maintenance of treatment gains over time. As the within-trial evaluation did not exceed
12 months, costs and outcomes were not discounted.
Resource use and costs
Resource use and associated costs were calculated across the following broad categories:
l the implementation and delivery of the group-based memory rehabilitation programme
l health and personal social care resource use.
All resource use data were valued in Great British pounds using published unit costs85–87 at 2016 prices. If a
2016 unit cost was not available, a unit cost from a previous version (e.g. an earlier edition of the Unit Costs of
Health and Social Care) was used and inflated to 2016 costs using the Bank of England inflation calculator.88
Costs associated with the implementation and delivery of the group-based memory
rehabilitation programme
We estimated the cost of implementation and delivery of the intervention during the trial using
information from the trial team and data obtained within the trial (e.g. number of participants). The key
resources and associated costs of delivering the intervention focused on the opportunity costs of:
l AP training to deliver the intervention
l delivery of the intervention by APs to trial participants.
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We assumed that, in standard clinical practice, the intervention would be delivered in a NHS setting, thus
the costs of travel and room hire and other capital costs were not included. Resources and associated costs
related to research and the management and administration of the trial were excluded. Costs of supplying
course booklets, stationery and refreshments were included. No provision for supervision was included in
the intervention cost. It was instead assumed that the costs and resources related to supervision were part
of standard clinical practice for the delivery of any intervention by APs.
The skill mix, time and grade of staff involved in delivering the intervention were obtained from information
collated by the trial team. These costs were aggregated to give a total cost, given the number of groups to
which participants were allocated and the number of sessions offered.
Individual-level resource use and associated costs within the group memory
rehabilitation programme
We assessed individual-level resource use using the SUQ, as previously described in Chapter 2. Resource
use was initially summated across each time point for each individual into discrete categories (primary care,
medication use within primary care, secondary care).
For primary care costs, we used published unit costs based on average contact times.85 We obtained NHS
net prices for medications from the British National Formulary (BNF).86 When the dosage and prescription
length were recorded by the participant, the cost of the medication was calculated. When the dosage or
prescription length was either not recorded by the participant or unclear, the cost of the standard adult
dosage as per the BNF was used. We calculated the cost of secondary care attendances by applying unit
costs from national published sources87 to the usage reported on the questionnaires. When possible for
inpatient admissions, the type of procedure and length of stay were matched and the national average
unit cost used. When no length of stay was stated, the lowest national average unit cost was used, based
on the lowest case-mix classification (CC) score (i.e. 0–1). As only a small number of participants did not
report any length of stay, this approach was preferred to a weighted cost approach, which would have
substantially overestimated the cost of service use contacts. When an unspecified or ambiguous visit to a
hospital was indicated, but no length of stay was stated, an average general surgery cost was used to
ensure that these contacts were appropriately captured.
Although the SUQ allowed participants to differentiate between resource use as a consequence of memory
problems and resource use for other reasons (e.g. other comorbidities), this information was not obtained for
medication use. We decided, in consultation with the trial team, that it would be difficult for participants to
classify resource use on the basis of whether it was for memory problems or for other problems. Therefore,
the decision was made to use total resource use (i.e. service use because of memory problems and for other
reasons) within the base-case analysis. Appropriate sensitivity analysis was undertaken to assess the impact
of including resource use attributed to memory problems only.
Resource use and costs were summated to give an overall cost for the memory rehabilitation arm (including
intervention costs) and usual-care arm over the trial period (12 months), with an interim assessment at the
6-month follow-up point also reported to reflect the time points of interest. The mean total cost and
difference in mean total cost (with 95% CIs) per participant between the memory rehabilitation arm and the
usual-care arm were compared using the two-tailed Student’s t-test, following the ITT principle.
A description of unit costs associated with service resource and medication use is presented in Appendices 20
and 21, respectively.
Health utilities and quality-adjusted life-years
Health-related quality-of-life data were collated using the EQ-5D-5L questionnaire, as described in Chapter 2.
The reported EQ-5D-5L values were used to derive utilities based on the UK social tariff.89 Individual-level
utility scores across each assessment point were summated for the memory rehabilitation and usual-care
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arms, with QALYs for each patient calculated based on the utility scores at different points using the AUC
approach. We assumed linear interpolation between the measurement points.
Summary statistics across each time point were used to describe and compare QALYs between the two arms
from baseline to 12 months for the primary analysis, with additional analysis to derive QALYs from baseline
to the 6-month follow-up. The impact of a baseline imbalance in utilities was examined, with adjusted
analyses on similar covariates (baseline score, treatment arm and site) undertaken, commensurate with the
statistical analysis methods of the clinical outcomes. Mean utilities and QALYs gained per participant were
evaluated between the memory rehabilitation arm and the usual-care arm using the difference-in-difference
approach and compared using the Student’s t-test.
Clinical outcomes
The primary outcome data (EMQ-p) and GHQ-30 scores were analysed with the difference in scores
(points) calculated (as described in Chapter 2) at the 6-month follow-up (as per the primary clinical analysis)
and at 12 months (to assess whether an improvement was maintained over time). The analysis of the
EMQ-p is commensurate with the clinical analysis, with a difference-in-difference approach adopted to
determine the incremental effect of the intervention compared with usual care. For the analysis of the
GHQ-30, the GHQ-30 (0–0–1–1) scoring methodology was applied. This differs from the clinical analysis,
which adopted the Likert (0–1–2–3) scoring methodology. Higher scores on the EMQ-p are indicative of
more frequent memory problems and higher scores on the GHQ-30 are indicative of greater psychological
distress. Therefore, ‘improvement’ over time would be characterised by a decreasing score.
Missing data
The problems concerning missing data are particularly relevant to health economic analysis as missing items
relating to health-care service usage may undervalue the total costs, whereas missing outcome data may be
correlated with effects, as those individuals without information may be systematically different from those
for whom all information is observed.90 A complete case analysis would therefore result in meaningful data
being excluded.90 We therefore adopted appropriate techniques to provide a comprehensive investigation of
the impact of missing data on our estimations of cost-effectiveness.
For the questionnaires used within the economic analysis (i.e. EQ-5D-5L, EMQ-p and GHQ-30) we followed
the same rules for missing data as applied to the analysis of clinical outcomes (see Chapter 2). To ensure
that comparable consideration was given to missing data in relation to the SUQ, we devised similar rules
with the trial team.
For both costs and outcomes, two imputation methods were used for the health economic analysis. Simple
imputation using the site-specific treatment arm mean and MICE were undertaken on costs and outcomes
for both the 6-month follow-up and the 12-month follow-up to impute missing items. Mean imputation
provides a single estimate for each missing item. However, it is unable to account for the uncertainty inherent
in missing data, resulting in a smaller standard error (SE), and can result in biased estimates because of
covariance and correlations being decreased in magnitude compared with alternative methods. The multiple
imputation method used was similar to the imputation of the primary outcome data performed, that is,
chained equations were undertaken separately for each allocated arm under the assumption that data were
missing at random, using similar predictor variables (with baseline EQ-5D-5L score used) with similar data sets
included and results of imputed sets combined following Rubin’s rules.91 Because of the typically skewed
distribution of cost data, predictive mean matching was used. Missing outcome data were imputed using
truncated regression to restrict imputed scores to the range of valid scores for each outcome.
For the base-case cost-effectiveness analyses, we used the multiply imputed data to construct incremental
cost-effectiveness ratios (ICERs). The non-imputed and mean imputed data are presented to fully reflect
the impact on the base-case ICERs when different scenarios for missing data are considered.
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Incremental-cost-effectiveness analysis
As summarised in the description of the within-trial evaluation, a series of cost-effectiveness analyses were
undertaken, with a cost–utility analysis undertaken as the primary analysis. This comparative analysis of
incremental costs and effects can be summarised in terms of an ICER.
The ICER can be represented as:
ICER =
C1− C0
E1− E0
=
ΔC
ΔE
, (1)
where C1 and E1 are the costs and effects of the memory rehabilitation arm, respectively; C0 and E0 are the
costs and effects of the usual-care arm, respectively; and ΔC and ΔE are the incremental costs and effects
of the intervention compared with usual care.
The ICER is reported to determine the cost-effectiveness of the intervention compared with competing
alternatives and to aid decision-making. Although NICE84 reports a base cost-effectiveness threshold of
£20,000 per QALY, cost-effectiveness is a spectrum rather than a dichotomy, with the maximum threshold
increasing dependent on circumstances. The reported ICERs from our analysis are presented to assist the
decision-making process and are not an absolute statement on whether the intervention can be deemed
cost-effective.
We also calculated net monetary benefits (NMBs) based on the following equation:
NMB = ΔEλ –ΔC. (2)
The NMB represents the value of the intervention in monetary terms given a willingness-to-pay (WTP)
threshold, λ.91 When the incremental NMB, calculated as the difference in NMB between the intervention
and usual care, is positive, the intervention is identified as cost-effective at the given threshold, relative to
usual care.92
For the cost-effectiveness analyses (i.e. incremental cost per point improvement in EMQ-p and GHQ-30
scores), no accepted WTP threshold could be identified. However, as the WTP threshold is based on
important end points of relevance and importance to the assessment of the effect of memory problems,
decision-makers and clinicians can judge the results against different thresholds as part of a full examination
of cost-effectiveness.
Sensitivity analysis
A series of one-way sensitivity analyses were undertaken to assess the impact of parameter and methodological
uncertainty on the estimates of cost-effectiveness. For primary and secondary outcomes, we assessed the
impact on the base-case ICER of altering key parameters (i.e. costs, QALYs and outcomes scores) based on
lower and upper 95% CIs for incremental costs and outcomes.
We also assessed the extent of uncertainty based on imputation method, as documented earlier. Scenario
analysis was conducted to ascertain the potential impact of changes to input parameters (as measured by
the EMQ-p and GHQ-30) on the base-case ICER. Sensitivity analyses of the intervention cost were
conducted on the available data case analysis.
Bootstrapping was undertaken to address the joint uncertainty and impact on the ICER; 1000 simulations
were undertaken using random sampling of the distributions of costs and outcomes, presented on a
cost-effectiveness plane. The cost-effectiveness plane is presented as a scatterplot of the point estimates
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obtained as a result of the 1000 runs depicted in four quadrants (see Appendix 22), which can be
summarised as follows:
1. North-west (upper-left) quadrant – the intervention is dominated by usual care. The intervention is more
costly and less effective than usual care.
2. North-east (upper-right) quadrant – further evaluation required. The intervention is more costly and
more effective than usual care. The ICER is computed to assess whether the net incremental health gain
is worth the incremental cost.
3. South-west (lower-left) quadrant – further evaluation required. The intervention is less costly and less
effective than usual care. The ICER is computed to assess whether the cost saving is worth the net
incremental health loss.
4. South-east (lower-right) quadrant – the intervention is dominant compared with usual care and
unambiguously preferred to usual care. The intervention is less costly and more effective than
usual care.
For consistency with the cost-effectiveness plane for QALYs, the incremental effect for the EMQ-p and GHQ-30
was reversed (i.e. multiplied by –1) such that a positive value was representative of an improvement in everyday
memory or mood. Cost-effectiveness acceptability curves (CEACs) were produced to present the probability
of the intervention being considered cost-effective at alternative WTP thresholds. For the cost per QALY
CEAC, the WTP threshold based on NICE guidance84 was used. No similar WTP threshold exists for the
clinical outcomes.
Long-term cost-effectiveness
We constructed a decision-analytic model to extrapolate the findings from the trial to estimate the
cost-effectiveness of the group-based memory rehabilitation programme compared with usual care beyond
the trial horizon of 12 months. A cost–utility analysis was undertaken. We based the modelling exercise on
extrapolating results from the within-trial analysis to longer-term cost per QALY estimates, supplemented
with data sources from the literature and, when necessary, clinical opinion from the trial team.
Modelling approach
We developed a Markov model given that TBIs are considered to have a disease and treatment pathway
consistent with chronic health conditions (e.g. with evolving progression of the condition over time). The
decision-analytic Markov model was developed using Microsoft Excel® 2013 with coding in Visual Basic for
Applications (Microsoft Corporation, Redmond, WA, USA). The Markov model simulated costs and QALYs
over a minimum 5-year time horizon using four mutually exclusive health states (low, moderate, high and
death). As the time horizon exceeded 12 months we discounted all future costs and QALYs at the UK
Treasury discount rate of 3.5% per year, as recommended by NICE.84
The cost and utility data reported at the 12-month follow-up within the trial were used alongside external
data such as UK life tables and standard mortality ratios to estimate longer-term costs and QALYs. Time
horizons of 5 and 10 years were chosen for the analysis although the model was constructed to undertake
a lifetime horizon should suitable data be available in the future. Although this was an amendment from
the original protocol, in which a lifetime horizon was proposed, we chose this approach (1) based on the
availability of plausible estimates of longer-term effects from external literature sources and (2) because,
when necessary, appropriate clinical assumptions could be made by the trial team.
We categorised psychological distress into three mutually exclusive states of no/mild distress, moderate
distress and severe distress, pro-rating the categories defined by Rai et al.93 for the GHQ-12 to the GHQ-30
as follows:
l GHQ-30 scores of < 5.5 were classified as no/mild distress
l GHQ-30 scores between 5.5 and 17.5 were classified as moderate distress
l GHQ-30 scores of ≥ 17.5 were classified as severe distress.
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Participants could also transition to a fourth state of death, which is an absorbing state with participants
unable to transition out of this state.
Model structure
The basic outline of the Markov model used to evaluate the longer-term cost-effectiveness of the
intervention is illustrated in Appendix 23. For the memory rehabilitation and usual-care arms, separate
Markov processes with different input parameters were obtained. The same structure, depicted in
Appendix 23, would, however, apply.
We assumed that the sample adhered to the trial protocol. For each 6-month cycle, individuals were
categorised into one of three mood states based on their GHQ-30 score or into the absorbing death
state. We assumed that psychological distress in individuals with TBI can either worsen or improve, that is,
the GHQ-30 score could either increase or decrease from the value observed at the previous time point.
Moreover, transitions from the high mood state to the low mood state (or vice versa) were permitted in
addition to sequential transitions, that is, high to moderate to low. Aside from death, we assumed
that there were no intervention-related adverse events that impacted on an individual’s state of
psychological distress.
Model inputs
The base-case analysis was estimated using a cohort of 10,000 patients. The population was consistent
with the trial, that is, men represented 72% of the model cohort and the mean age at entry was 45 years.
Base-case transition probabilities were defined by those observed in the trial between baseline and
6 months’ follow-up and between 6 months’ and 12 months’ follow-up. For intervals beyond the 12-month
within-trial horizon, we assumed that the 6-month to 12-month transition probabilities would persist at
intervals beyond 12 months. This assumption was made because of a lack of published data beyond the
12-month follow-up.
To account for missing items observed in the trial, mean imputed data were used, despite the limitations
highlighted earlier, to provide a single transition for each individual and prevent scenarios in which an
individual occupied multiple states at a given time point. This provided a single set of transition probabilities
at each time point. Sensitivity analysis was conducted to determine how changes in transition probabilities
influenced the ICER.
Details of the model parameters used are presented in Appendix 24. A summary of the base-case model
inputs and one-way sensitivity analyses is presented in Table 13.
TABLE 13 Base-case model inputs and one-way sensitivity analyses
Parameter Lower Base case Upper
Age (years) 30 45 65
Discount rate (%) 1.5 3.5 5.0
Intervention cost (£) 116.90 167 217.10
Cost per cycle in GHQ-30 state –30% Various (state dependent) + 30%
Utility per cycle in GHQ-30 state –30% Various (state dependent) + 30%
Transition probability to lower GHQ-30 state –20% Various (state dependent) + 20%
Transition probability to higher GHQ-30 states –20% Various (state dependent) + 20%
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Clinical/epidemiological inputs
No deaths were reported in the trial. We therefore assumed that patients would not be at an increased
risk of death from the intervention. Additionally, the model did not include any provision for the
occurrence of serious adverse events, as these were not assessed within the trial. In the model, all-cause
age-related mortality rates were obtained from the Office for National Statistics (ONS),94 based on mid-year
population estimates for 2013–15. Considering that individuals with a TBI are recognised to have a higher
all-cause mortality rate and shorter life expectancy than the general population,93,95 we adjusted the
general population mortality using the TBI standardised mortality ratio (SMR) presented by Brooks et al.96
Costs
All costs were based on the within-trial costs reported (see Appendix 25). Costs associated with each
health state defined by the model included the costs relating to delivery of the intervention and any
health-care service usage recorded by participants over the preceding 6-month interval. For cycles beyond
the in-trial 12-month horizon, costs were assumed to be the same as for the 6- to 12-month cycle.
No provision was made in the model for any top-up sessions relating to the intervention.
Utilities
The model applied different utility values to each of the non-dead health states, differentiated by trial arm.
In accordance with the manner in which costs were handled, all utilities were based on those observed in
the within-trial analysis reported. For cycles beyond the within-trial 12-month horizon, utilities were
assumed to be the same as for the 6- to 12-month cycle.
Incremental cost-effectiveness ratio
Incremental cost-effectiveness ratios were calculated as in the within-trial analysis, based on a 5- and
10-year time horizon. As this was a cost–utility analysis, we applied the same approach as in the
assessment of the base-case results against the WTP threshold set out by NICE.84
Sensitivity analysis
Similar sensitivity analyses were conducted as outlined for the within-trial evaluation.
We conducted a series of one-way sensitivity analyses by manipulating the values of the main parameters
in the model (i.e. costs, QALYs and transition probabilities) and assessing the subsequent impact on the
ICER. Table 13 presents a list of the one-way sensitivity analyses conducted.
In general, the upper and lower values of the input parameters were arbitrarily chosen, but were considered
appropriate given the uncertainty inherent in the parameter values. The lower discount rate of 1.5% is
consistent with NICE guidelines.84 Costs and QALYs were discounted at the same rate under all scenarios.
Sensitivity analyses on transition probabilities also affect the probability that an individual remains within
their current state; however, they do not affect the probability of transitioning to the death state.
To account for the simultaneous uncertainty regarding the input parameters, a probabilistic sensitivity
analysis was conducted. Cost-effectiveness planes and CEACs illustrating the probability that the
intervention is cost-effective across a range of threshold values were produced.
Results
Intervention cost
The resource use involved in delivering the intervention and associated costs are summarised in Table 14,
with a detailed account of each component presented in Appendix 25. The total cost of memory
rehabilitation per participant was £167.
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The first resource-intensive component was AP training in the memory rehabilitation programme.
One clinical psychologist (based on NHS Agenda for Change grade 8a) delivered the training across all
sites. We did not include any travel costs as training would occur on site in standard practice. In addition,
the opportunity cost of each of the APs attending the training was included, with costs estimated using
published unit costs.85 The training involved a one-off session. Ongoing monitoring/supervision of the APs
during the trial (one-to-one supervision between the AP and the clinical psychologist) was considered part
of standard clinical practice. Sensitivity analysis was conducted to determine the impact of the addition of
supervision on the intervention cost and the resulting ICERs.
The second component was the delivery of the intervention by the APs across the trial sites. This was
based on the 171 participants randomised to the memory rehabilitation arm, each of whom was allocated
to one of 35 groups of four to six individuals across the nine sites involved in the trial. Each group that
received the intervention was invited to attend 10 sessions, giving a total of 350 sessions. We made the
assumption that the costs of delivery would be the same for each session, regardless of attendance, for
example even if participants withdrew or did not attend. We assumed that the delivery of one 90-minute
session required 2 hours of time from the AP, inclusive of session preparation. Administrative support was
also included for 1 hour per group in total for the 10 sessions delivered.
Resource use and costs
The resource use and associated costs for available cases is summarised in Appendix 26 with summary of
costs presented in Table 15. We observed that visits to primary care services and use of inpatient services
are the primary cost drivers for both the memory rehabilitation and usual-care arms. The number of
participants with inpatient appointments for either arm at each time point is small (< 10%), yet costs
attributed to these contacts are high with a maximum of £9444. In contrast, a much higher proportion
(> 65%) report costs associated with visits to primary care or medication; however, these costs are typically
much lower yet more frequent. The costs per patient associated with resource use in the memory
rehabilitation and usual-care arms across the time points are summarised in Table 15.
The total mean cost per participant was £1449 (SE £199.19) and £1185 (SE £202.22) for the memory
rehabilitation and usual-care arms, respectively. The aggregate service use cost was £84 (95% CI £302.35
to £469.59) higher for the memory rehabilitation arm than for the usual-care arm. Including the cost of
the intervention, the memory rehabilitation arm had a higher total cost than the usual-care arm of £251
(95% CI –£135.35 to £636.59) at 12 months and £30 (95% CI –£340.62 to £400.85) at 6 months.
Impact of missing data on cost estimations
Service use questionnaire data were obtained for 98.8% of participants at baseline (see Appendix 27).
However, at the 6- and 12-month follow-ups, questionnaires were missing for approximately 20% and
29% of participants, in each arm, respectively, with more missing data in the usual-care arm (36%) than
TABLE 14 Resources and costs associated with training and delivery of the intervention
Resource Total (£)
Training costs (nine sites) 1818
Administration costs (35 groups) 875
Session costs (350 sessions) 24,500
Participant costs (171 participants) 1402
Total cost 28,595
Cost per participant (171 participants) 167
HEALTH ECONOMICS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
44
in the memory rehabilitation arm (29%) at the 12-month follow-up. The planned approach to missing data
was subsequently adopted.
Although numerical differences between the trial arms were seen depending on the imputation method
used, there was no statistically significant impact on the total costs, with the memory rehabilitation arm
showing a higher total mean cost per participant at the 12-month follow-up. With the inherent issues
associated with skewed costs, imputed costs were subsequently bootstrapped to derive means and 95% CIs
to be used in the base case (Table 16).
Outcomes
EuroQol-5 Dimensions five-level version utilities
The EQ-5D-5L utility scores and QALY increments, based on AUC analysis, across the trial assessment
points, based on the available cases for the memory rehabilitation and usual-care arms, are presented in
Table 17.
TABLE 15 Non-imputed (available cases) cost summary by trial arm
Group Cost (£), mean (SD) 95% CI (£)
Difference in mean
costs (£) (95% CI)a p-value
Baseline
Usual care (n= 155) 453.325 (849.822) 318.480 to 588.171 45.990
(–171.671 to 263.652)
0.697
Memory rehabilitation
(n= 170)
499.315 (1112.967) 330.805 to 667.826
6 months
Usual care (n= 111) 587.123 (1543.587) 297.903 to 876.344 –255.336
(–362.273 to –148.398)
< 0.001***
Memory rehabilitation
(n= 120)
328.078 (687.450) 203.816 to 452.339
12 months
Usual care (n= 101) 355.034 (824.026) 195.565 to 514.504 18.353
(–24.782 to 61.488)
0.403
Memory rehabilitation
(n= 121)
372.092 (824.026) 211.335 to 532.848
Total service resource usage costs up to 12 months (excluding intervention cost)
Usual care (n= 93) 1184.905 (1877.947) 811.303 to 1584.820 83.624
(–302.345 to 469.593)
0.670
Memory rehabilitation
(n= 103)
1281.685 (2001.812) 890.452 to 1672.919
Total costs up to 12 months (including intervention cost)
Usual care (n= 87) 1184.905 (1877.947) 782.903 to 1586.908 250.624
(–135.345 to 636.593)
0.202
Memory rehabilitation
(n= 102)
1449.329 (2001.812) 1054.196 to 1844.461
Total costs up to 6 months (including intervention cost)
Usual care (n= 110) 1002.020 (1537.326) 610.984 to 1393.056 30.113
(–340.619 to 400.845)
0.873
Memory rehabilitation
(n= 119)
1026.477 (2052.678) 746.240 to 1306.714
*** Significant at 1% level.
a Controlling for baseline service usage costs as a covariate.
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TABLE 16 Base-case (multiple imputed) cost used in the cost-effectiveness analyses
Group Mean (SE) 95% CI Difference (SE)
p-value of
difference
Baseline
Usual care (n = 157) 456.152 (70.206) 317.402 to 594.902 44.447 (111.880) 0.691
Memory rehabilitation (n = 171) 500.599 (85.388) 332.019 to 669.178
6 months
Usual care (n = 157) 576.071 (126.547) 325.267 to 826.875 –247.060 (138.067) 0.075
Memory rehabilitation (n = 171) 329.011 (63.367) 203.293 to 454.729
12 months
Usual care (n = 157) 391.396 (86.106) 220.008 to 562.784 8.718 (116.615) 0.941
Memory rehabilitation (n = 171) 400.115 (80.789) 239.918 to 560.311
Total service resource usage costs up to 12 months (excluding intervention cost)
Usual care (n = 157) 1423.619 (197.761) 1031.972 to 1815.265 –193.894 (249.157) 0.437
Memory rehabilitation (n = 171) 1229.724 (154.178) 924.911 to 1534.538
Total costs up to 12 months (including intervention cost)
Usual care (n = 157) 1423.619 (197.761) 1031.972 to 1815.265 –26.894 (249.157) 0.914
Memory rehabilitation (n = 171) 1396.724 (154.178) 1091.910 to 1701.538
Total costs up to 6 months (including intervention cost)
Usual care (n = 157) 1032.222 (165.900) 703.941 to 1360.504 –35.613 (201.227) 0.860
Memory rehabilitation (n = 171) 996.610 (119.018) 761.459 to 1231.760
TABLE 17 EuroQol-5 Dimensions, five-level version, utilities and QALYs gained at 6 and 12 months’ follow-up
(available cases)
Time point
Trial arm
Adjusted
differencea
(95% CI)
Usual care Memory rehabilitation
EQ-5D-5L
score, mean
(SD)
Change over
time (95% CI)
EQ-5D-5L
score, mean
(SD)
Change over
time (95% CI)
Baseline 0.581 (0.275)
(n= 157)
0.637 (0.266)
(n= 171)
6 months 0.581 (0.299)
(n= 119)
–0.020
(–0.063 to 0.024)
0.642 (0.269)
(n= 128)
–0.007
(–0.047 to 0.033)
0.060
(0.015 to 0.105)
12 months 0.625 (0.253)
(n= 123)
–0.001
(–0.043 to 0.041)
0.644 (0.264)
(n= 106)
–0.010
(–0.047 to 0.027)
0.019
(–0.026 to 0.063)
QALY gain at 6 months
(95% CI)
–0.005
(–0.016 to 0.006)
–0.002
(–0.012 to 0.008)
0.003
(–0.002 to 0.008)
QALY gain at 12 months
(95% CI)
0.000
(–0.011 to 0.010)
–0.002
(–0.012 to 0.007)
–0.004
(–0.016 to 0.007)
a Controlling for baseline utility as covariate.
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At 6 months, small QALY losses were observed for both arms; the incremental QALY gain of 0.003 in
the memory rehabilitation arm compared with the usual-care arm was not significant at the 5% level
(p = 0.154). At 12 months, small QALY loses were observed, with a small incremental QALY gain of 0.004
in the usual-care arm compared with the memory rehabilitation arm, which was not significant at the 5%
level (p = 0.743). The incremental QALY gains calculated from the mean imputed and multiply imputed
data are analogous to those calculated from the available cases presented above, with a small gain for the
memory rehabilitation arm at 6 months and a small gain for the usual-care arm at 12 months.
Impact of missing data
There was 100% completion of the EQ-5D-5L questionnaire at baseline, with the number of missing data
increasing at 6 months and 12 months across both arms. No clear pattern of missing data was evident.
Most participants who missed one follow-up assessment had another follow-up assessment available.
A descriptive profile of EQ-5D-5L questionnaire completion is presented in Appendix 28.
When the EQ-5D-5L utility and subsequent QALY gains were examined using the imputation methods,
there were no statistically significant differences in within-group utility scores or between-group QALY
gains at either the 6-month follow-up or the 12-month follow-up. Table 18 presents the results based on
multiple imputation; the results of the mean imputation are presented in Appendix 29.
Similar to the results presented in Table 17, there was a small QALY loss in both arms at 6 months’ follow-up
(memory rehabilitation: –0.003, 95% CI –0.013 to 0.007; usual care: –0.007, 95% CI –0.0018 to 0.004).
At the 12-month follow-up, this translated into a small QALY gain in the usual care arm (0.004, 95% CI –0.017
to 0.025) compared with a small QALY loss in the memory rehabilitation arm (–0.007, 95% CI –0.025 to 0.012).
These differences did not reach statistical significance, with p-values of 0.536 and 0.442 at 6 months and
12 months, respectively.
Clinical outcomes
The EMQ-p scores used for the health economic analyses are presented in Tables 7 and 10 and the
per-point improvements at the 6- and 12-month follow-ups for the GHQ-30 are presented in Table 19.
There was an improvement in everyday memory at both the 6-month follow-up and the 12-month follow-up
compared with baseline for both arms of the trial, but the difference between arms was not statistically
significant at the 5% level.
Although there was a significant difference between arms in GHQ-30 scores at 6 months, with the
memory rehabilitation arm having a greater reduction in mood score, there was no significant difference in
EMQ-p scores at either follow-up or in GHQ-30 scores at 12 months. The finding of a significant difference
TABLE 18 EuroQol-5 Dimensions, five-level version, scores and QALYs gained over time (6 and 12 months) based on
multiple imputation
Time point
Trial arm
Usual care (n= 157) Memory rehabilitation (n= 171)
EQ-5D-5L
score, mean
Change over
time (95% CI)
EQ-5D-5L
score, mean
Change over
time (95% CI)
Baseline 0.581 0.637
6 months 0.553 –0.028
(–0.071 to 0.015)
0.625 –0.012
(–0.050 to 0.027)
12 months 0.589 0.008
(–0.034 to 0.051)
0.624 –0.013
(–0.050 to 0.023)
QALY gain at 6 months (95% CI) –0.007 (–0.018 to 0.004) –0.003 (–0.013 to 0.007)
QALY gain at 12 months (95% CI) 0.004 (–0.017 to 0.025) –0.007 (–0.025 to 0.012)
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at 6 months in the GHQ-30 score differs from the findings of the statistical analysis of clinical outcomes.
This is because of the use of GHQ-30 scoring in the health economic analysis, rather than the Likert
scoring used in the analysis of clinical outcomes.
Impact of missing data
There were missing data within the questionnaires at each of the follow-up assessments. When the
imputation methods were examined, numerical differences were seen but these did not demonstrate any
statistically significant differences between the trial arms. The results using the multiply imputed data are
presented in Table 20 and mean imputations for the EMQ-p and GHQ-30 are reported in Appendices 30
and 31, respectively.
Reductions in the multiply imputed EMQ-p score were observed for both the memory rehabilitation arm
and the usual-care arm at 6 and 12 months’ follow-up. These results are commensurate with those
presented in the analysis of clinical outcomes. The difference was not statistically significant at either
6 months’ (p = 0.297) or 12 months’ (p = 0.560) follow-up.
TABLE 20 The EMQ-p and GHQ-30 scores: multiple imputation
Time point
Trial arm
Difference,
p-value
Usual care (n= 157) Memory rehabilitation (n= 171)
Mean (SD) score
Change over time
(95% CI) Mean (SD) score
Change over time
(95% CI)
EMQ-p
Baseline 50.075 (1.953) 47.363 (1.606)
6 months 45.622 (2.165) –4.453
(–7.756 to –1.149)
40.589 (2.061) –6.774
(–9.732 to –3.817)
0.297
12 months 44.370 (2.248) –5.705
(–9.118 to –2.292)
40.248 (2.112) –7.115
(–10.442 to –3.788)
0.560
GHQ-30
Baseline 9.601 (0.646) 9.670 (0.613)
6 months 9.901 (0.771) 0.300
(–1.127 to 1.727)
8.972 (0.683) –0.698
(–2.065 to 0.669)
0.320
12 months 10.143 (0.944) 0.542
(–1.324 to 2.409)
9.474 (0.771) –0.195
(–1.763 to 1.372)
0.551
TABLE 19 The GHQ-30 scores at the 6- and 12-month follow-ups
Time point
Trial arm
Adjusted
differencea
(95% CI)
Usual care Memory rehabilitation
GHQ-30 score,
mean (SD)
Change over
time (95% CI)
GHQ-30 score,
mean (SD)
Change over
time (95% CI)
Baseline (n = 157) 9.6 (8.1) 9.7 (8.0)
6 months (n= 110) 9.1 (8.4) 0.0 (–1.3 to 1.4) 8.6 (8.1) –1.2 (–2.7 to 0.2) –1.2 (–2.1 to –0.3)
12 months (n= 103) 8.2 (8.1) –0.4 (–2.1 to 1.3) 8.4 (8.8) –1.1 (–2.7 to 0.5) –0.7 (–1.7 to 0.4)
a Controlling for baseline covariates.
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For the GHQ-30 score, although a reduction was observed in the memory rehabilitation arm at both 6 and
12 months’ follow-up relative to baseline, an increase was observed relative to baseline in the usual-care
arm at both time points. This indicates an improvement in mood for the memory rehabilitation arm
compared with a worsening in mood for the usual-care arm. There was a worsening in mood for both the
memory rehabilitation arm and the usual-care arm between the 6-month follow-up and the 12-month
follow-up. Despite using the GHQ (0–0–1–1) scoring rather than the Likert (0–1–2–3) scoring, these results
are broadly comparable to the clinical outcomes, with no statistically significant difference in GHQ score
within or between arms at either the 6-month follow-up or the 12-month follow-up.
Incremental cost-effectiveness analyses
The results of the cost–utility analysis are presented in Table 21. This presents the ICERs calculated using
the available cases and multiple imputation approaches.
The base-case analysis (incremental cost per QALY gained at 12 months, based on multiple imputation)
showed the intervention to be slightly less effective but less costly than usual care, with a reported ICER
of £2445. At 6 months the intervention was found to dominate usual care, with slightly lower costs and
slightly higher QALYs, but these were not statistically significant. Uncertainty was seen in these findings as
the results changed at 12 and 6 months, depending on the imputation method used.
Incremental cost per point improvement in EMQ-p and GHQ-30 scores at 6 and
12 months
Table 22 presents the ICERs for the EMQ-p and GHQ-30, respectively. As higher scores in the EMQ-p represent
more frequent forgetting in daily life, and higher scores in the GHQ-30 indicate more psychological distress,
negative incremental effects will be observed where the intervention is more effective than usual care. To
calculate appropriate ICERs consistent with those for the EQ-5D-5L presented above, the denominator of the
equation presented earlier is multiplied by –1.
For both the EMQ-p and the GHQ-30, in the primary analysis based on multiply imputed data at 12 and
6 months, the intervention dominated usual care because of non-statistically significant lower costs and
improved EMQ-p and GHQ-30 scores. Again, uncertainty arises, with the results varying based on the
imputation method used.
TABLE 21 Incremental cost per QALY gained at the 6- and 12-month follow-ups
Imputation
method
Incremental
ICER (£) NMBa (£) NMBb (£)Cost (£) Effect
12 months
Multiply imputed –26.895 –0.011 2445 (SW quadrant, further investigation
required)
–193.10 –303.10
Available cases 250.62 –0.004 –62,656 (NW quadrant, usual care dominant) –330.62 –370.62
Mean imputed –26.197 –0.023 1139 (SW quadrant, further investigation
required)
–443.80 –663.80
6 months
Multiply imputed –35.612 0.004 –8903 (SE quadrant, intervention dominant) 115.61 155.61
Available cases 30.11 0.003 10,038 (NE quadrant, further investigation)
required
29.89 59.89
Mean imputed –38.146 0.001 –38,146 (SE quadrant, intervention dominant) 58.15 68.15
NE, north-east; NW, north-west; SE, south-east; SW, south-west.
a NMB at WTP threshold of £20,000.
b NMB at WTP threshold of £30,000.
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Sensitivity analysis
Sensitivity analysis using the upper and lower 95% CI bounds for the primary cost per QALY gained analysis
is presented in Appendix 32. For two of the four scenarios, the intervention was dominated by usual care
(higher costs and smaller effects for the intervention), namely when the upper 95% CI for both costs and
outcomes was used and when the upper bound for costs was compared with the lower bound for QALYs.
In summary, the results suggest that the findings are not robust to changes in these parameters.
A further sensitivity analysis (based on available cases) was conducted on the intervention cost by including
the costs of AP supervision by a clinical psychologist. Based on the recommendations for good practice
presented by the British Psychological Society,97 we assumed that a minimum of three one-to-one supervision
sessions of 1 hour were required at each site for the 10 weekly sessions. For a band 8a clinical psychologist
at £66 per hour and a mid-band 5 AP at £35 per hour,85 a total of £2727 is incurred in addition to the total
cost of rehabilitation presented in Table 14. The effect on the total cost and the ICER is presented in
Table 23.
Taking into account these changes to the intervention cost, the intervention was found to be dominated
by usual care at 12 months; at 6 months the ICER was £18,771 per QALY gained (Table 24).
TABLE 22 Incremental cost-effectiveness: EMQ-p and GHQ-30 at 6 and 12 months
Imputation method
Incremental
ICER (£)Cost (£) Effect
12 months
EMQ-p
Multiply imputed –26.895 –1.4 –19.07 (SE quadrant, intervention dominant)
Available cases 250.62 –4.8 52.21 (NE quadrant, further investigation required)
Mean imputed –26.197 –2.5 –10.58 (SE quadrant, intervention dominant)
GHQ-30
Multiply imputed –26.895 –0.7 –36.49 (SE quadrant, intervention dominant)
Available cases 250.62 –0.2 1253.10 (NE quadrant, further investigation required)
Mean imputed –26.197 0.4 70.23 (SW quadrant, further investigation required)
6 months
EMQ-p
Multiply imputed –35.61 –2.3 –15.34 (SE quadrant, intervention dominant)
Available cases 30.11 –2.1 14.34 (NE quadrant, further investigation required)
Mean imputed –38.146 –1.4 –27.36 (SE quadrant, intervention dominant)
GHQ-30
Multiply imputed –35.61 –1.0 –35.68 (SE quadrant, intervention dominant)
Available cases 30.11 –1.6 18.82 (NE quadrant, further investigation required)
Mean imputed –38.146 –0.2 –205.09 (SE quadrant, intervention dominant)
NE, north-east; NW, north-west; SE, south-east; SW, south-west.
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The results of the bootstrapped replications are presented as a cost-effectiveness plane and corresponding
CEAC for the primary cost–utility analysis (cost per QALY). As the multiply imputed base case for the
EMQ-p and GHQ-30 at both 6 months and 12 months, presented in Table 22, indicates dominance of the
intervention (lower cost and higher effects than usual care), cost-effectiveness planes and CEACs are not
presented for the secondary cost-effectiveness analyses. The cost-effectiveness plane for cost per QALY gained
is presented as a scatterplot of the point estimates obtained from the 5000 runs, depicted as quadrants
(north-east, south-east, south-west and north-west), as illustrated in Appendix 22. The CEAC graph shows
the probability of the intervention being considered cost-effective at different monetary thresholds.
Figures 2 and 3 present the cost-effectiveness plane and CEAC for the incremental cost per QALY gained
at 12 months, respectively.
Figure 2 characterises the uncertainty in the cost-effectiveness analysis, with point estimates distributed across
all four quadrants. The largest proportion of estimates is located in the south-west quadrant, consistent with
the intervention being less costly and less effective than usual care. The associated CEAC in Figure 3 shows
that, at a threshold value of ≤ £30,000 per QALY gained, the probability that the intervention is cost-effective
is 24.5%. At a threshold of £20,000 per QALY gained, the probability of cost-effectiveness is 29.0%. The
cost-effectiveness plane and corresponding CEAC for the additional analysis at 6 months are presented in
Figures 4 and 5, respectively.
TABLE 24 Incremental cost-effectiveness with inclusion of supervision in the intervention cost
Imputation
method
Incremental
ICER (£) NMBa (£) NMBb (£)Cost (£) Effect
12 months
Available cases 275.54 –0.004 –68,885 (NW quadrant, usual care dominant) –355.54 –395.54
6 months
Available cases 56.313 0.003 18,771 (NE quadrant, further investigation required) 3.687 33.687
NE, north-east; NW, north-west.
a NMB at WTP threshold of £20,000 per QALY gain.
b NMB at WTP threshold of £30,000 per QALY gain.
TABLE 23 Cost summary with inclusion of supervision in the intervention cost
Group Cost (£), mean (SD) 95% CI (£)
Difference in mean
costs (£) (95% CI)a p-value
Total costs up to 12 months (including intervention cost)
Usual care (n= 88) 1184.905 (857.282) 782.903 to 1586.908 275.539
(–70.275 to 678.959)
0.111
Memory rehabilitation (n = 102) 1460.444 (1678.229) 1130.808 to 1790.079
Total costs up to 6 months (including intervention cost)
Usual care (n= 110) 1002.020 (1190.572) 610.984 to 1393.056 56.313
(–314.273 to 426.898)
0.765
Memory rehabilitation (n = 119) 1040.160 (1634.991) 743.358 to 1336.962
a Controlling for baseline service usage costs as a covariate.
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In accordance with the 12-month results presented in Figure 2, at 6 months the cost-effectiveness plane
presented in Figure 4 further demonstrates the uncertainty inherent in the cost-effectiveness results, with
all four quadrants populated. In contrast to the 12-month analysis, the largest proportion of estimates is
located in the south-east quadrant, consistent with the intervention being less costly and more effective
than usual care; the intervention dominates usual care. The incremental effect is, however, small. The
associated CEAC presented in Figure 5 illustrates that, at a WTP threshold of £20,000 per QALY gained,
the intervention has a 68.1% probability of being cost-effective. At a higher WTP threshold of £30,000 per
QALY gained, the intervention has a 70.6% probability of being cost-effective.
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FIGURE 3 Cost-effectiveness acceptability curve for the bootstrapped incremental cost per QALY gained at
12 months.
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FIGURE 2 Cost-effectiveness plane for the bootstrapped incremental cost per QALY gained at 12 months.
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It should, however, be noted that bootstrapped replications of the cost per point improvement ICERs
for the EMQ-p and GHQ-30 based on mean imputed data produced cost-effectiveness planes that were
somewhat analogous to those presented in Figures 2 and 3 for the cost–utility analysis. Estimates are spread
across all four quadrants, further demonstrating the uncertainty observed within the results. For both
secondary outcomes at 12 months and 6 months, the largest proportion of point estimates is located in the
north-east and south-east quadrants, associated with the intervention being more effective than usual care.
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FIGURE 5 Cost-effectiveness acceptability curve for the bootstrapped incremental cost per QALY gained at
6 months.
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In Table 22 the base-case cost-effectiveness analyses of the EMQ-p and GHQ based on multiply imputed
data found that the intervention dominated usual care at both 6 months and 12 months. The resulting
cost-effectiveness planes for these outcomes show the largest proportion of bootstrapped estimates in
the south-east quadrant, consistent with the intervention being less costly and more effective than usual
care. The probability of intervention dominance based on the proportion of bootstrapped estimates in the
south-east quadrant of the cost-effectiveness plane was 43.9% and 50.1% for the EMQ-p and 43.5%
and 50.8% for the GHQ-30 at 6 and 12 months’ follow-up, respectively.
For both secondary health economic outcomes, the probability of dominance at 6 months is larger than
that at 12 months, consistent with the larger effect observed for the shorter time horizon. Similar levels of
dominance are, however, observed for the EMQ-p and GHQ.
Results of the model-based analysis to estimate longer-term cost-effectiveness
For a longer-term perspective, the cost-effectiveness estimates were extrapolated over horizons of 5 and
10 years using the Markov model presented in Appendix 23. The deterministic cost-effectiveness results
obtained from the model for the 5- and 10-year horizons are presented in Appendices 33 and 34, respectively.
The base-case analysis was carried out using a cohort of 10,000 patients aged 45 years, corresponding to the
average age of participants in the trial. The base-case results are presented in Table 25.
The results indicate that, for a 5-year horizon, the intervention is cost-effective, with an incremental cost
of £194.81 and incremental QALYs of 0.301, resulting in an ICER of £646.36 per QALY. For the 10-year
horizon, the intervention is again shown to result in higher costs and more QALYs, with an ICER of £887.76.
These results suggest that, for longer horizons, the intervention is cost-effective.
One-way sensitivity analyses were conducted on the base-case results presented in Table 25 using a variety
of parameter inputs, including age at which individuals enter the model, the discount rate applied to
costs and outcomes, the intervention cost, costs and outcomes related to each health state and transition
probabilities. A summary of the results is presented in Appendices 33 and 34.
In general, the ICER results for both the 5-year horizon and the 10-year horizon appear robust to one-way
sensitivity analysis changes in the input parameters, with positive incremental costs and QALYs. However,
by reducing the cost associated with one cycle in each health state by 30%, for both the 5-year and the
10-year horizons, the intervention becomes less costly than usual care, with incremental QALYs remaining
positive. This represents a shift from the base case, in which the intervention was more effective and more
costly than usual care, generating a positive ICER (north-east quadrant of the cost-effectiveness plane),
to a scenario in which the intervention is dominant, being less costly but more effective than usual care
(south-east quadrant of the cost-effectiveness plane).
TABLE 25 Longer-term cost per QALY estimates for the memory rehabilitation programme compared with usual care
Horizon
Trial arm
Incremental
ICER (£)
Memory rehabilitation Usual care
Cost (£) QALYs Cost (£) QALYs Cost (£) QALYs
5 years 3599.08 2.952 3404.27 2.651 194.81 0.301 646.36
10 years 6451.25 5.340 5976.51 4.806 474.73 0.535 887.76
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The one-way sensitivity analyses presented above suggest that the base-case scenario is generally
insensitive to a range of model inputs. The results of the probabilistic sensitivity analyses, which consider
uncertainty regarding a variety of input parameters simultaneously, are illustrated in cost-effectiveness
planes and corresponding CEACs in Figures 6–9.
Consistent with the cost-effectiveness planes for the within-trial analysis (incremental cost per QALY
gain at the 12-month and 6-month follow-ups), the 5-year and 10-year horizons illustrate substantial
uncertainty, with all four quadrants populated (see Figures 6 and 8). The CEACs presented in Figures 7
and 9 indicate that the probability that the intervention is cost-effective is around 45% for both the 5-year
horizon and the 10-year horizon, irrespective of the threshold value, λ.
1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0
0 20 40 60
Threshold (£000)
Pr
o
b
ab
ili
ty
 c
o
st
-e
ff
ec
ti
ve
80 100
Usual care
Trial arm
Memory
rehabilitation
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Discussion
Overall, the findings from the health economic evaluation show that there was ambiguity in the findings,
with results not remaining robust when different imputation approaches and time points were taken
into account and when the impact of variation in costs and outcomes was examined, given the small
(statistically non-significant) differences between treatment arms and wide CIs seen.
The cost-effectiveness planes for all outcomes and time horizons in the analyses showed dispersion of
point estimates of incremental costs and effects across all four quadrants and illustrate the uncertainty in
our findings.
It is important to consider our results not just from the point of view of the technical assessment of
cost-effectiveness. Memory rehabilitation was estimated to cost £167 per participant (based on the
multiply imputed data); this resulted in small cost differences between treatment arms. We also based our
comparator on usual care and, given the pragmatic nature of the trial, this could have reflected different
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FIGURE 8 Probabilistic cost-effectiveness plane: 10-year horizon.
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models of care within the trial arm and associated resources (and costs). However, the interpretation of
small effect sizes is also important in the health economic analysis; the numerically small QALY gains seen
are not statistically significant and are unlikely to be considered clinically meaningful. The analysis of our
findings based on a ‘per point improvement’ basis should also be considered fully in light of the fact that
no statistically significant or clinical meaningful differences were seen, as reported in Chapter 3.
There are limitations to our health economic analyses. The methods used to collect resource use data
within this population should be carefully considered, for example, whether recall bias was a potential
issue (albeit this applies to both arms). The SUQ used and data derived were not sufficiently clear to enable
us to fully examine resource use specifically attributed to memory problems and thus we took all resource
use and costs into account. Although this may have overestimated costs, this applied to both arms. We
undertook a thorough investigation of our data, given the scenario that, in the non-imputed analysis,
costs were higher for the memory rehabilitation arm at baseline and 6–12 months. Although there was
evidence of a reduction in service usage costs between baseline and 6 months for the memory
rehabilitation arm, after including the cost of the intervention, the difference in costs between the memory
rehabilitation arm and the usual-care arm was not statistically significant.
One potential limitation of our analysis of service usage data is that we considered only a health and
personal social services perspective; because of the nature of rehabilitation, there could be potential
downstream effects on the patient, carer and family and wider impacts, such as on employment, that have
not been evaluated by this study. Instead, the health economic analysis used the EQ-5D-5L as its primary
outcome measure. This provided a more ‘general’ assessment of patient outcomes and could (in theory)
capture broader aspects of HRQoL rather than a single dimension of mood or function, as captured in the
other trial outcomes. However, the trade-off is that the use of such a generic measure can often result in a
lack of precision in the estimation of health effects.
We fully considered whether or not it was feasible and plausible to undertake a model-based analysis to
explore the longer-term cost-effectiveness of the intervention, which had been set out in the protocol
and health economics analysis plan. In light of the trial findings, we chose to do so to ensure that we
conducted a comprehensive analysis as originally set out. The results of the longer-term cost-effectiveness,
based on our model-based evaluation, should be interpreted with caution, although they do give a useful
indicator of expected benefits. We created a de novo model (as far as the data and external evidence
allowed us) using the results of a robustly conducted trial alongside reasonable, albeit basic, assumptions to
examine the longer-term cost-effectiveness. This may provide a basis for future health economic analyses.
We argue that the decision to amend the original protocol and not undertake analyses using a lifetime
horizon but instead base analyses on mid-term horizons (5 and 10 years) was a sensible compromise.
Sufficient evidence is not available to precisely determine the costs and outcomes associated with
longer-term horizons. Therefore, extrapolating the trial results in the model to a lifetime horizon would
likely lead to misleading or erroneous conclusions.
One potential area for consideration is how future analyses could capture some of the ‘wider’ benefits of
such interventions, given that the qualitative findings in Chapter 5 indicate the potential for benefit across
broader outcomes. This raises potential questions including further examination of patient preferences for
interventions to support memory rehabilitation and the inclusion of other outcomes of interest to fully
consider the impact of group memory rehabilitation in terms of value for money.
The trial has raised important questions with regard to how future trials should be developed in this area.
Similar questions should also be considered in the development of any future health economic evaluations.
Although the conclusions from our health economic analyses are appropriately cautious as they must be
made ‘on the evidence’ as presented, the need for high-quality methodically driven but ‘real world’-led
economic evaluations must be part of any future agenda in deriving the evidence on whether to invest in
this area of patient care.
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Chapter 5 Qualitative feedback interviews
Rationale
Mixed-methods designs are increasingly being used in evidence-based practice research.98,99 Qualitative
research can explore and explain the real-world complexities involved in participating in a trial or being
a recipient of health-care interventions. This nested qualitative study provided a separate evaluation of
memory rehabilitation, which served as an adjunct to the primary trial. We believed that insights from
these qualitative data and the analysis would serve to inform developments of the intervention programme
in the future and to generate user-oriented proposals about areas for further investigations.
Aims
Although there is an overlap in terms of the broad aims of the trial and this study, the specific focus of
this study was an experiential and phenomenological one, with a view to provide a nuanced account of
participant experiences. The aims of this substudy were therefore linked to the main aim of the trial
(i.e. to evaluate the effectiveness of memory rehabilitation in TBI), but specifically, we wanted to explore
participant experiences of:
l being involved in the trial
l receiving group memory rehabilitation
l using strategies to cope with memory impairment
l usual care.
Methods
We conducted one-to-one feedback interviews with participants enrolled in the trial within 2 months of
completion of the 6-month follow-up assessment.
Sampling
Participants were purposefully selected from a subgroup of trial participants who had originally consented
to being invited for interview. We used a maximum variation sampling strategy, a purposive sampling
technique used to identify and select participants who have important shared experiences that cut across
different subgroups based on demographic, clinical or other variables (see Palinkas et al.100 for a review of
purposive sampling techniques). Maximum variation sampling was used to achieve multiple perspectives
that demonstrate real-world complexities.101 The selection strategy was designed to include participants
with varying demographic features (age, gender, ethnicity) and levels of memory impairment (based on the
EMQ-p conducted at baseline) and from different sites. Once the first few participants had been interviewed,
we then selected others who were different from the first interviewees (in terms of demographics and
memory impairment). This iterative process continued until we had recruited the required number
of participants.
Sample size
In determining the sample size for the feedback interviews, we followed Onwuegbuzie and Leech’s102
recommendation of identifying a corpus of studies that used the same design and in which data saturation
was reached and examining the sample sizes in these studies. Data saturation (the point at which further
data collection is unlikely to lead to new insights) has been described as an ‘elastic’ concept and the
desirable degree of saturation depends, in part, on the nature and breadth of the research question.103
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Indeed, the concept of saturation is a contested one and there is no one-size-fits-all method to reach
data saturation.104,105
Our meta-synthesis of published qualitative studies of group-based memory rehabilitation106 revealed
sample sizes of 10–38 participants. We therefore opted to recruit 32 participants, aiming for 16 from the
usual-care arm and 16 from the memory rehabilitation arm. We believed that data saturation would be
achieved with this number of interviews. Furthermore, this would allow us to sample four participants each
from the memory rehabilitation and usual-care arm from four sites. However, as we increased the number
of sites as the trial progressed, we altered the sampling frame to recruit at least two participants from each
site where possible.
Procedure
Consent to be interviewed was checked with the participants selected for this study and, when participants
were willing to participate, an interview was arranged. To reduce social desirability response bias, a researcher
who was not involved with the participants’ assessment or treatment conducted the interviews. This researcher
was not blind to treatment allocation, as she needed to follow a semistructured interview schedule (see
Appendix 35), which included general questions for all participants and specific questions for those who had
received the intervention and those who were in the usual-care arm.
The interviews took place face to face in participants’ homes. At the interview, the researcher reiterated
the purpose of the interview and informed participants that the interview was being audio recorded on a
dictaphone. During the interview, participants were invited to discuss their thoughts as freely as possible,
although the researcher used the interview schedule to guide the interview agenda and to create some
comparability across the interviews.107 Participants were assured confidentiality and had the option to
pause or stop the interview or skip questions if they chose to. The audio recordings were transcribed
verbatim by a professional transcription service.
Analysis
The transcripts were analysed using framework analysis.108 Framework analysis is a specific type of thematic
analysis109 that is atheoretical and allows researchers to collapse large data sets of qualitative data along
broad areas of research interest determined a priori. It is more deductive and structured than other forms
of thematic analysis and usually yields a matrix of cases and codes, with data placed in ‘cells’ that contain
chunks of the interview data transcripts. Through a constant comparison method (both within and across
cases), the data are then reduced to the key themes. Themes can be broken down to subthemes and
further subsidiary themes. This method is useful in multidisciplinary research teams with more than one
researcher analysing the data.109
Two researchers (SC and HC) read and reread the interview transcripts a number of times to familiarise
themselves with the data. Each separately conducted a line-by-line coding of half of the transcripts before
swapping over to check the codes. Disagreements were resolved by discussion with another researcher
(RdN). Thereafter, we created a ‘master map’ based on the aims of this substudy, which served as the
framework to map the data onto. Mind maps for each transcript based on its coding, which was discussed
with the third researcher (RdN), were then created. Use of mind maps is not common in framework analysis,
but we included this step because mind maps allow us to see how the various themes, subthemes and codes
connect with each other, thereby suggesting possible relations between them. We then populated the
framework matrix and four themes (and subthemes) were extracted from the condensed data.
In Results, we discuss each theme and subtheme. For each theme and subtheme we provide relevant
quotes from the participant feedback interviews, with quotes attributed to participants (demarcated by a
unique participant identification number, gender, age and treatment allocation). We describe our results
using quantity measures such as ‘all participants’, ‘most’, ‘half’, ‘almost half’ and ‘a few’, with this order
representing decreasing values.
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Quality considerations
To ensure the quality of the study, we adopted the criteria of Mays and Pope110 by providing a clear
exposition of the methods of data collection, sampling and analysis; our reflexive position; attending to
negative cases; the context; and ‘fair dealing’ with respect to providing different perspectives so as not to
privilege one group over another.
We approached this substudy from a critical realist epistemological perspective. Critical realism, where
language is assumed to be used to construct our social realities but that these constructions are limited to
that which is grounded in the material world,111 functions as a ‘general methodological framework for
research but is not associated with any particular set of methods’.112 This perspective helps researchers
explain social events or issues and suggest ways to address these.112
Results
Thirty-two participants (10 women and 22 men) were interviewed. Interviews were conducted in two
tranches and lasted between 13 and 69 minutes. Participants were aged between 24 and 68 years at
randomisation and all were white. The time since TBI ranged from approximately 9 months to > 34 years.
We recruited participants from eight of the nine sites. We did not recruit from one site because the site
was closed to recruitment before participants reached the 6-month follow-up. Details of the sites that
we recruited from and the composition of the participants in terms of whether they were memory
rehabilitation or usual-care participants are shown in Appendix 36.
Feedback on the trial
The first theme relates to how participants felt about taking part in the trial. Participants described their
motivation for taking part, experiences of specific trial procedures, experiences of the assessment
procedures, preferences for the group format and reactions to the allocation. Participants also provided
their overall impressions of the trial (Figure 10).
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FIGURE 10 Thematic map of the ‘feedback on trial’ theme.
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Motivation for taking part
Most participants appeared to be driven to take part in the study by altruism. Many spoke of wanting to
help others:
I’m just helping you guys out so that, so that what you can get can help somebody else out, you
know, in the future.
01003, male, 58 years, usual care
So to go onto this [study] was good because I thought if this gets other people out of a situation that I
was in then that’s why I wanted to do it.
06049, male, 68 years, usual care
Participants also thought that by taking part in the study they would receive some information about their
memory problems and some help to deal with these problems:
It was a matter of floundering around thereafter [after discharge from hospital], er that’s why when
this [study] came up we jumped at the opportunity to take part.
04005, male, 56 years, intervention
I wanted to get as much information as I could really about how it [brain injury] affects me and how
I can deal with it. So that was my idea of going along with it [the study] in the first place.
05042, male, 51 years, intervention
Trial procedures
Participants had positive feedback regarding the organisation of the trial. In addition, the qualitative study
was praised for providing an opportunity to raise more attention about TBI and memory rehabilitation,
including the need for increased funding for such services:
From the practical viewpoint I thought the study was done well. You’re kept informed people, errm,
kept appointments, etc. it was all organised, kept to there’s no issues there.
04010, male, 55 years, usual care
I’m very pleased that I’ve been part of this feedback . . . I think it [trial] is a very good thing to do I
think more emphasis, more pressure on the powers that be to allocate more funding to this [TBI
memory rehabilitation] because it’s very important and it does not receive anywhere near the amount
of attention that it deserves.
07012, male, 37 years, usual care
The trial also helped usual-care arm participants understand that they were not alone with their TBI,
despite not attending the memory rehabilitation groups as part of the intervention:
It’s [taking part in the trial] opened my eyes an awful lot, of how things are, and how I’ve got to accept
my life is now and it’s not just me, there’s god knows how many out there are in the same position.
01005, male, 43 years, usual care
It [taking part in the trial] was good, it, it was informative, it helped me understand I’m not the only
one with the problems.
01017, female, 30 years, usual care
Experience of assessments
Overall, participants were positive about the assessments that they undertook as part of the trial. The fact
that they were conducted at home or at other convenient locations (e.g. local hospital) was highlighted as
ideal in terms of travel arrangements and as a way of allowing participants to remain in their comfort
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zone. Additionally, participants found the assessments helpful with regard to highlighting their specific
memory impairments and strengths:
The assessments have been done; it was either at [names location] when we were first looking at
enrolling in the course, not exactly far to travel and then all the assessments and discussions
afterwards have been here at the home – so that’s ideal for us.
03004, female, 39 years, intervention
Well my psychologist comes here [home] . . . I prefer it, it’s awful, it’s terrible . . . but this is my comfort
zone . . . I feel better in my own home . . . I feel safe. I don’t know why, it’s weird isn’t it.
09018, female, 51 years, usual care
It was helpful that they [researchers] got back to me and showed me where the deficits were, with
where I was lacking sort of thing.
03022, male, 25 years, usual care
However, one participant reported that she did not like the fact that the assessments highlighted her
specific memory weaknesses:
I’m not sure if it [assessment] wasn’t useful but I didn’t really like the faces when she [researcher]
showed me the faces [from an assessment] . . . which is probably because I needed more help with
that, do you know what I mean? . . . But I knew that was a weakness and I don’t like weakness.
08007, female, 41 years, intervention
Although most participants were positive about the assessments, some felt that they were challenging and
not necessarily reflective of real-life memory concerns. Additionally, one participant did not understand the
need for repeated assessments throughout the trial:
I found it [the assessments] taxing in a way . . . some of the tests were OK, others because of problems
with my memory and that was a bit taxing, do you know what I mean, but overall it was good to do,
if that makes sense, yeah.
09018, female, 51 years, usual care
It’s [assessments] either focused on stuff I’m not very good at anyway, so like remembering names and
faces, you’ve got so many faces and they all look similar and they all have like are relatively the same
. . . they’re people I don’t really know or care about, I’m not going to remember them.
08002, male, 31 years usual care
You start thinking, why are you doing this [the assessment] . . . and then I had a reassessment and we
had to do it all again which I thought was quite, well we’ve been here before haven’t we, do we need
to do it again kind of thing.
03005, female, 56 years, intervention
Preference for rehabilitation format
The majority of participants stated that they would rather experience memory rehabilitation as part of a
group than on a one-to-one basis, with the reason often being the benefit of sharing ideas with other
participants who have first-hand knowledge of having a TBI.
In a group it’s much better cause then you can get the impact of someone else and they can give you
an idea or vice versa so, erm but individual, no disrespect, but it’s like, yeah well I’m telling you all
these things and you’ll try tell me, but they [group members] know what it’s like, but the actual
person [AP] doesn’t.
01010, female, 24 years, intervention
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It would probably be helpful to have a group-based thing . . . because one-on-one you don’t
necessarily know what you, what you currently want help with . . . if you’re in a group you kind of
hear other people’s struggles and you kind of come out and go ‘yeah, I have some problems
with that’.
08002, male, 31 years, usual care
However, a few participants would have preferred one-to-one memory rehabilitation. They felt that
one-to-one sessions would allow their relevant concerns to be addressed and enable them to discuss
personal issues, as well as allowing them to concentrate more easily than in group situations:
One-to-one probably because I have had, I’ve been to other group sessions where I’ve found it’s not
necessarily been very relevant which might sound a bit stupid . . . but I’ve definitely found, from my
experiences, one-to-one sort of treatment and rehabs have been more useful. Because you can talk
about your personal issues.
04008, female, 25 years, usual care
I would probably prefer one-to-one . . . I tell you why because in [rehabilitation centre] sometimes
I cannot concentrate because there’s so much rambling, because there’s people with different levels
of head injury, right, and some of them really ramble on and on and on and on and arrgghh!
So sometimes I have to sit right at the back.
09018, female, 51 years, usual care
A few participants were unsure of their preference because they could see the benefits of both one-to-one
and group rehabilitation formats.
I don’t know. I think you could cover the same things more tailored to individuals faster [in] one-to-one,
but then obviously, you know, other patients . . . have got contributions to make that the person that’s
running it [groups] don’t have, as well, and . . . it is quite nice to see other people with the same issues.
07002, female, 29 years, intervention
I think given my character I’m a very vivacious person I probably would have been good in a group
but as you might have seen today I can go off on a tangent and I’m probably better with someone
focusing on me . . . I don’t think a group would have been the wrong thing but better might have
been I should try both.
07012, male, 37 years, usual care
Reaction to ‘usual-care’ allocation
Half of the participants randomised to the usual-care group stated that they had no problem with their
allocation. This was often because of an understanding of the need for a control arm, although one
participant expressed relief at not having to fit the weekly memory rehabilitation group sessions into his busy
working schedule:
Which I don’t have a problem with [being in a control group] because I do understand the concept of
how you need to have a baseline and I’d said that I was quite happy to participate in the study and,
yes you’ve got to have willing baseline otherwise a study’s meaningless.
04010, male, 55 years, usual care
Kind of a bit relieved . . . a bit of me was worrying, thinking ‘how am I going to squeeze that
[rehabilitation sessions] in with everything else?’
08002, male, 31 years, usual care
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However, a few participants were disappointed with being allocated to the usual-care arm because they
had hoped to receive the intervention, which they believed would improve their memory:
It would have been nice to have been in the other [i.e. treatment] group . . . Just to see what you were
doing and if it worked and made a difference.
04008, female, 25 years, usual care
I was a little disappointed actually I was hoping that I might erm, experience something new that
would help my memory.
04009, male, 46 years, usual care
A few participants misunderstood the randomisation process and believed that it was their performance on
the baseline assessments that decided their allocation:
I didn’t really mind which, which group I’d, I‘d end up in er cause obviously we went through the
various er questions and, that determine over time which group you went into.
03014, male, 27 years, usual care
It [the study test] was to see whether I’d be allocated into the, a group to go on to other tests or
another different group, which obviously, which wouldn’t go on to the tests.
03022, male, 25 years, usual care
Overall impressions of the trial
When asked for their overall impressions of the trial, a few participants mentioned the personal
characteristics of the trial staff:
All the assistants that have been involved in the study with me have been you know very easy going
and explained everything to me.
03014, male, 37 years, usual care
I would like to say that erm all the people I’ve met and talked to have been very happy and very polite
and very pleasant.
04009, male, 46 years, usual care
Overall, participants expressed satisfaction with taking part in the trial, but when asked specifically for
suggestions for improvement they recommended that usual-care arm participants be sent the intervention
manual at the end of the trial, a crossover study design (so that everyone received the intervention), a
wider variety of assessments, more frequent assessments, more detailed feedback on assessments and a
written timescale of key study dates (e.g. assessments):
Maybe the number maybe there could be more assessments, that would have been more helpful and
give me a better idea between one and the next.
07012, male, 37 years, usual care
Experience of the rehabilitation group
The second theme related to how participants randomised to receive the intervention experienced the
memory rehabilitation groups. Participants described the timing of the intervention in relation to their TBI,
the format of the group, the content of the intervention manual, their experience of the group facilitator
and the perceived effects of the group (Figure 11).
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Timing of the intervention
Participants randomised to the memory rehabilitation group stated that they would have preferred to
receive the memory rehabilitation sooner after their TBI, but ‘not too soon’ because of difficulty processing
information immediately after their injury:
Yes, earlier would have been good . . . But not right at the beginning, because right at the beginning,
it would have just gone in one ear and out the other, effectively.
07002, female, 29 years, intervention
Personally, from my point of view, it [memory rehabilitation] would have helped me if it was like
6–12 months after the accident rather than 4 years later.
03004, female, 39 years, intervention
Although participants in the usual-care arm were not asked specifically about the timing of memory
rehabilitation, one usual-care arm participant’s feedback is valuable here. This participant felt that there was a
need for memory rehabilitation at the optimal time after TBI. She described a lack of engagement with a
neurorehabilitation centre in the year after her TBI:
They [clinical staff] were quite keen to do different courses and different things with me but at the
time I was very reluctant, I just wasn’t in the right frame of mind I think, but had it been further down
the line, because I was still quite unwell and not myself after the accident and I just wasn’t interested.
04008, female, 25 years, usual care
The extended length of time between participants’ TBI and the intervention meant that some participants
found it challenging to adopt the new strategies being taught in the memory rehabilitation group:
So trying to learn, it’s like with a head injury and that you, you’re learning stuff like, it’s like you’re
learning from new kind of thing, but trying to learn new strategies like, oh what was the one she [AP]
said, like a dictaphone for instance, see that wouldn’t work for me, so I wouldn’t have tried it.
01010, female, 24 years, intervention
I’d muddled through and found strategies that worked for me and then to be thrown into a group,
that’s the wrong term to use but to attend that group, and I’d be thrown 101 other strategies it’s like,
hang on a minute I’m doing the, I’m using these strategies and it works for me and I can forget all
those strategies and look at applying new ones and that takes effort and it takes energy and it takes
thinking whereas had I not been going into a routine and using some of my own strategies I might
have been a bit more susceptible to taking some of those on board.
03004, female, 39 years, intervention
This was linked to participants having already developed their own strategies. Almost half of the participants
in the memory rehabilitation arm already knew some of the strategies taught in the memory rehabilitation
group either because they had worked them out themselves or because they had attended other
rehabilitation sessions:
Er yeah the, these strategies er, the strategies er I used most, I found at least half of them I use anyway.
01012, male, 59 years, intervention
I was doing quite a lot of it anyway from my own work but there were some extra tips that I picked up.
08007, female, 41 years, intervention
Format
The majority of participants described benefits gained from the group format of the memory rehabilitation.
This included a feeling of not being alone with their TBI, sharing experiences with people in a similar
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situation, conversing with people who understand (as opposed to a lack of understanding outside the
group), social interaction and sharing ideas or strategies:
We both [participant and other group member] found that talking to other people who’d had brain
injury made you feel more normal, made you feel like it wasn’t just you.
05053, male, 32 years, intervention
the good thing about it [group] was the problems that the other people at the group were having
which were the same as mine with the memory and everything, very, very similar.
06045, male, 56 years, intervention
I liked meeting others who’ve had brain injury and how they go about their day-to-day life and
conversing really erm on how . . . other people you know in the, in the work, in their day-to-day life
do not always understand you, maybe you’re a bit slower or a bit, you know.
03001, female, 54 years, intervention
The benefit of the group was to erm [pause] to realise that er, [pause] that, that I could get out and
about and, and interact with these people socially.
01012, male, 59 years, intervention
It was really good to see us like, not only me giving ‘em ideas but them, them throwing ideas back at
me, maybe that they haven’t tried yet.
01010, female, 24 years, intervention
Participants also commented on the composition of the group in relation to group attendance, the benefits
of seeing other people with TBI looking well, feeling like a ‘fraud’ because of self-comparison of ability
with the ability of those with more severe disabilities in the group, and conflicts within the group:
The other thing as I say, sadly er a, a couple of the guys erm didn’t turn up, I mean one was working
. . . I just thought it was a shame that erm people didn’t turn up.
04005, male, 56 years, intervention
The hopes and dreams of these people [participants] have been er have been shattered you know,
where, and er because of their circumstances but still they were, still they were happy within
themselves and that to me was, that was important.
01012, male, 59 years, intervention
When you listen to the other people [participants] and especially two of the other people and you
think oh my god it happened so long ago and they’re still really struggling. And it was really, it used
to upset me, I felt like a fraud.
03005, female, 56 years, intervention
I’d had enough of it and I just said ‘will you shut up, you’re putting me off’ [to another group member]
and it was like, even though everyone else was thinking it, I was the only one that had to say it but I
thought no, it’s no use for me, you’re spoiling it [attending the group] for me, because I even thought
of not going because the thought of seeing her [participant] again I thought oh, here we go.
05042, male, 51 years, intervention
Most participants were satisfied with the format of the memory rehabilitation group. However, the following
suggestions were made when participants were specifically asked for ways that we could improve the
intervention: more group sessions, longer sessions so that the information could be taught at a slower pace,
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the use of social events before and after the intervention, and a follow-up group to check the maintenance
of memory strategy use:
Apart from being able to erm [pause] do the course for a longer period of time to be able to actually
utilise things, [pause] but what I, what I want and what is really achievable, I don’t know if it’s feasible.
01015, male, 33 years, intervention
Instead of having I don’t know how many hours in a session I, I thought that if you could get an
afternoon session, now maybe you classify it as too long, to go through things, I’d say a little bit slower.
04005, male, 56 years, intervention
I think the group was such a nice group I think we should be a good thing to organise like at the end
of it was sit down and have a night out or go to the pub or something.
04002, male, 24 years, intervention
Well whether it was between the sessions or, erm if the sessions continues say, if they continued like,
you know say you meet once every 3 months or once every, whatever and you, you met up with those
people and you, and you know perhaps the lady [AP] or, or somebody from the memory place said
you know have you, how’ve you been getting on with your er, your diaries, have you got all your
diaries, have you been filling them out regularly.
03003, male, 55 years, intervention
Content of the manual
Almost half of the participants provided positive feedback on the content of the manual used in the memory
rehabilitation groups. This included an appreciation of the group tasks, the belief that the structure of the
sessions was good and stating that the language used in the manual was clear:
You have activities toward the end of each week, that’s good, because sometimes it is the practical
experience of doing something that actually kind of consolidates the learning of it.
09008, male, 33 years, intervention
But I think the way it was set out was good, the way the leaflets – well, like a booklet explaining
everything, which you followed where they explained what they were trying to do.
05042, male, 51 years, intervention
So the material was clear and concise and targeted so I don’t think er, I don’t think anything could
be [improved].
01012, male, 59 years, intervention
However, one participant felt that the manual was written in a way that was difficult to understand:
I think there are elements of it which are written in PhD language.
09008, male, 33 years, intervention
In terms of negative feedback, a few participants stated that each session contained too much
information. Additionally, one participant reported that the content was repetitive and another expressed a
strong dislike for a particular relaxation exercise:
If I had to be really picky it was just that some of the sessions were very intense and there was a lot of
information in that.
03004, female, 39 years, intervention
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I think some of the stuff was repetitive. Because I’d never come across these sort of strategies they
were using for improving memory, I found it a bit confusing, Some sort of overlapped with each other.
I’m trying to think, what am I trying to do with it? It’s just like the last bit or something else.
05042, male, 51 years, intervention
There were certain points where it was – there was one page, I remember exactly what page it was, it
really, it just pressed my button of ‘I don’t like this!’ It was page, I think it was 74, and it talked about
relaxing . . . and I remember thinking I’m not going to relax. I’m not being told to relax. What made
me totally not relax was being told to relax.
09008, male, 33 years, intervention
Group facilitator
Half of the participants spoke positively about the facilitators (APs) who led the memory rehabilitation
groups. In particular, participants praised the facilitators’ knowledge, skill and positive personality traits:
[Facilitator] was very good and she listened too, we’d get into our own little debates and you know
sort of, you sit there for a minute and she was very good at explaining things and she’d go over things
at the beginning of the next session.
03005, female, 56 years, intervention
I thought [facilitator] was she was a nice person. I mean she was very, she was like, she obviously, you
could tell she obviously cared by what she was doing it wasn’t just pay check. So that was nice.
04002, male, 24 years, intervention
However, one participant felt that the group facilitator treated him differently from the other group
members. This was particularly in relation to how the facilitator was perceived to spend more time with,
and give more attention to, some individuals than others:
He [other group member] could see there was a – I don’t want to say ‘favouritism’, but it was like – it
was like he would get . . . 60% of attention, if you like. And the other one would get 30% and I’d get
10% [laughing]. It wasn’t equal.
09006, male, 53 years, intervention
Effects of the group
All participants reported positive effects of attending the memory rehabilitation group sessions. Besides
the general positive comments [‘I found it all helpful’ (05053, male, 32 years, intervention)], participants
commented on learning new strategies, the reinforcement of existing strategies, increased external strategy
use, improvement in memory, increased understanding of how memory works, improvement in mood,
increased confidence, reduced frustration/increased acceptance and contact with group members outside
the group:
But now you guys have given me more techniques like how to use them, my phone, my laptop, my
iPad, so erm and erm I’m erm my card in my wallet, just check and they’re all there and I texted me
my card in my wallet.
04002, male, 24 years, intervention
I’m going to say reiterated, er what, what we’d found that we were doing the right things.
04005, male, 56 years, intervention
Memory wise, well I write a hell of a lot more down now so, I don’t forget half of much on that sense
of things.
01015, male, 33 years, intervention
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My wife says it [memory] has [improved], yes it has [pause and sighs] . . . I think it’s improved.
04005, male, 56 years, intervention
I suppose I’m more understanding, I’ve got more understanding of how brain injuries affect you,
especially your memory, day-to-day things.
05042, male, 51 years, intervention
It’s given me confidence for a start to be able to travel outside of me little bubble, before it came to
that point I never could quite get on a bus.
01015, male, 33 years, intervention
I mean it’s got better since I’ve been going to the group especially, has got better I’m not getting,
I’m not getting as frustrated when people move things.
01010, female, 24 years, intervention
One of the girls there [name], I mean, we met a couple of times, yeah for coffee and it was nice,
really nice.
03001, female, 54 years, intervention
However, two participants reported that the groups had a negative impact on their mood. One participant
found it very upsetting to hear the other group members talk about their struggles with their TBI (see
quote from participant 03005 under the format of the group subtheme), the other occasionally worried
about her use of strategies:
It’s just err a reminder to be me to try and be, as you know, as more on the ball or more, more,
but that gives me, that aches, how, how can I put it, that gives me a headaches when I worry or
con-concern or not so concern, when I am thinking about that too much.
03001, female, 54 years, intervention
Strategy use
Participants from the memory rehabilitation group spoke about the strategies that they were taught in the
group sessions and which ones they found helpful or unhelpful. This is covered in some of the quotations
related to the effects of the group in the previous theme. This theme therefore relates to the participants’
use of strategies to improve their memory that were learnt outside the group. Participants described
strategies that they had learnt and were using prior to their TBI, strategies that they generated themselves,
strategies that were offered by other sources and the significance of their strategy use (Figure 12).
Learnt pre traumatic brain injury
A minority of participants reported developing memory rehabilitation strategies before their TBI as part of
their employment:
Several years before the accident I’d done some, I’d learnt some memory techniques for use in work
when, when I was a consultant, erm and for use around presentations so I’ve learnt like pegging and
erm you know sort of weaving in a story.
03015, male, 36 years, usual care
Well a lot of the strategies I had . . . er a lot of the strategies [at the group] was stuff that er we used
in the police . . . for er evidence gathering, erm investigations, etc., erm so a lot of the strategies I
already knew but not with this context, if that makes sense.
04005, male, 56 years intervention
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Self-generated strategies
Linked to the preceding subtheme, almost half of the participants had generated their own memory
rehabilitation strategies. For some participants these were internal strategies, including name association
and attempting to remember specific aspects of an event:
I mean I try to do association, so name association, erm, I’m, I’m terrible, I mean [name] I’ve got,
but only because you’re, you’re here on your own, erm if there was two or three of you I probably
wouldn’t get who was who.
04009, male, 46 years, usual care
I try and make something memorable happen . . . even if it’s talking to a new person and talking to
them and erm, in that situation I think oh yeah I remember him, he had the bright yellow jacket on,
I spoke to him, that was a day, it was a Thursday.
01017, female, 30 years, usual care
The majority of self-generated strategies were external memory aids. Writing things down was the most
frequently used self-generated strategy, followed by inputting notes into a mobile phone. The use of a
calendar, wall planner or a diary was the least frequently used strategy:
You find your own way of doing things and getting around and doing stuff, which for me is writing a
lot of things down.
03004, female, 39 years, intervention
So I kind of always have my phone with me, so I’ve got lots of notes and things in there, written down.
07002, female, 29 years, intervention
Well, the main thing really is mainly with this, a calendar . . . Everything’s on there.
05042, male, 51 years, intervention
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Yeah over the years I’ve found having a, a diary to hand, always, I can always keep track of my main
events during the day.
03014, male, 37 years, usual care
Almost one-quarter of participants reported the use of other self-generated strategies. This was
predominantly relying on routines, although one participant used word substitution and another used
relaxation techniques:
I try and think, ok I’ll do things at certain times and put things, I try and put things in places which I
usually forget to do but I try and look in certain places first and see if I’ve put it there.
04008, female, 28 years, usual care
If it happens in a sentence or something like that I can kind of er slide my way around it, the word
that I can’t remember, so that people know what I’m talking about.
01003, male, 58 years, usual care
Almost one-quarter of participants specifically stated that they had had to generate their own strategies
because of a lack of memory rehabilitation or support from other sources. For one participant this was
cause for considerable distress:
I just give up and work it out myself. ’Cause I guess, in a way, I’m lucky in that I do – I’m, you know,
clever enough or whatever to have that own resources to try and do that. So, yeah – so I know that I
looked up things online and I got things from memory charities and stuff like booklets myself, to try
to help myself . . . it would be better for them [doctors] to be giving me information, rather than not
even telling me to go away, look it up and for me to have done something like this [intervention]
group or – you know, just anything rather than just the feeling of, like – you know, as if it’s then your
fault because it’s not been acknowledged that it’s actually an issue. [Crying]
07002, female, 29 years, intervention
I’ve done a lot of things just myself . . . I had to do a lot of recovery on my own.
01017, female, 30 years, usual care
This lack of memory rehabilitation or support is described further under the fourth theme, ‘usual care’.
Offered by other sources
Just under half of the participants had received advice or support on keeping a routine from other sources:
I have a routine, that’s another thing that I learnt in either the TBI team there and that or maybe is it
[name of occupational therapist].
01010, female, 24 years, intervention
We [ABI team] did do some strategy stuff, sort of around making, er you know sort of substituting
routine for memory if you like . . . making sure you always put things in the, in the same place and,
and that sort of thing.
03015, male, 36 years, usual care
In terms of external memory strategies offered by other sources, writing things down was the most
frequently used strategy, followed by the use of a calendar or diary:
That [inpatient rehabilitation] was one of the places that we, you know started to . . . say that it would
be a good idea if you are not sure . . . where you want to go, what you want to wear or what you
want to do, you know, write it down.
03001, female, 54 years, intervention
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I put them all up there, like phone numbers and stuff like that on the calendar. I’ve got one next to
me when I sit down if I’m in there. I write down on me calendar, like, ‘got to see me home Friday at
1 o’clock’, or whatever [suggested by the Brain Injury Trust].
05067, male, 53 years, usual care
She [from the TBI team] told me that it was the right thing to do, get a diary and that it would help.
01005, male, 43 years, usual care
Significance of strategies
A few participants felt an initial resistance to adopting memory strategies after their TBI. However, these
participants did persevere with the strategies and were then able to experience the benefits:
I do remember my opinion at the time was I’ve never had a diary, don’t need a diary . . . I gave in and
got one and now it’s got to the point, that, yeah again she was right, I was wrong cause I live by it.
01005, male, 43 years, usual care
I find them quite tedious and patronising and really you know, saying ‘Ohhh’, you know like sort of
getting a pad out or whatever and writing things down and you know . . . But it does help.
03022, male, 25 years, usual care
Almost one-third of participants relied heavily on their strategies (particularly external memory strategies) in
their daily activities:
I had to have an alarm to pick my children up from school, because otherwise I would forget.
07002, female, 29 years, intervention
I use, erm like my memory as my diary and my phone, this is like my lifeline, without them I’m you
know, I’m just not, I, I’m useless.
01010, female, 24 years, intervention
Usual care
The fourth theme related to the participants’ experience of rehabilitation external to the trial. Participants
described a lack of memory rehabilitation, the types of memory rehabilitation that they did access and
rehabilitation offered for non-memory issues (Figure 13).
Lack of memory rehabilitation
The level of memory rehabilitation received by the participants following their TBI varied greatly, with the
majority reporting that they had received no memory rehabilitation at all external to the trial:
I do think that there is a massive gap in between there’s a massive gap I think for me I mean this is my
personal experience after the accident hospital you’re discharged goodbye, good luck.
07012, male, 37 years, usual care
He [group member] got the care package, if you like, from day 1 . . . mine has been a DIY job . . .
learning how to cope and – with not understanding other people – you know, people think you’re
taking the mickey by forgetting to do that task or doing – you know, etcetera.
09006, male, 53 years, intervention
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One participant felt that she did not receive memory rehabilitation because of performing adequately on
memory tests shortly after her TBI, whereas, for her, her score represented a deterioration compared with
before her injury:
So what I then found really difficult was they’re like, ‘Oh, well, you’re middle of the range on these
tests. You’re fine’. And I’m like, ‘Yes, but I wouldn’t have been middle of the range so, actually, I’m not
fine’ . . . And I think that I wasn’t able to articulate that at the time, because I wasn’t able to explain my
thoughts properly then. So I think I just kind of got dismissed . . . I felt a huge amount of frustration and
powerlessness, because I didn’t get any help, because I wasn’t able to explain that I needed it.
07002, female, 29 years, intervention
Perhaps not surprisingly, many participants stated that they wanted more support and rehabilitation to
help with their memory:
It would be nice if there was access to errm memory techniques or a programme.
04010, male, 55 years, usual care
I would like more support, or – and certainly ideas and what I could do, not necessarily, well and
probably also techniques of helping myself, but also stuff I could do to improve it [memory] as
opposed to just working around, because I don’t want to just take notes all the time.
08002, male, 31 years, usual care
Memory rehabilitation received outside the trial
Almost half of the participants discussed the types of memory rehabilitation that they had accessed
through sources other than the trial. The most common sources accessed were brain injury teams and
Usual care
Rehabilitation for
non-memory
issues
Lack of
memory
rehabilitation
Memory
rehabilitation
accessed
Fatigue
No memory
rehabilitation
Brian injury
team
Neuropsychologist
Desire for more
rehabilitation
Mood
issues
Physiotherapy
Other professionals
Balance
FIGURE 13 Thematic map of the ‘usual-care’ theme.
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neuropsychologists, with other sources including inpatient rehabilitation teams, charities, work, private
companies and social workers:
The way I see it is what I’ve had with rehab and the TBI team and everything else they’ve, they’ve just
been amazing.
01010, female, 24 years, intervention
Obviously I’ve gone through a few things with [neuropsychologist], and you know . . . sort of how, you
know how I can help with writing things down and certain strategies.
03022, male, 25 years, usual care
Well when I was in hospital, when I was like an inpatient I think I did have erm I did have some
memory but wasn’t very common.
04002, male, 24 years, intervention
That’s the Brain Injury Trust did that to me [suggested strategies], yeah.
05067, male, 53 years, usual care
I’ve had like coaching, like kind of business kind of coaching and various different things to try and
put strategies in place so I, I’ll try anything.
03015, male, 36 years, usual care
I saw the rehab assistant from . . . July 2015 to December then got discharged officially in January this
year, so the length of time that [private rehabilitation company] had been around for is a kind of, sort
of, story of what . . . like cognitive rehab and all daily independent living.
09008, male, 33 years, intervention
Yeah, yeah, yeah, the social worker from the brain injury unit, I think she’s from [place], she was
brilliant, she was good, she was very, very good . . . and she, you know, obviously because she works
with the brain injury department, they knew a lot of the pitfalls of having this accident and a lot of the
problems that you will have in the future, so she sort of pre-empted and tried to prevent a lot of them
as well, which did work.
06045, male, 56 years, intervention
Other (non-memory) rehabilitation received
As could be expected, participants experienced a range of other health issues comorbid to their TBI for
which they also attended rehabilitation. The most common ‘other’ rehabilitation was for mood issues
and a few spoke about fatigue management groups and courses, physiotherapy and balance
rehabilitation:
Well now they [Brain Injury Trust] come round and just check me mood swings because I used to get
in bad moods and that like, but I’m not scared of nothing . . . they come round and check me pills and
they put me on these anti-depressant pills even though I don’t feel depressed. But then they put me
dose up and it has calmed me down a bit.
05067, male, 53 years, usual care
I’ve been to [place name, fatigue management group] and they showed me what happens because
that’s why I sleep all the time.
05067, male, 53 years, usual care
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But I got seen by the physios a bit longer than, than I should have done. I got seen by the
intermediate community team longer than I should have been and they tried to have more of a
smooth transition, that’s why they looked after me a bit longer, they wanted to just hand over as they
see it, me being ready for life.
08002, male, 31 years, usual care
After my head injury yes, because I couldn’t balance, I lost my sense of balance . . . So through
[neurological rehabilitation unit] . . . erm I was under the care of a couple of people there erm there
was actually one who I can speak really highly of, [staff member], she put in place coping mechanisms.
04010, male, 55 years, usual care
Discussion
One of the challenges of an interview study requiring people with memory problems to recall specific events
that happened over the 6 months previously is that some people tend to forget some details. Indeed, this
was the case with five participants, who could not remember the study. Four participants who had received
the intervention also had limited memory of the groups, but did recall that they were taught to use some
‘strategies’ to cope with their memory problems and that some of these strategies were useful. Five participants
could not recall whether or not they had received any memory rehabilitation outside the trial. However, the
majority of the interviewees provided detailed and rich accounts of their experiences of being involved in the
trial and also their experiences before the trial. Therefore, the results of this study should be interpreted in light
of the difficulties that some participants faced.
Some participants were motivated to participate in the trial by altruism, feeling that their participation,
even if it did not help them, would help others in the future. The other major reason for participation was
because participants needed help with their memory problems. Participants were clear that there was a lack
of provision of memory rehabilitation as part of their usual care. Some participants received rehabilitation for
other non-memory issues (for problems with mood, fatigue and balance), with only a few receiving help for
their memory problems from their TBI team, neuropsychologists and other allied health professionals. This
support was often felt to be insufficient.
Although most participants reported that they preferred the group intervention to one-to-one interventions,
there were some who were ambivalent and some who would have preferred one-to-one sessions. The
reasons for this are that participants felt that there would have been greater focus on them as individuals
and their problems in individual sessions and that intervention material that was not seen as ‘relevant’ to
them would be left out. Although the majority felt that the groups were beneficial, there are aspects related
to the composition of the groups, timing of the groups, the materials used in the groups and the groups’
facilitators that need to be carefully considered when delivering group interventions.
Diversity in a group can be a strength but also a problem for some. Having people with different levels of
severity of TBI was frustrating for those with milder levels of memory problems; one participant even felt
like a ‘fraud’ because their memory problems were not as severe as those of some of the other group
members. Participants also felt that their preference for a group format was based on their own personality
(e.g. being ‘vivacious’). Most, however, felt that being with others with a similar condition made them feel
‘not alone’ and that learning from peers was a beneficial aspect of the intervention. Although some
participants felt good about seeing others who appeared to be coping well after their TBI, others felt bad
about seeing people, even years after their TBI, not coping.
Another aspect of the delivery of the group related to the time since participants’ TBI. Participants described
an ‘optimal’ time (not too early but not too late) after TBI when they thought that they would have benefited
the most from memory rehabilitation. Although some participants felt that they already had strategies in
place, because they had been living with their TBI for some time before the trial, we had hoped that the
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memory rehabilitation group sessions would enable them to fine tune the use of these strategies. However,
because of the length of time since their TBI, some participants felt that incorporating new strategies with
their old ones was a challenge. When participants had strategies in place, these were often self-generated,
having been learnt and used successfully before the TBI. However, some participants were taught these
strategies (e.g. keeping a routine, using external memory aids) by rehabilitation professionals after their TBI.
Most attested to the positive benefits of using such strategies.
All participants reported benefits from having attended the intervention groups. The aspects that they
felt had improved as a result of the intervention have also been reported in previous studies.24,106,113
Improvements related to learning new strategies, reinforcing the use of existing strategies and increased
use of external strategies, all related to improved memory. Furthermore, participants also felt that they
understood how memory worked. Concomitant improvements in confidence and acceptance and reduced
frustrations (with themselves) were also reported. Although most participants reported improved mood as
a result of attending the group sessions, a few felt that being in a group with severely memory-impaired
people affected them adversely.
For some participants the group served an important social function. Participants enjoyed meeting others
‘like them’, who ‘understood them’ (because of their shared condition). In fact, some participants wanted
to extend the relatively formal group meeting to more informal social outings. Some participants did not
want the groups to end. The social aspect of being part of a group of people with TBI helped participants
to not feel isolated. Indeed, people with TBI often report that their social networks have markedly declined
following their injury114 and the groups may serve to establish new networks.
Most participants found the manual useful. They thought that the content was useful and it was easy to
understand. There were a few, however, who thought that the language was too academic and that too
much information was covered in too short a time. However, others thought that there was too much
repetition. We had structured the manual to provide a summary at the end of each session and, in addition,
at the beginning of the next session there was a reminder of what had been covered in the previous session.
Some participants found this helpful, but this is perhaps what others felt was repetition. This again may
point towards the challenges of running a group with participants of very different cognitive abilities.
The group facilitators played a key role in the success of the groups. Most participants found that the facilitators
were knowledgeable and competent to manage the groups. Others spoke about the importance of the
facilitators’ listening skills and making participants feel understood. A few participants did have interpersonal
issues with their facilitator. This may have been because of the facilitators’ inability to deal effectively with a
problem within the group or may have arisen because of the participants’ interpersonal communication style,115
difficulties with personal relationships116 and neurobehavioural problems (such as impulsive behaviour and
reduced frustration tolerance), which are documented psychosocial sequelae of TBI.117 Further training and
support for facilitators may help in this regard.
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Chapter 6 Discussion
Context
This pragmatic trial was designed and conducted in response to a commissioned call for ‘proposals
concerning people needing physical or psychological rehabilitation following trauma in a military or civilian
context’ from the HTA programme.39 This call recognised the need for further research to develop services
that support those who live with the disabilities that are sequelae of trauma, which includes TBI. Cognitive
problems, especially memory problems, are common among those with TBIs and negatively affect people’s
personal, social and professional lives. Indeed, cognitive impairments are the leading cause of TBI-related
disability and affect approximately 43% of those with moderate to severe injuries.118 The intervention in
the ReMemBrIn trial included memory retraining and both internal and external strategies (thereby making
it a comprehensive memory rehabilitation intervention) and the trial addressed most of the limitations
identified in previous memory rehabilitation trials in that it was an adequately powered pragmatic
observer-blinded Phase III RCT that assessed both clinical effectiveness and cost-effectiveness and which
included outcomes at an activity and participation level.
Summary of findings
Clinical effectiveness
Our results indicate that there was no benefit of this memory rehabilitation programme for this group of
people with TBI, with no clinically important difference on the EMQ-p (the primary outcome) between the
two arms at the 6-month follow-up. Although the difference in mean EMQ-p scores between the arms for
those with borderline/moderate memory impairment favoured the memory rehabilitation arm, there was
no statistical evidence of any overall subgroup effect. There were also no important differences between
the arms in terms of memory ability, mood, quality of life, and cognitive, emotional and social well-being
at the 6- or 12-month follow-up. Goal attainment scores, however, favoured the memory rehabilitation
arm at both 6 and 12 months’ follow-up. No safety concerns were raised and no deaths were reported.
Cost-effectiveness
There was ambiguity in our cost-effectiveness findings, which was driven by methodological uncertainty
(based on the impact of different imputation methods) and parameter uncertainty (based on different time
points, outcomes and costs). Although some of the findings suggest that memory rehabilitation could be
seen as cost-effective, with lower costs and lower effects observed for the cost per QALY gained at
12 months, this was based on small, imprecise differences in costs and outcomes. When we take into
account all of the uncertainty in our results, memory rehabilitation is unlikely to be considered cost-effective.
The results of the cost-effectiveness analyses based on the two clinical outcomes (EMQ-p and GHQ-30)
showed consistent results, with the intervention seen as dominant for the base-case multiply imputed data
(i.e. lower cost, greater effect). Again, these results are based on small, non-significant differences in costs
and effects and uncertainty in our findings was seen when these results were further examined. It should be
noted that any technical finding of cost-effectiveness does not overwrite that there was no clinical benefit of
memory rehabilitation for this group of participants.
Qualitative analysis
Despite having memory problems, most people could recall their experience of being involved in the trial,
and those who had received the intervention could recall what they felt about the group sessions. Most
participants’ experiences of being involved in the trial were positive. Most participants preferred a group
format to one-to-one memory rehabilitation, but this finding may have been the result of a selection bias
(i.e. people agreed to take part knowing that they may receive a group intervention). Many participants
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reported the benefits of being in a group in terms of their improved use of strategies and improved levels
of confidence, acceptance and mood. For many, the group also served a social function. The composition
of the group (in terms of the severity of people’s disabilities) affected participants’ experiences of the
sessions. There appeared to be an ‘optimal’ time after injury when people felt that they would have
benefited most from the sessions, which was not too early but not too late either. Participants found the
intervention manual helpful. The success of the group also depended on the knowledge and skills of the
group facilitator.
Interpretation
There are several reasons why this intervention may not have been effective overall. The following factors
may have had an impact on the overall outcome of the trial.
Time since traumatic brain injury
One consideration is that a high proportion of participants were recruited relatively late after TBI, with a
median time since injury of just over 4 years. Hoofien et al.119 found that, even a decade post injury,
people with TBI had cognitive problems and needed professional assistance to maintain a reasonable
quality of life. Therefore, we expected rehabilitation at this late stage to be useful because people’s
lifestyle and expectations change after discharge from rehabilitation and new demands may require the
use of different strategies. In addition, Tsaousides and Gordon120 suggested that cognitive rehabilitation
is effective at any time post injury.
It may be that people had already learnt many of the strategies that were taught in the group sessions or had
established ways of coping that suited them and they were unlikely to adopt new methods of coping. Our
qualitative study provided some support for this assumption (see Timing of the intervention in Chapter 5).
Indeed, other studies121,122 have found that there are various factors related to the use of strategies (particularly
external memory aids). From their survey of people with ABIs, Evans et al.121 observed that many people were
using memory aids, with many more aids being used after the ABI than premorbidly. They also found no
relationship between rehabilitation and the level of memory aid use. Interestingly, they also found that the
longer the time since the injury, the fewer memory aids were used. This again calls into question the impact of
time since injury on strategy use and benefit finding from the rehabilitation programme.
However, our results suggest that additional rehabilitation at this late stage conferred no benefits over
usual care alone. Post hoc subgroup analysis in relation to time since injury (categorised into ≤ 2 years,
2–10 years and > 10 years) found no differences in outcomes. Therefore, this is an aspect that needs to be
investigated further in future studies.
Severity of memory impairment
As this was a pragmatic trial, we recruited people with a wide range of severity of memory problems, which
reflects the range of patients seen in clinical practice. Some reported memory problems in daily life but were
within the average range or above average on the RBMT-3. Although this may be an impairment relative
to their premorbid level, it could also reflect mood problems. It is well recognised that there is a strong
relationship between reported memory problems in daily life and mood problems in people with neurological
conditions.123–126 Therefore, some of those recruited may have reported memory problems associated with
low mood and, therefore, would be unlikely to benefit from memory rehabilitation. However, despite some
previous studies demonstrating better mood in those who had cognitive rehabilitation than in those who did
not,127,128 and previous meta-syntheses of qualitative studies demonstrating this,106,113 our quantitative data
suggested no significant differences between the memory rehabilitation arm and the usual-care arm at the
6- or 12-month follow-up in relation to mood. Interestingly, our qualitative study (see Effects of the group in
Chapter 5) found mixed results, with some people finding benefits in relation to mood as a consequence of
attending the group sessions, but others finding the groups distressing. Furthermore, there were some
participants with very severe problems who may have been too impaired to cope with the demands of the
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intervention. This is supported by the finding that, although we found no benefit overall, those with a
moderate level of impairment on the RBMT-3 showed the greatest benefit from rehabilitation. This is also
consistent with recommendations38 that suggest teaching memory rehabilitation strategies based on the level
of severity of memory impairment.
Format of memory rehabilitation delivery
The intervention was provided on a group basis because we felt that this was more likely to be
cost-effective and resource efficient than individual sessions and, based on previous research,24,106 we
also felt that participants may benefit from interacting with others in a similar situation. The latter point
was supported by the qualitative feedback in which the group aspect was seen to be useful by most
participants (see Preference for rehabilitation format and Format in Chapter 5). Furthermore, Cicerone
et al.,25 on the basis of their systematic review, recommended that ‘Group-based interventions may be
considered for remediation of memory deficits after TBI’ as a ‘Practice Option’ (defined as evidence based
on class II or III studies). However, groups do not suit all (again, evident from our qualitative findings) and
selecting only those who prefer group to individual treatment may have enhanced any benefits. Perhaps
providing a few individual sessions before participants are allocated to a group or alongside group sessions
may enable therapists to better prepare patients for group sessions (e.g. helping them to deal with issues
such as being with others with severe disabilities) and improve attendance at groups.129
The treatment was structured to be delivered as weekly sessions for 10 weeks. Perhaps greater spacing
between sessions would have allowed participants to practise their between-session tasks and to become
more familiar with one strategy before learning about another. In addition, the provision of top-up sessions
over a longer period of time may have helped participants retain information that had been learnt. Indeed,
our qualitative study documented the perceived need for longer sessions and top-up sessions (see Format in
Chapter 5). However, additional sessions may incur additional costs.
Attendance at and dose of memory rehabilitation
Given that our sample had memory problems, attendance at the memory rehabilitation groups was good,
with 77% of participants attending four or more sessions. We assumed, based on our previous studies,23,24
that, given the modular structure of the programme, people would find some benefit from attending at
least four sessions. This is also consistent with our clinical practice. Furthermore, in this study, the reasons
given for non-attendance were also mainly the reasons that are encountered in clinical practice, such as
clashing appointments, rather than because participants withdrew or did not want to continue with
the group sessions. In the Rohling et al.13 meta-analysis, the mean treatment duration was 13.3 weeks
(SD 14.2 weeks), which is similar to the 10 weekly sessions in our trial.
However, one challenge that clinicians and researchers face is determining the optimum ‘dose’ of the
intervention. Very few rehabilitation studies have investigated in detail the optimum dose and format
of memory rehabilitation. Even the large systematic reviews13,25 have not been able to consider the
dose–response effect in memory rehabilitation. One reason for this is that primary studies do not always
provide sufficient details of interventions.130 We expect that reporting guidelines such as the Template for
Intervention Description and Replication (TIDieR) checklist and guide131 and other more specific guidelines
for reporting group memory rehabilitation programmes130 will improve the reporting of these interventions.
Therefore, it seems that more Phase II studies are needed to optimise the recruitment of suitable participants
and to provide the optimum format of the intervention before progressing to a Phase III trial. Indeed,
Cicerone et al.25 stated that ‘future research should move beyond the simple question of whether cognitive
rehabilitation is effective, and examine the therapy factors and patient characteristics that optimise the
clinical outcomes of cognitive rehabilitation’. Thus, attendance rates may have affected outcomes.
Choice of outcomes
We included a variety of outcomes relating to memory (subjective and objective, patient and relative
reports), mood, cognitive, social and emotional well-being and goal attainment, as well as health
economic outcomes.
DOI: 10.3310/hta23160 HEALTH TECHNOLOGY ASSESSMENT 2019 VOL. 23 NO. 16
© Queen’s Printer and Controller of HMSO 2019. This work was produced by das Nair et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
81
There is debate among researchers and clinicians working in neuropsychological rehabilitation about the
most appropriate outcome measures.132 When the trial was designed, we felt that a subjective report
should be the primary end point because this assesses the effect of memory problems on everyday life and
provides a patient-centred outcome rather than the views of health-care professionals. This is also suitable
for independent completion and return by post, which helped to ensure blind assessment of the outcome.
Other studies have considered goal attainment as a primary outcome.65,133 Although we consider this a
valid and useful measure, we felt that it would be more suitable as a secondary outcome measure because
the goals set are strongly influenced by the expectation of the treatment and the goals are likely to change
over the course of the year when follow-up assessments are conducted.
Although GAS, in which goals are set and assessed in collaboration between patients and clinicians, is
considered very much a part of rehabilitation in clinical practice, its application as an outcome measure in
rehabilitation studies poses certain challenges.134 Indeed, Bovend’Eerdt et al.135 documented the challenges
of using GAS as a blinded outcome measure by an independent assessor (who has not been part of a
patient’s clinical team). In a previous crossover trial136 that used goal attainment as a primary outcome, the
randomisation protocol had to be modified to accommodate patient-relevant goals that would fit with the
timing of the intervention. For instance, participants originally allocated to the intervention phase were
moved to the control phase during school holidays if the goal was to remind them to pick up their children
from school. This therefore potentially biased the study.
When we compare the findings from the quantitative and qualitative parts of this study, we find a
discrepancy, with the qualitative study finding benefits of memory rehabilitation. Rohling et al.13 noted that ‘it
is not uncommon for patients and providers to report improvements in the real-world task of compensating
for memory impairment, while the psychometric measures show little or no change’. Goal attainment may
be one way to accurately capture individual patient targets in a systematic and quantitative way, without
having to resort to general preformatted questions that may not be applicable to all. The use of GAS may
also help bridge the gap between what we find in qualitative studies and what we find in quantitative studies
of memory rehabilitation, because it has the ability to identify what matters most to patients. For instance, in
our trial the qualitative findings suggested that participants found improvements in levels of confidence and
acceptance, aspects of improvement that may not have been identified in standardised questionnaires.
Indeed, in our trial, participants’ individually set goals were better met in the memory rehabilitation arm than
in the usual-care arm at both 6 and 12 months’ follow-up. Therefore, if some of the concerns raised about
the use of GAS can be allayed, GAS may be a useful outcome to consider in future trials.
Strengths and limitations
The findings from this trial should be viewed in light of its strengths and limitations. The key limitations are
discussed in the following sections.
Limitations
Heterogeneity
As a pragmatic trial, our inclusion criteria were necessarily broad, which replicates how memory rehabilitation
is delivered in clinical practice and contributes to the generalisability of the findings. However, this also meant
that the sample was heterogeneous, but our trial was not designed to detect differences in the effect of the
group memory rehabilitation (i.e. subgroup effects) according to baseline factors. Therefore, we intend to
further analyse the data in this respect; the findings will provide us with some indications of which groups of
people may benefit most from memory rehabilitation, and this would need to be tested out in future trials.
Generalisability
It was necessary to screen a large number of potential participants to recruit the required sample size,
and a large proportion of those screened were not enrolled. This is largely because of the methods of
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recruitment used, which relied on postal invitations, which are known to suffer from poor response
rates;137 indeed, non-response to the postal invitations accounted for 43% of people screened but not
consented in the current trial. By comparison, only 28% of people were excluded on the grounds of
eligibility, lending support to the representativeness of the current sample.
As a pragmatic trial, to reduce selection bias, we used multiple recruitment sources and strategies,
including self-referrals. Unfortunately, this meant that we did not have demographic data on all those who
were approached and invited or those who chose to self-refer as a result of the study publicity material.
Furthermore, we were unable to collect this information at the recruitment stage because those interested
had not given consent for us to collect these data for research purposes. Therefore, we cannot be certain
whether or not there were differences between the characteristics of those who wanted to take part in the
study and the characteristics of those who did not.
Research suggests that white, middle-class, highly educated men tend to be over-represented in health-care
research in most Western countries.138 Indeed, in our trial 96% of our sample identified as white. Surprisingly,
the literature is sparse regarding racial and ethnic variations in the epidemiology of TBI in the UK. One older
study,139 however, found substantial differences based on ethnic groups in relation to seasonal variations and
differences in length of hospital stay following TBI. In relation to gender, typically men are over-represented
by 3 : 1 in all subgroups of TBI.140 Men formed more than two-thirds of our sample.
Comparability with other trials
Rather than reviewing individual studies, we have opted to compare our findings with those of published
reviews. More men than women sustain brain injuries, with ratios estimated to be between 2 : 1 and
3 : 1.141 This is consistent with our findings, with 73% of participants being male. In the Rohling et al.13
systematic review of cognitive rehabilitation following ABI, the authors identified eight studies that
considered rehabilitation of memory difficulties in TBI. In this review, the mean age of TBI participants
was 29.1 years (SD 15.9 years), whereas our participants were older, with a mean age of 45.4 years
(SD 12 years). The mean treatment duration was 13.3 weeks (SD 14.2 weeks), which is similar to our
treatment duration of 10 weekly sessions.
The Cicerone et al.25 review discusses the various treatment strategies covered in memory rehabilitation in
ABI. Studies that they included in the review used internal memory aids (e.g. visual imagery techniques),
memory retraining and external memory aids (e.g. diaries, pagers and other compensatory strategies). This
suggests that the content of our intervention programme was comprehensive, elements of which have
been investigated in other trials. Most of these trials suggested that participants benefited from using
these strategies.
Fidelity of the intervention
It was a strength of the study that we were able to assess the fidelity of the intervention. The video
analysis suggested that the therapists were delivering the intervention as planned and in accordance with
the manual. However, the main limitation of the video analysis is that recordings were incomplete and did
not include all sites. Some sessions were only partially recorded; recordings stopped partway through a
session, probably because of the camera battery running low, or did not continue after the break, possibly
because of the AP forgetting to turn the camera on again. Some recordings were lost and not transferred
to the main site. This limited the recordings that could be included in the analysis and meant that not all
sessions were observed at each site. Therefore, we cannot be certain that all sessions at all sites were
delivered consistently in accordance with the manual. However, based on feedback obtained during our
monthly peer and supervisor meetings with the APs, we do not expect that the unrecorded sessions were
markedly different from the recorded ones.
Lack of an ‘active’ control arm
One of the challenges of conducting complex intervention trials, particularly in rehabilitation contexts, is
having an ‘active’ control arm. In our pilot trial,23 we included an attention placebo self-help group as the
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control arm. In this group, participants met to discuss their health and memory problems and were taught
relaxation exercises. The group facilitator did not initiate any memory talk. Our fidelity analysis of these
sessions compared with the treatment sessions142 demonstrated that the self-help group underwent
very little discussion around ‘memory’ and significantly less than in our treatment groups. However, our
qualitative research24 suggested that even people in this self-help group were reporting some benefits of
attending the sessions. Therefore, in the ReMemBrIn trial, we opted to have a treatment-as-usual control
arm. However, based on the qualitative data (see Chapter 5, Usual care), it would appear that most people
did not get much by way of usual care. This is a challenge that has been recognised in evaluating complex
intervention and rehabilitation trials.143
Strengths
Despite the limitations reported in the previous section, we believe that this study has several strengths and
has avoided many of the methodological weaknesses identified in previous trials of memory rehabilitation
in TBI.
Methodological quality
The ReMemBrIn trial was a RCT. We took care to ensure allocation concealment and blinding of outcome
assessors. Our SAP was agreed in advance of the data-lock stage. We have reported the trial in line with
the Consolidated Standards of Reporting Trials (CONSORT) guidelines144 and the content, format and
delivery of the intervention in line with the TIDieR131 and other relevant guidelines.130 This should enable
other researchers who wish to replicate this study to deliver the intervention as we have.
Sample size
Most previous studies of memory rehabilitation have been small and underpowered. This is an issue within
the wider field of cognitive rehabilitation studies. The systematic review of Rohling et al.13 identified RCTs
of TBI with sample sizes ranging from 4 to 22. The ReMemBrIn trial was powered to detect a minimum
clinically significant difference in mean EMQ-p score of 12 between the memory rehabilitation arm and the
usual-care arm, taking into account between-site variations and clustering as a result of the intervention
being delivered in a group. The target sample size of 312 was exceeded, with a total of 328 randomised
participants, making this, to our knowledge, the largest trial of its kind to date.
Standardised manualised treatment
We were able standardise the treatment by having a manual and facilitator notes for facilitators at each
site and a workbook for all participants in the memory rehabilitation arm. Facilitator training happened
centrally, and monthly peer supervision and one-to-one supervision with one supervisor for all APs who
delivered the intervention enabled sharing of experiences, which we hoped would encourage APs to
adhere to the manual and facilitator notes. In the training programme and through supervision, we also
taught the APs how they could adhere to the manual but also adapt the contents of each session to the
needs of individuals within the group and the group as a whole.
Assessment of treatment fidelity
Our videos of the rehabilitation sessions from the various sites were coded and rated by two independent
raters, which enabled us to determine the consistency of delivery of the intervention. There was some
variation between sites, but part of this may have been because of variations in the sessions available for
analysis between sites. Site 5 recordings were mainly from early sessions whereas recordings from sites 3,
8 and 9 were mainly from later sessions. This may account for the high proportion of time spent discussing
the venue and organisational issues in the recordings from site 5 rather than discussing strategies. This site
also included more facilitation of discussion, probably because this was needed more in the early sessions
than in the later sessions.
Time sampling, in which behaviours are observed and recorded for a specific period of time,145 has been
used mainly for ward-based observations of behavioural problems but we have found it useful to adapt
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this method to assess the ‘content fidelity’ of group-based rehabilitation interventions delivered in a
research context with participants with neurological conditions.142,146
Content fidelity has been defined as ‘the extent to which each intervention component was effectively
delivered to the participants in terms of required content’.147 The recording of activities indicated that
appropriate content was covered. ‘Process fidelity’ was evident from the therapist skills observed, such
as facilitating discussion, summarising and paraphrasing. However, process fidelity also involves the
interpersonal skills of the therapist147 and there was no attempt to rate the quality of the interactions.
The fidelity to the intervention manual and consistency between therapists could have been improved if
we had analysed the first group conducted by all APs and provided them with detailed feedback. This
could then have been carried out routinely to ensure that there was no ‘drift’ in terms of intervention
delivery for the rest of the trial. This of course has resource implications; therefore, in this trial, we analysed
the video data only at the end of the trial.
In the delivery of complex interventions, we cannot be certain what the key ingredients are that would
contribute to a positive outcome. In this study, we decided on the coding frame based on the activities
and skills described in the manual. However, there may be other important aspects of the group sessions,
such as group cohesiveness and therapist experience, which were not monitored.
Follow-up completion rates
Although 84% of the sample completed the assessment visit at the 6-month follow-up, only 75% and
78% of the participant questionnaires from the memory rehabilitation and usual-care arms, respectively,
could be included in the primary analysis. This is slightly below our 80% response rate target; however,
sensitivity analyses using multiple imputation to impute missing outcome data gave very similar results to
the analysis using the available data.
Activity- and participation-level outcomes
Outcomes related to activity and participation levels of the ICF framework.31 Frontera et al.,143 in their
summary of the Rehabilitation Research at the National Institutes of Health: Moving the Field Forward
conference, stated that ‘In rehabilitation research, outcomes are often complex, occur across the domains
of the International Classification of Function, and include patient-reported as well as performance-based
and instrumented outcomes’. Many of the previous studies used impairment-level measures to assess
the outcome of memory rehabilitation. Although impairment-level measures are useful in understanding
the potential mechanisms that underlie changes effected by rehabilitation, as outcomes, they may not
generalise to meaningful functional outcomes for patients.148 Many of these impairment-level measures
are ‘objective’ measures (i.e. based on cognitive tests). However, studies have also shown discrepancies
between perceived and objective cognitive functioning,149,150 with subjective ratings being influenced by
mood and self-efficacy. We acknowledge that the EMQ-p would have been influenced by these factors,
but felt that it was the appropriate primary outcome because we expected participants who received the
intervention to report a reduction in forgetting and improvements in coping with memory problems, which
is in keeping with the spirit of cognitive rehabilitation.70 Furthermore, we also included an objective
measure of memory and relatives’ assessment of participants’ memory failures as secondary outcomes.
Goal attainment was also a secondary outcome.
Another strength related to outcomes is that we assessed participants at both 6 and 12 months’ follow-up;
therefore, in this study we were able to evaluate the longevity of the treatment effect, if any. Most previous
studies have assessed outcomes only proximal to the end of the intervention.
Economic analysis
Past studies have considered only the clinical effectiveness of memory rehabilitation. To our knowledge, this
is the first trial to have determined the cost of delivering memory rehabilitation and the cost-effectiveness of
memory rehabilitation.
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Lessons learnt
Throughout the trial we experienced some delays. These largely occurred as a result of unforeseen
circumstances beyond our control. At one site, the AP was not allowed access to the patient database
after there was disagreement between the trust’s Caldicott Guardian and its research and development
(R&D) department (after all approvals were granted) in relation to data access. This resulted in us having to
raise this with the head of R&D at that trust and required us to recruit a new AP at the trust (instead of a
secondment from the sponsoring trust). One site changed its organisational structure from being a NHS
trust to being a social enterprise without a R&D department. We therefore had to subcontract a research
consortium to act as that site’s R&D approvers. At one site, there was a delay in recruiting the AP because
of an impasse between the comprehensive local research network and the NHS trust regarding finances.
This took 5 months to resolve. In these instances, a considerable amount of time was spent in escalating
the issue to the trust’s R&D directors and chief executives, with a view to resolving the issues.
In addition to these problems, we did have one recurrent problem: keeping APs in post. We chose to appoint
APs to deliver the intervention because they had the qualifications and skills to deliver low-intensity manualised
interventions under the supervision of a clinical psychologist. They often deliver such interventions in the NHS
and are seen as a safe, cost-efficient way of providing psychological therapies for some circumscribed problems.
Assistant psychologists are graduates who work in NHS trusts, typically for 1 year, before they move on to
work in another area (seeing a different patient group) or they are successful in obtaining a place on a
doctorate in clinical psychology programme. Therefore, by appointing the best and most experienced APs,
we could retain them only for a year, needing to readvertise and recruit to each post a number of times at
each site. To mitigate delays in recruitment, we developed and shared to the principal investigators at all of
the sites’ draft advertisements, job descriptions and person specifications for the job. We also kept a log of
when APs’ contracts were coming to an end and worked closely with the APs to ensure that they would
give us sufficient notice to allow us to recruit someone to their post, preferably before they left. Knowing
the patterns of when APs were scheduled to leave the team to start on their doctoral course (if successful
in obtaining a place) allowed us to factor this in to our recruitment projections, with a slowing down of
participant recruitment around this time. This therefore provided us with a more realistic monthly
recruitment target.
These delays caused an overall delay in participant recruitment. However, when we did have staff available
in active sites, participant recruitment was not a problem (see Figure 14 and Appendix 5).
We attempted to recruit military personnel into the trial. We obtained the necessary research ethics
approval from the Ministry of Defence, had a TSC member who had experience of working with military
charities and recruited a PIC to identify potential participants. Despite various attempts to identify potential
participants with this PIC and relevant military charities, we did not succeed in recruiting many participants
from the military. Future studies may benefit from having a military co-applicant within the research team
and may need to have confirmed support from military command.
Another delay occurred between assessing and randomising participants. Participants waited a median of
18 days between the second assessment and randomisation. This is inevitable in studies in which the
intervention is delivered in a group format. We needed to gather a sufficient number of participants
who were eligible to take part in the study and could attend at a particular time and place. We did learn,
however, that targeting a specific geographical area (e.g. postcodes within a small area) by sending our
recruitment mailouts in small batches as opposed to one large mailout to a large area enabled us to form
clusters faster, as participants were able to travel to the venue where the groups were held. Interestingly,
the delay did not deter people from wanting to participate. However, in conditions in which people’s
cognitive function can fluctuate or deteriorate, such as in multiple sclerosis, this may mean that their
baseline assessments may not reflect their cognitive ability at the start of the intervention.
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We experienced problems in collecting postal outcome questionnaires from our participants, as their
memory problems resulted in them forgetting to complete the questionnaires or send them back to us.
This resulted in a lower than expected initial response rate for the outcome questionnaires. However, we
were able to identify this problem quite early on and institute a recovery plan. This plan necessitated the
outcome assessor checking with participants at the time of their 6-month outcome visit whether or not
they had completed the questionnaire. If they had not, a new questionnaire pack was provided for them
to complete and for the outcome assessor to return to the NCTU. This change to our procedure resulted in
an increase in our response rate for the 6-month questionnaire, from 73% before we instituted this plan
to 81.5% after.
We trust that the lessons that we have learnt serve to inform future researchers when they develop their
research protocols.
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Chapter 7 Conclusions
Implications for practice
This trial has not shown any benefit of this group memory rehabilitation for people with TBI late after their
injury. However, people continue to report memory problems later after injury and the qualitative feedback
from the participants who received the intervention was positive. Clinicians therefore need to identify what
interventions may be useful at this late stage after TBI.
Recommendations for research
The results of this study highlight the need for more adequately powered studies of memory rehabilitation
in patients with TBI. Despite extensive development work and early studies suggesting that the intervention
was potentially effective, the findings suggest that our group-based memory rehabilitation conferred no
benefit over usual care in the NHS.
l There are a range of other memory rehabilitation strategies, such as computer games, mnemonics
training and visual imagery, and these all need full-scale evaluation. Interventions can be delivered in
individual or group formats and can be delivered face to face or on a computer. Future research may
consider the usefulness of online and internet-based memory rehabilitation. The effect of the format of
delivery on outcomes needs to be established. In addition, the question of what works best for whom
requires further consideration of participant selection to ensure that people receive the treatment that
is most appropriate to their needs. All of these issues require more RCTs of high methodological quality.
l We used a usual-care control arm to determine whether the memory rehabilitation programme
conferred any benefits over and above what was provided in the NHS. However, usual care is difficult
to document and varies between sites. Future studies would benefit from developing appropriate
attention control interventions to assess the specific effects of the intervention. Although we have
previously used an attention control for memory rehabilitation,23 this proved difficult to deliver as a
plausible control activity of equivalent duration and intensity. Utilising other support services, such a
Headway groups, as a control intervention may enable better identification of the essential components
of treatment.
l Future research will need to consider more small-scale efficacy studies to establish appropriate selection
criteria for group memory rehabilitation programmes, so that interventions can be tailored to those
who can benefit. Research will also need to offer more information on usual care for people with
memory problems following TBI so that group memory rehabilitation can be evaluated in those who
have not already been taught the strategies covered in the group programme.
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Appendix 1 Participating sites
TABLE 26 Participating sites
Lead NHS trust Date opened to recruitment Number of months open
Cheshire and Wirral Partnership NHS Foundation Trust 6 February 2013 23
Nottingham University Hospitals NHS Trust 7 February 2013 31
Birmingham Community Healthcare NHS Trust 18 April 2013 5
Central Surrey Health 30 April 2013 7
The Walton Centre NHS Foundation Trust 12 March 2014 21
Sheffield Health and Social Care NHS Foundation Trust 3 November 2014 13
St George’s Healthcare NHS Trust 18 March 2015 9
North Bristol NHS Trust 1 May 2015 7
South Tees Hospitals NHS Foundation Trust 12 June 2015 6
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Appendix 2 Plan of study procedures and
data collection
TABLE 27 Data collection
Assessments
Time point
Initial screening
assessment
Second
assessment visit
6-month
follow-up
12-month
follow-up
Initial eligibility screening ✓a
Informed consent ✓a
Demographic information ✓a
EMQ-p ✓a ✓b ✓b
RBMT-3 ✓a ✓a ✓a
SST ✓a
NART ✓a
GHQ-30 ✓a ✓b ✓b
Setting of short- and long-term goals ✓a
EQ-5D-5L ✓a ✓b ✓b
SUQ ✓a ✓b ✓b
EMQ-r ✓b ✓b ✓b
Check availability for treatment group ✓a
EBIQ-p ✓b ✓b
EBIQ-r ✓b ✓b
RA opinion on participants’ treatment group
before and after assessment of goals
✓a ✓a
Assessment of individual goal attainment ✓a ✓a
Qualitative feedback interviews with a
sample of participants
✓c
Clinical data collected from medical notes
where available
✓
a Completed during visit.
b Included in the questionnaire pack.
c Completed within 2 months of the 6-month follow-up visit.
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Appendix 3 Treatment fidelity coding schedule
TABLE 28 Coding schedule for analysis of video recordings
Activites
Non-rehabilitation Rehabilitation
Activities Code AP skills Code AP activities Code Participant Code
Introductions T1, P1 Facilitating discussion
(non-specific prompts)
T7 Presenting/discussing
educational material
T10 Discussing/filling
in educational
material
P10
Social chat T2, P2 Providing feedback
not directly related to
content of manual
T8 Presenting/discussing
strategies
T11 Discussing
strategies
P11
Preparing materials,
tasks, etc.
T3, P3 Providing
encouragement/
reassurance
T9 Providing general
information related
to memory that is
not covered in
educational material
T15 Asking for
information
P12
Information about
sessions, venue, group,
etc.
T4, P4 Summarising T16 Recap of previous
session
T18 Feedback on
home activities
P13
Hospital visit discussion T5, P5 Paraphrasing T17 Describing
problems related
to memory
P14
Describing emotions
and coping strategies
T6, P6
P, participant; T, assistant psychologist.
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Appendix 4 Estimates of the intracluster
correlation coefficient in the memory rehabilitation
arm for each outcome calculated from the
multilevel models
TABLE 29 Estimates of the ICC in the memory rehabilitation arm
Outcome
Time point
6 months 12 months
EMQ-p – frequency of problems 0.05 0.00
EMQ-p – importance of problems 0.00 0.00
GHQ-30 0.07 0.00
RBMT-3 (GMI) 0.00 0.00
Short-term goal achievement average score 0.13 0.00
Long-term goal achievement average score 0.06 0.00
EBIQ-p – cognitive 0.00 0.00
EBIQ-p – depression 0.00 0.00
EBIQ-p – communication 0.09 0.03
EBIQ-p – difficulties in social interactions 0.00 0.00
EMQ-r – frequency of problems 0.00 0.00
EMQ-r – importance of problems 0.00 0.01
EMQ-r – cognitive 0.08 0.00
EMQ-r – depression 0.00 0.00
EMQ-r – communication 0.04 0.09
EMQ-r – difficulties in social interactions 0.00 0.00
ICCs calculated using the multilevel linear model used for the analysis of each outcome.
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Appendix 5 Cumulative recruitment against
target
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Appendix 6 Further details of patients who did
not enrol in the trial
TABLE 30 Reasons that participants were not eligible for the trial
Reason Number of participants Percentage of those screened
Unsuitable for group 236 6
Involved in other study 1 0
Impairment of language 26 1
TBI < 3 months previously 8 0
Aged < 18 years 33 1
Aged > 69 years 622 15
Unable to travel 196 5
Unable to consent 7 0
Total 1129 28
TABLE 31 Other reasons for non-enrolment in the trial
Other reasons for non-enrolment Number of participants Percentage of those screened
Deceased 119 3
Not TBI 167 4
No memory difficulties 105 3
Declined 75 2
Unable to contact 66 2
English-language difficulties 36 1
Working or no time 24 1
Out of area 23 1
Other illness 16 0
Not accepted/did not engage 12 0
Cause of brain injury unknown 10 0
Did not attend 9 0
Clinician’s advice 9 0
Other rehabilitation 7 0
Recruitment closed at site 5 0
Student, so unable to attend 2 0
Not known 33 1
Total 718 18
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Appendix 7 Randomisation by trial arm and site
TABLE 32 Cluster and participant randomisation by trial arm and site
Summary
Trial arm, n
Total, nUsual care Memory rehabilitation
Number of clusters randomised
Site 1 8 8 16
Site 2 0 1 1
Site 3 4 6 10
Site 4 2 1 3
Site 5 7 7 14
Site 6 6 6 12
Site 7 1 2 3
Site 8 1 2 3
Site 9 2 2 4
Number of participants randomised
Site 1 38 39 77
Site 2 0 5 5
Site 3 19 27 46
Site 4 10 4 14
Site 5 36 33 69
Site 6 33 33 66
Site 7 5 8 13
Site 8 4 11 15
Site 9 12 11 23
Size of cluster randomised
4 10 12 22
5 9 15 24
6 12 8 20
Days between initial screening and randomisation
Median (25th, 75th centile) 39 (20, 110) 29 (21, 62) 33 (21, 78.5)
Min., max. 6, 455 5, 317 5, 455
Days between second assessment and randomisation
Median (25th, 75th centile) 22 (7, 90) 15 (8, 42) 18 (8, 54.5)
Min., max. 0, 444 0, 282 0, 444
max., maximum; min., minimum.
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Appendix 8 Other clinical data collected
at baseline
TABLE 33 Other clinical data collected at baseline
Variable
Trial arm
Total (N= 328)Usual care (N= 157) Memory rehabilitation (N= 171)
Clinical notes available, n (%) 58 (37) 42 (25) 100 (30)
Clinical notes not available, n (%) 99 (63) 129 (75) 228 (70)
Type of head injury, n (%)
Open 5 (9) 4 (10) 9 (9)
Closed 39 (67) 31 (74) 70 (70)
Unknown 14 (24) 7 (17) 21 (21)
Severity of the head injury (GCSa)
Closest to admission
Median (25th, 75th centile) 10 (6, 14) 12 (6, 15) 11.5 (6, 14)
Min., max. 3, 15 3, 15 3, 15
n 25 21 46
Unknown, n (%) 33 (57) 21 (50) 54 (54)
Worst total score
Median (25th, 75th centile) 8.5 (4, 14) 9 (4, 14) 8.5 (4, 14)
Min., max. 3, 15 3, 15 3, 15
n 22 18 40
Unknown, n (%) 36 (62) 24 (57) 60 (60)
Other neurological conditions,b n (%)
None 35 (60) 31 (74) 66 (66)
Stroke 0 2 (5) 2 (2)
Subarachnoid haemorrhage 3 (5) 5 (12) 8 (8)
Epilepsy 8 (14) 4 (10) 12 (12)
Multiple sclerosis 0 0 0
Parkinson’s disease 0 0 0
Otherc 4 (7) 0 4 (4)
Unknown 8 (14) 1 (2) 9 (9)
max., maximum; min., minimum.
a GCS scores range from 3 to 15, with lower scores indicating more severe brain injury.
b Not mutually exclusive, two conditions ticked for one participant.
c Other neurological conditions reported were paraplegic T9/T10 spinal cord severed, attention deficit disorder, seizures
undiagnosed – under investigation and transient ischaemic attack.
Note
Percentages for type of head injury and other neurological conditions use the number of participants with clinical notes
available as the denominator.
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Appendix 9 Attendance at group
memory rehabilitation
TABLE 34 Attendance at each session of group memory rehabilitation
Session
Attendance Duration (minutes) Size of group in attendance
n % Median Min., max. Median Min., max.
1 124 73 90 60, 110 4 1, 6
2 124 73 90 60, 110 4 1, 6
3 114 67 90 75, 185 3 1, 6
4 108 63 90 70, 110 3 1, 5
5 108 63 90 60, 100 3 1, 5
6 101 59 90 60, 95 3 1, 5
7 103 60 90 60, 105 3 0, 6
8 106 62 90 60, 110 3 0, 6
9 94 55 90 50, 110 3 0, 5
10 101 59 90 60, 120 3 0, 5
max., maximum; min., minimum.
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Appendix 10 Additional details of the treatment
fidelity analysis
TABLE 35 Video recordings available for inclusion in the analysis
Site Group
Videos
Available Included in analysis
1 003 Sessions 4–10 Sessions 4–6 and 8–10
011 Sessions 5 and 7–9 Sessions 8 and 9
012 Sessions 9 and 10 Sessions 9 and 10
020 Sessions 1, 2, 4, 6 and 7 Sessions 1, 2, 4 and 6
023 Sessions 2–5 and 8 Sessions 2 and 5
024 Sessions 2–4 Sessions 3 and 4
031 Sessions 1, 3–5 and 8–10
036 Sessions 1 and 3–8
2 008 First group
3 001 First group
017 Session 4, 5, 9 and 10 Sessions 9 and 10
018 Sessions 8 and 9 Session 8
021 Sessions 3 and 8
029 No recordings
032 No recordings
4 004 First group
5 016 Sessions 1–5 Sessions 1 and 4
028 No recordings
041 No recordings
042 No recordings
044 No recordings
061 No recordings
066 No recordings
6 038 First group
039 No recordings
045 Session 6 Session 6
047 Sessions 2 and 9 Session 2
050 No recordings
055 No recordings
7 048 First group
062 Camera missing
8 053 First group
057 Sessions 8–10 Sessions 8 and 10
9 056 First group
058 Sessions 5–9 Sessions 5–8
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TABLE 36 Summary of number of recorded sessions included in the analysis
Site
Session
Total1 2 3 4 5 6 7 8 9 10
1 1 2 1 3 2 2 0 2 3 2 18
3 0 0 0 0 0 0 0 1 1 1 3
5 1 0 0 1 0 0 0 0 0 0 2
6 0 1 0 0 0 1 0 0 0 0 2
8 0 0 0 0 0 0 0 1 0 1 2
9 0 0 0 0 1 1 1 1 0 0 4
Total 2 3 1 4 3 4 1 5 4 4 31
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TABLE 37 Frequency of AP activity observations for each sitea
Category
Site
Total1 3 5 6 8 9
n % n % n % n % n % n % n %
Non-rehabilitation activities
Introductions 3 0.5 0 0 0 0 0 0 0 0 2 1.1 5 0.4
Social chat 24 3.7 4 3.4 3 4.5 1 1.3 2 3.0 4 2.2 38 3.2
Preparing materials, tasks, etc. 17 2.6 2 1.7 1 1.5 0 0 3 4.5 0 0 23 2.0
Information about sessions,
venue, group, etc.
32 4.9 4 3.4 14 20.9 1 1.3 1 1.5 4 2.2 56 4.8
Hospital visit discussion 0 0 0 0 1 1.5 0 0 0 0 1 0.5 2 0.2
Describing emotions and coping
strategies
6 0.9 1 0.9 0 0 0 0 0 0 1 0.5 8 0.7
Rehabilitation skills
Facilitating discussion
(non-specific prompts)
18 2.7 1 0.9 11 16.4 2 2.5 6 9.0 3 1.6 41 3.5
Providing feedback not directly
related to manual
19 2.9 0 0 2 3.0 2 2.5 5 7.5 0 0 28 2.4
Providing encouragement/
reassurance
24 3.7 1 0.9 3 4.5 3 3.8 0 0 6 3.2 37 3.2
Summarising 3 0.5 0 0 0 0 0 0 0 0 0 0 3 0.3
Paraphrasing 13 2.0 1 0.9 1 1.5 6 7.5 0 0 1 0.5 22 1.9
Rehabilitation activities
Presenting/discussing educational
material
200 30.4 40 34.5 19 28.4 43 53.8 28 41.8 39 21.0 369 31.5
Presenting/discussing strategies 216 32.9 42 36.2 11 16.4 11 13.8 18 26.9 122 65.6 420 35.8
Providing general information on
memory not related to manual
35 5.36 0 0 1 1.5 3 3.8 1 1.5 2 1.1 42 3.6
Recap of previous session 47 7.2 20 17.2 0 0 8 10.0 3 4.5 1 0.5 79 6.7
Total 657 100 116 100 67 100 80 100 67 100 186 100 1173 100
a n= number of observations; % = percentage of observations.
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APPENDIX 10
126TABLE 38 Frequency of participant activity observations for each siteaNCategoryIHR Journals Library www.journalslibrary.nihr.aSitec.ukTotal1 3 5 6 8 9n % n % n % n % n % n % n %Non-rehabilitationIntroductions 7 1.1 0 0 2 2.2 0 0 0 0 0 0 9 0.8Social chat 109 16.4 25 17.1 9 10.0 2 4.4 14 20.0 26 16.5 185 15.8Preparing materials, tasks, etc. 6 0.9 0 0 0 0 0 0 0 0 0 0 6 0.5Information about sessions,
venue, group, etc.11 1.7 1 0.7 4 4.4 0 0 1 1.4 1 0.6 18 1.5Hospital visit discussion 1 0.2 0 0 10 11.1 0 0 0 0 0 0 11 0.9Describing emotions and coping
strategies50 7.5 9 6.2 3 3.3 1 2.2 10 14.3 1 0.6 74 6.3RehabilitationDiscussing/filling in educational
material147 22.1 31 21.2 32 35.6 8 17.8 16 22.9 48 30.4 282 24.0Discussing strategies 216 32.5 62 42.5 15 16.7 12 26.7 11 15.7 66 41.8 382 32.6Asking for information 10 1.5 4 2.7 0 0 5 11.1 0 0 2 1.3 21 1.8Feedback on home activities 32 4.8 9 6.2 0 0 4 8.9 13 18.6 11 7.0 69 5.9Describing problems related to
memory75 11.3 5 3.4 15 16.7 13 28.9 5 7.1 3 1.9 116 9.9Total 664 100 146 100 90 100 45 100 70 100 158 100 1173 100a n= number of observations; %= percentage of observations.
Appendix 11 Baseline characteristics and
assessments completed according to primary outcome
completion and allocated trial arm
TABLE 39 Baseline characteristics and assessments completed prior to randomisation according to EMQ-p
completion at 6 months and allocated trial arm
Characteristic/assessment
Trial arm
Usual care Memory rehabilitation
No primary outcomea
(N= 35)
Primary outcome
(N= 122)
No primary outcomea
(N= 42)
Primary outcome
(N= 129)
Age (years)
Mean (SD) 45.4 (11.1) 45 (12.9) 44.1 (11.6) 46.3 (11.5)
Median (25th, 75th centile) 46 (38, 54) 44.5 (35, 55) 45 (35, 53) 48 (39, 54)
Min., max. 25, 63 19, 69 20, 65 21, 68
Gender, n (%)
Men 28 (80) 88 (72) 30 (71) 93 (72)
Women 7 (20) 34 (28) 12 (29) 36 (28)
Ethnicity, n (%)
White 30 (86) 117 (96) 42 (100) 125 (97)
Black 4 (11) 2 (2) 0 2 (2)
Mixed ethnicity 0 3 (2) 0 1 (1)
Other 1 (3) 0 0 1 (1)
Residential status, n (%)
Lives alone 8 (23) 36 (30) 11 (26) 32 (25)
Lives with others 25 (71) 81 (66) 28 (67) 92 (71)
Living with informal care 1 (3) 1 (1) 0 1 (1)
Living with formal care 0 2 (2) 0 0
Living in care home 1 (3) 2 (2) 3 (7) 4 (3)
Highest educational attainment, n (%)
Below GCSE 7 (20) 19 (16) 10 (24) 19 (15)
GCSE 17 (49) 37 (30) 16 (38) 33 (26)
A Level 4 (11) 38 (31) 8 (19) 26 (20)
Degree 6 (17) 18 (15) 5 (12) 36 (28)
Higher degree 0 10 (8) 3 (7) 14 (11)
Not known 1 (3) 0 0 1 (1)
Current military service, n (%)
Military 3 (9) 1 (1) 0 0
TA/reservist 0 0 0 2 (2)
Non-military 32 (91) 121 (99) 42 (100) 127 (98)
continued
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TABLE 39 Baseline characteristics and assessments completed prior to randomisation according to EMQ-p
completion at 6 months and allocated trial arm (continued )
Characteristic/assessment
Trial arm
Usual care Memory rehabilitation
No primary outcomea
(N= 35)
Primary outcome
(N= 122)
No primary outcomea
(N= 42)
Primary outcome
(N= 129)
Previous military service, n (%)
Military 4 (11) 10 (8) 3 (7) 8 (6)
TA/reservist 1 (3) 1 (1) 2 (5) 2 (2)
Non-military 30 (86) 111 (91) 37 (88) 119 (92)
TBI during service, n (%) 2 (6) 1 (1) 0 1 (1)
Time since TBI (months)
Mean (SD) 103.9 (139.3) 97.6 (107.4) 102.4 (106.5) 102.7 (116)
Median (25th, 75th centile) 44 (21, 101) 49 (24, 119) 68 (24, 151) 55 (27, 139)
Min., max. 4, 491 4, 520 4, 410 3, 587
Length of initial hospital stay for TBI (days)
Mean (SD) 61.2 (95.5) 87.7 (111.7) 97.4 (200.5) 83 (120.5)
Median (25th, 75th centile) 21 (7, 63) 36 (7, 122) 35 (9, 84) 38 (11, 120)
Min., max. 1, 468 0, 465 0, 999 0, 999
n 33 115 39 121
Length of hospital stay
unknown, n
2 7 3 8
EMQ-p score – frequency of problems
Mean (SD) 54.1 (26.5) 48.9 (23.9) 51.9 (20.5) 45.9 (21)
Median (25th, 75th centile) 53 (33, 75.4) 48 (32, 64) 56 (43, 68) 44 (30, 60)
Min., max. 12, 105 0, 105 8, 93 5, 102
n 35 121 42 129
EMQ-p score – importance of problems
Mean (SD) 76.7 (18.3) 68.8 (23.2) 66.7 (19.8) 65.4 (24.6)
Median (25th, 75th centile) 80.9 (67, 89) 70.5 (54, 85) 69.5 (51, 81.9) 69 (51.5, 84)
Min., max. 27, 108 2, 112 5, 101 0, 112
n 34 118 42 128
RBMT-3 GMI score
Mean (SD) 73.5 (13.8) 77.2 (14.6) 74 (12) 78.8 (13.9)
Median (25th, 75th centile) 71 (63, 84) 76 (66, 86) 74.5 (65, 83) 78 (68, 85)
Min., max. 53, 106 53, 114 53, 98 56, 127
n 35 122 42 129
GHQ-30 score
Mean (SD) 39.4 (17.7) 34.2 (15.8) 34.7 (14.5) 36.6 (15.7)
Median (25th, 75th centile) 36.5 (27, 52) 32.5 (21, 45) 32.5 (24, 39) 34.5 (25, 45.3)
Min., max. 10, 90 6, 82 6, 70 10, 84
n 34 120 42 128
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TABLE 39 Baseline characteristics and assessments completed prior to randomisation according to EMQ-p
completion at 6 months and allocated trial arm (continued )
Characteristic/assessment
Trial arm
Usual care Memory rehabilitation
No primary outcomea
(N= 35)
Primary outcome
(N= 122)
No primary outcomea
(N= 42)
Primary outcome
(N= 129)
Estimated premorbid IQ (NART)
Mean (SD) 105.4 (9.5) 106.9 (10.1) 106 (10.2) 108.8 (10.1)
Median (25th, 75th centile) 102 (100, 116) 103 (99, 117) 103 (100, 114) 112 (100, 117)
Min., max. 89, 121 86, 126 88, 124 87, 128
n 33 122 42 128
SST score
Mean (SD) 19.4 (0.9) 19.3 (0.9) 19.1 (1.0) 19.5 (0.8)
Median (25th, 75th centile) 20 (19, 20) 20 (19, 20) 19 (19, 20) 20 (19, 20)
Min., max. 17, 20 17, 20 17, 20 17, 20
n 35 122 42 129
Level of memory impairment based on RBMT-3 score, n (%)
Significant memory
impairment (≤ 69)
16 (46) 45 (37) 15 (36) 35 (27)
Borderline/moderate
memory impairment
(70–84)
11 (31) 43 (35) 18 (43) 59 (46)
Average range or above
average range (≥ 85)
8 (23) 34 (28) 9 (21) 35 (27)
Relative/friend agreed to
participate in trial, n (%)
17 (49) 83 (68) 27 (64) 83 (64)
EMQ-r score – frequency of problems
Mean (SD) 53 (28) 45.2 (23.7) 56.8 (29.7) 37.4 (26.6)
Median (25th, 75th centile) 55.5 (24, 77.6) 41 (27, 58.2) 62 (30, 83) 32.3 (17, 58.5)
Min., max. 10, 98 0, 107 6.2, 108 0, 104
n 14 81 25 80
EMQ-r score – importance of problems
Mean (SD) 78.3 (14.6) 70.2 (25.9) 74.5 (19.5) 70.8 (21.6)
Median (25th, 75th centile) 80.8 (67.4, 88) 76 (58, 87) 71 (63, 88.4) 72.6 (60, 87)
Min., max. 52.7, 104 0, 112 33, 112 4, 112
n 15 75 27 74
GCSE, General Certificate of Secondary Education; IQ, intelligence quotient; max., maximum; min., minimum.
a The ‘no primary outcome’ group includes participants who did not complete the questionnaire, participants who
completed the questionnaire > 9 months after randomisation and participants who completed the questionnaire but
missed more than three items on the EMQ.
Notes
EMQ scores range from 0 to 112, with higher scores indicating more frequent/important memory problems.
RBMT-3 GMI scores range between 52 and 174 and have been standardised to have a mean of 100 and a SD of 15 in a
demographically representative sample from the UK.
GHQ-30 score ranges from 0 to 90, with higher scores indicating increased psychological distress.
A total SST score of ≥ 17 was required to participate in the trial (maximum score 20).
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Appendix 12 Unblinding of outcome assessors
TABLE 40 Unblinding of outcome assessors at the 6- and 12-month follow-up visits and opinion of treatment
allocation
Variable
Follow-up time point
6 months 12 months
Usual care
(N= 133),
n (%)
Memory
rehabilitation
(N= 143), n (%)
Kappa
statistic
Usual care
(N= 124),
n (%)
Memory
rehabilitation
(N= 132), n (%)
Kappa
statistic
Unblinded prior to the visit 9 (7) 35 (24) 9 (7) 28 (21)
Unblinded during the visit 16 (12) 52 (36) 7 (6) 36 (27)
Unblinded prior to and/or
during the visit
21 (16) 64 (45) 13 (10) 42 (32)
Opinion of treatment
allocation prior to goal
assessment
0.24 0.26
Definitely control 9 (7) 0 7 (6) 1 (1)
Probably control 109 (82) 92 (64) 111 (90) 90 (68)
Probably intervention 15 (11) 19 (13) 4 (3) 14 (11)
Definitely intervention 0 32 (22) 2 (2) 27 (20)
Opinion of treatment
allocation after goal
assessment
0.42 0.46
Definitely control 21 (16) 2 (1) 9 (7) 2 (2)
Probably control 97 (73) 64 (45) 108 (87) 61 (46)
Probably intervention 14 (11) 17 (12) 6 (5) 28 (21)
Definitely intervention 1 (1) 60 (42) 1 (1) 41 (31)
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Appendix 13 Relative/friend questionnaire
booklet return
TABLE 41 Rates of return of relative/friend questionnaire booklet at follow-up
Variable
Follow-up time point
6 months 12 months
Usual care
(N= 100),
n (%)
Memory
rehabilitation
(N= 110), n (%)
Total
(N= 210),
n (%)
Usual care
(N= 100),
n (%)
Memory
rehabilitation
(N= 110), n (%)
Total
(N= 210),
n (%)
Questionnaire bookleta
Returned 73 (73) 71 (65) 144 (68) 61 (61) 70 (64) 131 (62)
Not returned 21 (21) 27 (25) 48 (22) 24 (24) 22 (20) 46 (22)
Participant
discontinued
6 (6) 12 (11) 18 (8) 15 (15) 18 (16) 33 (16)
Days to completion from randomisation
Median
(25th, 75th centile)
171
(167, 179)
174
(168, 184)
173
(167, 181)
352
(349, 360)
358
(353, 365)
355
(350, 363)
Min., max. 161, 277 156, 268 156, 277 341, 433 345, 420 341, 433
Questionnaire
completed within
3 months of
due dateb
72 (72) 71 (65) 143 (68) 61 (61) 70 (64) 131 (62)
max., maximum; min., minimum.
a Percentages for questionnaire booklet return use the number of relatives/friends agreeing to participate in the trial as
the denominator.
b Questionnaire completion within 9 months of randomisation at the 6-month follow-up and within 15 months of
randomisation at the 12-month follow-up.
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Appendix 14 Sensitivity analyses for the
primary outcome
TABLE 42 Analysis after Rasch conversion of the EMQ-p score
Trial arm
Time point, mean (SD)
Adjusted difference in means
(95% CI)Baseline 6 months
Usual care (n = 122) 21.7 (8.1) 20.0 (8.3)
Memory rehabilitation (n= 129) 21.3 (6.8) 17.7 (9.5) –1.2 (–3.0 to 0.5)
Note
For Rasch scoring, EMQ items were first rescored as 00112 and totalled. The total score was then converted to the Rasch score
using a conversion table for TBI patients (Rachel Johnson, Roshan das Nair and Nadina B Lincoln, University of Nottingham, 2017,
personal communication). Rasch-converted scores range from 0 to 56.04.
– 32 – 28 – 24 – 20 – 16 – 12 – 8 – 4
Difference in mean EMQ-p score at 6 months
0 4 8 12 16
With multiple imputation (n = 328)
Multiple imputation (n = 328)
Further adjustment (n = 251)
Primary analysis (n = 251)
Sensitivity
Observed at 6 months (n = 251)
Complier average causal effect
FIGURE 15 Sensitivity analysis for the difference in mean EMQ-p score at the 6-month follow-up.
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Appendix 15 Subgroup analyses conducted on
baseline memory impairment
– 28 – 24 – 20 – 16 – 12 – 8 – 4
Difference in mean EMQ-p score at 6 months
0 4 8 12 16
RBMT-3 severe (n = 80)
RBMT-3 average or above (n = 69)
Primary analysis (n = 251)
Baseline memory impairment
RBMT-3 moderate (n = 102)
FIGURE 16 Difference in mean EMQ-p scores at the 6-month follow-up on the basis of impairment at baseline.
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Appendix 16 Subgroup analyses conducted on
time since traumatic brain injury
Note: this subgroup analysis was not prespecified in the SAP.
The categories for time since TBI were discussed at a trial management meeting prior to analysis. The
categories initially proposed were quartiles, that is, ≤ 2 years, 2–4 years, 4–10 years and > 10 years.
However, it was felt that there was a minimal clinical difference between those at 2 years post injury and
those at 4 years post injury. Three categories were therefore agreed: ≤ 2 years, > 2 years to 10 years and
> 10 years.
TABLE 43 Subgroup analyses conducted on time since TBI
Subgroup
Time point, mean (SD)
Adjusted difference
in means (95% CI)
Adjusted interaction
effect (95% CI)Baseline 6 months
≤ 2 years since TBI
Usual care (n= 31) 50.0 (22.5) 43.1 (28.0)
Memory
rehabilitation (n = 30)
43.4 (20.4) 34.3 (25.8) –2.1 (–10.9 to 6.7)
> 2 years to 10 years since TBI
Usual care (n= 61) 46.6 (23.9) 42.7 (24.1)
Memory
rehabilitation (n = 58)
41.6 (20.5) 34.5 (24.0) –4.9 (–11.3 to 1.6) –2.8 (–13.5 to 7.9)
> 10 years since TBI
Usual care (n= 30) 52.6 (25.7) 47.8 (22.1)
Memory
rehabilitation (n = 41)
53.8 (20.5) 48.1 (27.3) 1.5 (–6.7 to 9.7) 3.6 (–8.3 to 15.5)
p-value for interaction effect: 0.48.
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Appendix 17 The EMQ-p importance scores at
the 6- and 12-month follow-ups
TABLE 44 The EMQ-p importance scores
Time point and trial arm
Score, mean (SD)
Adjusted difference in
means (95% CI)Baseline Follow-up
6-month follow-up
Usual care (n= 119) 69.5 (23.0) 73.9 (24.3)
Memory rehabilitation (n = 124) 65.5 (24.9) 68.7 (25.8) –4.0 (–9.8 to 1.8)
12-month follow-up
Usual care (n= 106) 69.9 (23.9) 73.6 (25.2)
Memory rehabilitation (n = 123) 66.9 (23.2) 67.9 (24.5) –4.3 (–10.3 to 1.7)
Note
EMQ-p scores range from 0 to 112, with higher scores indicating more important memory problems.
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Appendix 18 Analysis of goal attainment for
SMART goals
TABLE 45 Analysis of goal attainment for SMART goals
Summary
6 months 12 months
n Mean (SD)
Adjusted difference
in means (95% CI) n Mean (SD)
Adjusted difference
in means (95% CI)
Short-term goal attainment average score
Usual care 126 1.2 (1.1) 119 1.6 (1.1)
Memory rehabilitation 126 1.8 (1.0) 0.6 (0.3 to 0.9) 117 1.9 (1.0) 0.2 (0.0 to 0.5)
Long-term goal attainment average score
Usual care 123 1.0 (0.9) 117 1.3 (1.0)
Memory rehabilitation 121 1.5 (1.0) 0.6 (0.3 to 0.8) 114 1.7 (1.0) 0.4 (0.1 to 0.7)
Notes
Goal attainment was assessed on a four-point Likert scale: 0, not met; 1, met a little; 2, mostly met; and 3, fully met. The
average achievement score across the goals set was calculated for each participant. The number of SMART goals set was
included in the analysis model.
Of those completing the 6-month follow-up, no SMART short-term goals were set for seven participants in the usual-care
arm and 16 in the memory rehabilitation arm and no SMART long-terms goals were set for 10 participants in the usual-care
arm and 21 participants in the memory rehabilitation arm.
Of those completing the 12-month follow-up, no SMART short-term goals were set for five participants in the usual-care arm
and 15 in the memory rehabilitation arm and no SMART long-term goals were set for seven participants in the usual-care
arm and 18 participants in the memory rehabilitation arm.
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Appendix 19 The EMQ-r importance scores at
the 6- and 12-month follow-ups
TABLE 46 The EMQ-r importance scores
Time point and trial arm
Score, mean (SD)
Adjusted difference in
means (95% CI)Baseline Follow-up
6-month follow-up
Usual care (n= 64) 68.2 (27.8) 71.8 (25.2)
Memory rehabilitation (n = 69) 69.4 (22.0) 68.7 (25.3) –4.8 (–11.2 to 1.6)
12-month follow-up
Usual care (n= 57) 69.5 (27.6) 65.3 (28.2)
Memory rehabilitation (n = 64) 69.7 (21.4) 64.5 (26.4) –0.6 (–8.1 to 6.9)
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Appendix 20 Unit costs associated with service
resource use
TABLE 47 Unit costs associated with service resource use
Resource input Unit cost (£) Source Notes
Community-based health care
GP surgery visit (per surgery
consultation lasting 9.22 minutes)
36 PSSRU 2016 (p. 145)85
GP telephone consultation (per
telephone consultation lasting on
average 4 minutes)
14.60 PSSRU 2016 (p. 147)85
GP home visit (per out-of-surgery
visit lasting 23.4 minutes)
120 PSSRU 2013 (p. 191)85
(inflated to 2016 prices
using Bank of England
inflation calculator)
Practice nurse surgery
consultation
43 PSSRU 2016 (p. 143)85
Surgery nurse telephone
consultation (per telephone
consultation lasting on average
6.56 minutes)
7.90 PSSRU 2016 (p. 147)85
Specialist nurse (Agenda for
Change band 7)
52 PSSRU 2016 (p. 142)85
Community pharmacist 42 PSSRU 2016 (p. 201)85 This cost is based on ‘Cost per
working hour’ from the PSSRU. It
was assumed that this would cover
the cost of prescribing as well as
any possible consultations
Community physiotherapist 32 PSSRU 2016 (p. 200)85
Community occupational
therapist
32 PSSRU 2016 (p. 200)85
Community speech and language
therapist
32 PSSRU 2016 (p. 200)85
Podiatrist 32 PSSRU 2016 (p. 200)85
Dietitian 32 PSSRU 2016 (p. 200)85
Clinical psychologist (per hour of
client contact)
74 PSSRU 2016 (p. 201)85
Assistant clinical psychologist
(per hour of client contact)
32 PSSRU 2016 (p. 201)85
Psychiatrist 74 PSSRU 2016 (p. 201)
Elective surgery as inpatient
Muscular, Balance, Cranial or
Peripheral Nerve Disorders,
Epilepsy or Head Injury, with CC
Score 15+
7605 NHS Reference Costs
2015 to 2016 (AA26C)87
continued
DOI: 10.3310/hta23160 HEALTH TECHNOLOGY ASSESSMENT 2019 VOL. 23 NO. 16
© Queen’s Printer and Controller of HMSO 2019. This work was produced by das Nair et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
147
TABLE 47 Unit costs associated with service resource use (continued )
Resource input Unit cost (£) Source Notes
Muscular, Balance, Cranial or
Peripheral Nerve Disorders,
Epilepsy or Head Injury, with
CC Score 6–8
2932 NHS Reference Costs
2015 to 2016 (AA26F)87
Headache, Migraine or
Cerebrospinal Fluid Leak, with CC
Score 0–6
1672 NHS Reference Costs
2015 to 2016 (AA31E)87
Minor, Cataract or Lens
Procedures
919 NHS Reference Costs
2015 to 2016 (BZ33Z)87
Major, Mouth or Throat
Procedures, 19 years and over,
with CC Score 2+
2951 NHS Reference Costs
2015 to 2016 (CA83A)87
Complex Maxillofacial Procedures
with CC Score 0
5507 NHS Reference Costs
2015 to 2016 (CA91B)87
Reduction or Fixation, of Jaw 2854 NHS Reference Costs
2015 to 2016 (CA96Z)87
Pulmonary, Pleural or Other
Tuberculosis, without
Interventions, with CC Score 0–2
1923 NHS Reference Costs
2015 to 2016 (DZ14J)87
Unspecified Chest Pain with CC
Score 11+
1345 NHS Reference Costs
2015 to 2016 (EB12A)87
Major General Abdominal
Procedures, 1 year and under,
with CC Score 0–1
5090 NHS Reference Costs
2015 to 2016 (FZ12U)87
Low Back Pain without
Interventions, with CC Score 0–2
1510 NHS Reference Costs
2015 to 2016 (HC32K)87
Foot Fracture with Single
Intervention, with CC Score 0–1
5544 NHS Reference Costs
2015 to 2016 (HE31C)87
Intermediate Knee Procedures for
Non-Trauma, 19 years and over,
with CC Score 0–1
2647 NHS Reference Costs
2015 to 2016 (HN24C)87
Non-Malignant Prostate Disorders
without Interventions, with CC
Score 6+
1926 NHS Reference Costs
2015 to 2016 (LB28E)87
Major Open, Scrotum, Testis or
Vas Deferens Procedures, with
CC Score 0–1
2638 NHS Reference Costs
2015 to 2016 (LB52B)87
Labour without Specified Delivery 1110 NHS Reference Costs
2015 to 2016 (NZ25Z)87
Allergy or Adverse Allergic
Reaction
1288 NHS Reference Costs
2015 to 2016 (WH05Z)87
Unspecified Oedema with CC
Score 2+
2360 NHS Reference Costs
2015 to 2016 (WH10A)
Percutaneous Single Drainage
of Abdominal Abscess, with
CC Score 2–4
5226 NHS Reference Costs
2015 to 2016 (YF04B)87
Open Arteriovenous Fistula, Graft
or Shunt Procedures
2451 NHS Reference Costs
2015 to 2016 (YQ42Z)87
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TABLE 47 Unit costs associated with service resource use (continued )
Resource input Unit cost (£) Source Notes
Non-elective surgery as an inpatient
Muscular, Balance, Cranial or
Peripheral Nerve Disorders,
Epilepsy or Head Injury, with
CC Score 15+
6687 NHS Reference Costs
2015 to 2016 (AA26C)87
The SUQ does not distinguish
between elective and non-elective
surgery; therefore, assumptions
were made based on the
description given by the participant,
the assumed severity given the
description and the length of stay
provided. All three of these
considerations were used to
estimate whether surgery was
elective or non-elective
Liver Failure Disorders with
Multiple Interventions
6199 NHS Reference Costs
2015 to 2016 (GC01C)87
Very Major Knee Procedures for
Non-Trauma with CC Score 0–1
6692 NHS Reference Costs
2015 to 2016 (HN22E)87
Allergy or Adverse Allergic
Reaction (non-elective long stay)
1298 NHS Reference Costs
2015 to 2016 (WH05Z)87
Unspecified Pain with CC Score 0 1537 NHS Reference Costs
2015 to 2016 (WH08B)87
Tendency to Fall, Senility or Other
Conditions Affecting Cognitive
Functions, without Interventions,
with CC Score 0–1
1847 NHS Reference Costs
2015 to 2016 (WH09G)87
Fever of Unknown Origin without
Interventions, with CC Score 0–3
1576 NHS Reference Costs
2015 to 2016 (WJ07D)87
Allergy or Adverse Allergic
Reaction (non-elective short stay)
375 NHS Reference Costs
2015 to 2016 (WH05Z)87
Outpatient
General surgery 130 NHS Reference Costs
2015 to 201687
Because of ambiguous descriptions
of outpatient visits (e.g. ‘gone to
hospital’), this figure was used to
capture items not able to be
individually costed
Medications
Prescribed medication Various BNF86 Various costs. See Appendix 21 for
full list of medication
PSSRU, Personal Social Services Research Unit.
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Appendix 21 Unit costs associated with
medication use
TABLE 48 Unit costs associated with medication use
Drug
Dose (per oral tablet
unless other stated) Cost (£)
Aladronic acid 10 mg 0.96
Allopurinal (AAH Pharmaceuticals Ltd) 100 mg 1.12
Amitriptyline (AAH Pharmaceuticals Ltd) 10 mg 0.96
Amiodarone (AHH Pharmaceuticals Ltd) 100 mg 1.29
Amlodipine (AAH Pharmaceuticals Ltd) 10 mg 0.91
Amoxicillin (AAH Pharmaceuticals Ltd) 250 mg 1.30
Mesalazine (Asacol®, MR Allergan Ltd) 400 mg 26.72
Ascorbic acid 200 mg 18.59
Aspirin (AAH Pharmaceuticals Ltd) 75 mg 0.81
Salbutamol Airomer 100 ml (100mg per 1 dose) (Autoinhalver®, Teva UK Ltd) 200 doses 7.87
Atenolol (AA Pharmaceuticals) 50 mg 0.87
Atorvastatin (AAH Pharmaceuticals Ltd) 10 mg 1.57
Avistatin 10 mg 1.57
Azathioprine (AAH Pharmaceuticals Ltd) 25 mg 3.24
Baclofen (AAH Pharmaceuticals Ltd) 10 mg 1.92
Beclometasone 50mg/dose (AAH Pharmaceuticals Ltd) 200 doses 5.36
Bendroflumethiazide (AAH Pharmaceuticals Ltd) 2.5 mg 0.80
Bezafibrate (AAH Pharmaceuticals Ltd) 200 mg 3.25
Bisoprolol (Sandoz Ltd) 1.25 mg 0.91
Buprenorphine (Actavis UK Ltd) 440 mcg 1.60
Buscopan (Sanofi) 10 mg 3.00
Buprenorphine (Butrans® 5 mcg/hour transdermal patches,
Napp Pharmaceuticals Ltd)
1 patch 17.60
Beclometasone 50mcg/dose (Dipropionate Nasobec Aqueous® 50 mcg/dose
nasal spray, Teva UK Ltd)
2.49
Clobetasone Buyrate (Eumovate® 0.05% ointment, GlaxoSmithKline UK Ltd) 500 mcg per 1 g 1.86
Calcium carbonate (Adcal-D3®, Kyowa Kirin Ltd) 1500 mg 3.65
Cabergoline (AAH Pharmaceuticals Ltd) 500 mcg 34.93
Carbamazepine (Tegretol®, Novartis Pharmaceuticals UK Ltd) 110 mg 2.51
Co-amilofruse (AAH Pharmaceuticals Ltd) 2.5 mg/20 mg 5.57
Co-codamol (Galen Ltd) 15 mg/500 mg 6.74
Codeine (AAH Pharmaceuticals Ltd) 15 mg 1.44
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TABLE 48 Unit costs associated with medication use (continued )
Drug
Dose (per oral tablet
unless other stated) Cost (£)
Colecalciferol (AAH Pharmaceuticals Ltd) 800 units 3.60
Colesevelam (Sanofi) 625 mg 96.10
Colestyramine (Oral powder sachets, Teva UK Ltd) 4 g 31.85
Desogestrel (Cerelle® Consillient Health Ltd) 75 mcg 3.17
Cyanocobalamin (AAH Pharmaceuticals Ltd) 50 mcg 8.99
Cyclizine (AMCo) 50 mg 10.85
Cardicor (Medreich PLC) 1.25 mg 2.35
Cerazette® (Merck Sharp and Dohme Ltd) 75 mcg 9.55
Certraline (Accord Healthcare Ltd) 50 mg 1.83
Cetirizine hydrochloride (Teval UK Ltd) 10 mg 1.87
Chlorhexidine [Gluconate Mouthwash (mint) 0.2%, Numark Ltd] 2 mg per 1 ml 1.26
Cholecalciferol (AAH Pharmaceuticals Ltd) 800 unit £3.60
Cinchocaine 0.5%/hydrocortisone 0.5% (Ultraproct Ointment®,
Meadow Laboratories Ltd)
5 mg per 1 g 10.34
Cinnarizine (AAH Phamaecuticals Ltd) 15 mg 5.59
Citalopram (AAH Pharmaceuticals Ltd) 10 mg 1.21
Clomipramine (AAH Pharmaceuticals Ltd) 10 mg 1.55
Clonazepam N/A 6.94
Clonidine (Sandoz Ltd) 25 mcg 10.08
Clopidogrel (Macleods Pharma UK Ltd) 75 mg 1.82
Digoxin (Actavis UK Ltd) 62.5 mcg 2.44
Dihydrocodeine (AAH Pharmaceuticals Ltd) 30 mg 1.43
Diltiazem (Modified-release, AAH Pharmaceuticals Ltd) 60 mg 37.91
Dioxepan 10mg/2 ml 3.77
Disulfiram (AAH Pharmaceuticals Ltd) 200 mg 31.00
Ducusate (DulcoEase®, Sanofi) 100 mg 2.09
Doxazosin (Actavis UK) 4 mg 0.90
Duloxetine (Aspire Pharma Ltd) 60 mg 27.72
Desmopressin (AAH Pharmaceuticals Ltd) 200 mcg 8.76
Tolterodine (Detrusitol® Pfizer Ltd) 2 mg 30.56
Diazepam (Teva UK Ltd) 20 mg 1.02
Diclofenac (AAH Pharmaceuticals Ltd) 25 mg 1.25
Digoxin (Actavis UK Ltd) 62.5 mcg 2.44
Enalapril (AAH Pharmaceuticals Ltd) 10 mg 1.15
Erythromycin (Phoenix Healthcare Distribution Ltd) 250 mg 5.61
Ezetimibe (AMCo) 10 mg 26.31
Felodipine (Modified Release, DE Pharmaceuticals) 5 mg 4.21
Felodipine (Modified Release, DE Pharmaceuticals) 2.5 mg 6.31
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TABLE 48 Unit costs associated with medication use (continued )
Drug
Dose (per oral tablet
unless other stated) Cost (£)
Ferrous fumarate (Galfer, Thornton & Ross Ltd) 305 mg 2.30
Ferrous sulfate (AAH Pharmaceuticals Ltd) 200 mg 1.06
Fexofenadine hydrochloride (AAH Pharmaceuticals Ltd) 180 mg 3.65
Finasteride (AAH Pharmaceuticals Ltd) 5 mg 1.73
Flucloxacillin Sodium (AAH Pharmaceuticals Ltd) 550 mg 2.46
Fluoxetine (Wockhardt UK Ltd) 20 mg 1.11
Fluticasone (Accuhaler®) 50 mcg 6.38
Folic acid (Intrapharm Laboratories Ltd) 5 mg 1.02
Frusemide (AAH Pharmaceuticals Ltd) 20 mg 0.83
Gabapentin (Accord Healthcare Ltd) 600 mg 4.36
Gliclazide (Almus Pharmaceuticals Ltd) 80 mg 2.06
Glucosamine and chondroitin (combined) N/A 18.40
Hayfever Tablets 10 mg 2.91
Hormone replacement therapy N/A 6.52
Hydrocortisone (AMCo) 10 mg 78.50
Hydroxychloroquine (Creo Pharma Ltd) 200 mg 5.31
Ibuprofen (Wockhardt UK Ltd) 200 mg 0.20
Imipramine (AAH pharmaceuticals Ltd) 10 mg 1.32
Inhaler N/A 18.00
Insulin for sub-cutaneous injection 100 unit per 1 ml 30.68
Irbesartan (Macleods Pharma UK Ltd) 150 mg 2.72
Levetiracetam (Keppra®, UCB Pharma Ltd) 250 mg 28.01
Lacidipine [Alliance Healthcare (Distribution) Ltd] 2 mg 2.95
Lactulose oral solution (300 ml) (AAH Pharmaceuticals Ltd) 680 mg per 1 ml 1.95
Lamictal (lamotrigine) (GlaxoSmithKline) 100 mg 69.04
Lamotrigine (Accord Healthcare Ltd) 25 mg 2.21
Lansoprazole (AAH Pharmaceuticals Ltd) 30 mg 1.10
Lantus® N/A 1.10
Levetiracetam (Aurobino Pharma Ltd) 250 mg 7.24
Levothyroxine (AAH Pharmaceuticals Ltd) 25 mcg 2.02
Lisinopril (Accord Healthcare Ltd) 20 mg 0.89
Loperamide (Norimode®, Tillomed Laboratories Ltd) 2 mg 2.15
Loratadine 10mg 1.06
Losartan potassium (Mylan) 25 mg 1.15
Lymecyline capsule (AAH Pharmaceuticals Ltd) 408 mg 8.58
Lactulose oral solution (300 ml) (AAH Pharmaceuticals Ltd) 680 mg per 1 ml 1.95
Lamictal (lamotrigine) (GlaxoSmithKline) 100 mg 69.04
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TABLE 48 Unit costs associated with medication use (continued )
Drug
Dose (per oral tablet
unless other stated) Cost (£)
Lamotrigine (Accord Healthcare Ltd) 25 mg 2.21
Lansoprazole (AAH Pharmaceuticals Ltd) 30 mg 1.10
Lantus® N/A 1.10
Levetiracetam (Aurobino Pharma Ltd) 250 mg 7.24
Levothyroxine (AAH Pharmaceuticals Ltd) 25 mcg 2.02
Lisinopril (Accord Healthcare Ltd) 20 mg 0.89
Loperamide (Norimode®, Tillomed Laboratories Ltd) 2 mg 2.15
Loratadine 10mg 1.06
Mebeverine (Alliance Health Care Distribution Ltd) 135 mg 4.22
Metformin modified release (Almus Pharmaceuticals Ltd) 500 mg 2.66
Methotrexate (Sandoz Ltd) 2.5 mg 2.40
Metronidazole N/A 15.99
Mirtazapine (AAH Pharmaceuticals Ltd) 15 mg 2.03
Montelukast (Actavis UK Ltd) 10 mg 2.41
Mebeverine (Alliance Health Care Distribution Ltd) 135 mg 4.22
Metformin modified release (Almus Pharmaceuticals Ltd) 500 mg 2.66
Methotrexate (Sandoz Ltd) 2.5 mg 2.40
Metronidazole N/A 15.99
Mirtazapine (AAH Pharmaceuticals Ltd) 15 mg 2.03
Montelukast (Actavis UK Ltd) 10 mg 2.41
Mebeverine (Alliance Health Care Distribution Ltd) 135 mg 4.22
Mesalazine (Pentesa® Suppositories Ferring Pharmaceuticals Ltd) 1 g 36.89
Nortriptyline (Focus Pharmaceuticals Ltd) 10 mg 12.06
Naproxen (Actavis UK Ltd) 250 mg 1.54
Neproxin (AAH Pharmaceuticals) 500 mg 1.12
Nicorandil [Alliance Healthcare (Distribution) Ltd] 20 mg 3.66
Nicotine N/A 7.54
Nifedipine N/A 1.74
Nitrazepam 5mg 1.74
Neproxin (AAH Pharmaceuticals) 500 mg 1.12
Nicorandil [Alliance Healthcare (Distribution) Ltd] 20 mg 3.66
Nitrofurantion 100 mg 3.53
Olanzapine 2.5 mg 1.13
Omeprazole gastro-resistant (Tillomed Laboratories Ltd) 20 mg 13.80
Oxcarbazepine (AAH Pharmaceuticals Ltd) 150 mg 9.29
Oxybutynin (AAH Pharmaceuticals Ltd) 5 mg 2.06
Oxycodone hydrochloride 5 mg (Ethypharm UK Ltd) 11.43
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TABLE 48 Unit costs associated with medication use (continued )
Drug
Dose (per oral tablet
unless other stated) Cost (£)
OxyNorm (Hydrochloride Oxeltra® modified release, Wockhardt UK Ltd) 10 mg 22.86
Oxytetracycline (Cresent Pharma Ltd) 250 mg 1.14
Pantoprazole (Sandoz Ltd) 40 mg 1.18
Paracetamol 500 mg 0.19
Paroxetine (AAH Pharmaceuticals Ltd) 20 mg 2.70
Phenytoin sodium (AAH Pharmaceuticals Ltd) 100 mg 15.98
Phenytoin sodium 100mg 57.38
Pizotifen (Soverign Medical Ltd) 1.5 mg 7.22
Pramipexole 180 mcg 2.25
Pravastatin (Mylan) 10 mg 1.85
Prednisolone steroid (AAH Pharmaceuticals Ltd) 2.5 mg 1.24
Prednisolone [Strides Shausn (UK) Ltd] 1 mg 1.07
Pregabalin (Lyrica®, Pfizer Ltd) 20 mg 64.40
Prochlorperazine (Alliance Healthcare Ltd) 5 mg 1.12
Propranolol Bedranol (Almus Pharmaceuticals Ltd) 80 mg 3.22
Propiverine Hydrochloride (Detrunorm®, AMCo) 15 mg 18.00
Propranolol (AAH Pharmaceuticals Ltd) 10 mg 1.45
Quetiapine N/A 1.44
Quinine sulphate (AAH Pharmaceuticals) 200 mg 2.17
Ranitidine (Accord Healthcare Ltd) 150 mg 1.37
Ramipril [Alliance Healthcare (Distrbution) Ltd] 1.25 mg 1.07
Risperidone (AAH Pharmceuticals Ltd) 4 mg 1.76
Rivaroxaban (Xarelto®, Bayer Plc) 10 mg 58.80
Rosuvastatin Tablets (AAH Pharmaceuticals) 10 mg 18.03
Salbutamol (Inhaler 100 mcg/dose, AAH Pharmaceuticals Ltd) 200 doses 1.91
Senna (Senokot® Forum Health Products) 7.5 mg/5 ml 3.99
Fluticasone with Salmeterol (Seretide 100® Accuhaler 100 mcg per 1 dose,
GlaxoSmithKline UK Ltd)
60 doses 18.00
Sertraline (Accord Healthcare Ltd) 50 mg 1.83
Simvastatin (Brown and Burk UK Ltd) 20 mg 2.02
Sitagliptin with Metformin (Janumet® 50 mg/1000mg Merck Sharp & Dohme Ltd) 1 g/50 mg 33.26
Sodium valporate Gastro-resistant (Alliance Healthcare Distribution Ltd) 200 mg 4.75
Sodium Valporate (Epilim®, Sanofi) 200 mg 7.70
Solifenacin (Vesicare®, Astellas Pharma Ltd) 5 mg 27.62
Co-codamol (Solpadol®, Sanofi) 30 mg/500 mg 2.20
Statins N/A 0.84
Sublingual tablets (Buprenorphine with Naloxone Suboxone®, Indivicor UK Ltd) 8 mg/2 mg 76.19
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TABLE 48 Unit costs associated with medication use (continued )
Drug
Dose (per oral tablet
unless other stated) Cost (£)
Sumatriptan (Mylan) 50 mg 1.61
Symbicort Inhaler & Ventolin 100 mcg/6 mcg/dose 33.00
Tamsulosin 400mcg (Contiflo XL, Ranbaxy UK Ltd) 400 mcg 4.47
Tegretol Carbamazepine (Novartis Pharmaceuticals UK Ltd) 400 mg 5.02
Temazepam N/A 10.70
Thiamine (Kent Pharmaceuticals Ltd) 100 mg 10.13
Levothyroxine (Teva UK Ltd) 25 mcg 2.02
Temazepam (AAH Pharmaceuticals) 10 mg 10.70
Topiramate 100 mg 2.37
Tovias (Fesoterodine fumarate) 8 mg 25.78
Tramadol 50 mg 1.20
Tranexamic Acid 500 mg 6.73
Trazodone (Focus Pharmaceuticals Ltd) 150 mg 30.34
Ticagrelor (Brilique, AstraZeneca) 60 mg 54.60
Trihexyphenidyl 2 mg 8.27
Trileptal (Oxcarbazepine, Novartis Pharmaceuticals UK Ltd) 150 mg 12.24
Tylex (Co-codamol, UCB Pharma Ltd) 30 mg/500 mg 9.06
Venlafaxine (Venaxx XL, AMCo) 75 mg 10.44
Venlafaxine hydrochloride (Venlalic XL) 75 mg 2.35
Ventolin 100 mcg/dose 1.50
Sildenafil (Viagra, Pfizer Ltd) 25 mg 16.59
Vitamin B N/A 1.95
Vitamin D N/A 8.99
Valproic Acid (Depakote® Imported United States) 125 mg 17.08
Vitamins with Minerals and Trace elements (Ketovite® Tablets Essential
Pharmaceuticals Ltd)
N/A 9.21
Warfarin 1 mg 0.31
Zinc sulfate monohydrate (Effervescent Tablets Sugar Free) 125 mg 4.32
Zolmitriptan 5 mg 1.22
Zolpidem 7.5 mg 1.19
Zopiclone 7.5 mg 1.17
N/A, not applicable.
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Appendix 22 Illustration of the
cost-effectiveness plane
Intervention more costly
Intervention
less
effective
North-west quadrant
• Usual care dominant
• Intervention more costly and
   less effective than usual care 
North-east quadrant
• Further evaluation required
• Intervention more costly and
      more effective than usual care 
       Intervention
more
effective
South-west quadrant
• Further evaluation required
• Intervention less costly and
      less effective than usual care 
   
South-east quadrant
• Intervention dominant
• Intervention less costly and
         more effective than usual care 
   
Intervention less costly
FIGURE 17 Illustration of the cost-effectiveness plane.
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Appendix 23 Markov model
Intervention
Dead
Low
GHQ score
Moderate
GHQ score
High
GHQ score
FIGURE 18 Markov model structure.
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Appendix 24 Model parameters
F rom Brooks et al.,96 for the low and moderate categories of GHQ-30 scores, the SMR was defined bythe ‘walks well’ category whereas the ‘some walking’ SMR was used for those with high GHQ-30
scores. As detailed by Briggs et al.,151 to transform probabilities between periods of differential length, the
derivation of instantaneous rates from which the appropriate probabilities can be calculated is required.
To convert the yearly SMR adjusted mortality probability presented by Brooks et al.,96 for a cycle length of
6 months, the following formulae were used, where pn and rn are the n-month probability and rate of
death, respectively:
r1 = −
½ln(1−p12)
12
. (3)
p6 = 1− e
−6r1 . (4)
Using these formulae, the 12-month mortality probability was transformed to the monthly death rate,
which was subsequently transformed back to a 6-month probability. The adjusted 6-month mortality
rates are presented in Table 49.
Given the adjusted mortality rates presented in Table 49, Table 50 defines the baseline transition
probabilities for an individual aged 45 years.
For the three non-dead health states, the mean costs and utilities and associated SEs are presented in
Table 51.
TABLE 49 Adjusted 6-month mortality rates
Age (years)
Unadjusted mortality
rate (1 year)
Mortality rates
Low/moderate High
SMR –
‘walks well’
Adjusted mortality
rate (6 months)
SMR –
‘some walking’
Adjusted mortality
rate (6 months)
20 0.000442 3.10 0.00058 3.80 0.00071
30 0.000464 3.10 0.00092 3.80 0.00113
40 0.000455 2.90 0.00189 4.50 0.00294
50 0.000530 2.90 0.00414 4.50 0.00643
60 0.000527 1.40 0.00500 2.70 0.00966
70 0.000557 1.40 0.01215 2.70 0.02357
80 0.000594 0.70 0.01808 1.50 0.03916
90 0.000608 0.70 0.05733 1.50 0.12745
100 0.000597 0.70 0.13712 1.50 0.32723
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TABLE 50 Baseline transition probability matrix
GHQ-30 category
Trial arm
Distribution Source
Memory rehabililation Usual care
Low Moderate High Death Low Moderate High Death
Transition probability: 0–6 months
Low GHQ-30 0.715 0.188 0.094 0.003 0.716 0.239 0.043 0.002 Beta Trial data, Brooks et al.,96 ONS94
Moderate GHQ-30 0.347 0.499 0.152 0.003 0.288 0.466 0.244 0.002 Beta Trial data, Brooks et al.,96 ONS94
High GHQ-30 0.159 0.358 0.478 0.004 0.199 0.299 0.498 0.004 Beta Trial data, Brooks et al.,96 ONS94
Death 0.000 0.000 0.000 1.000 0.000 0.000 0.000 1.000 Beta Trial data, Brooks et al.,96 ONS94
Transition probability: 6–12 months
Low GHQ-30 0.802 0.117 0.078 0.003 0.696 0.162 0.139 0.002 Beta Trial data, Brooks et al.,96 ONS94
Moderate GHQ-30 0.332 0.526 0.138 0.003 0.374 0.561 0.062 0.002 Beta Trial data, Brooks et al.,96 ONS94
High GHQ-30 0.111 0.387 0.498 0.005 0.124 0.373 0.498 0.004 Beta Trial data, Brooks et al.,96 ONS94
Death 0.000 0.000 0.000 1.000 0.000 0.000 0.000 1.000 Beta Trial data, Brooks et al.,96 ONS94
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TABLE 51 Mean costs and utilities
GHQ-30 category
Trial arm
Distribution Source
Memory rehabilitation Usual care
Mean cost (£) SE (£) Mean cost (£) SE (£)
0–6 months
Low GHQ-30 242.88 54.23 304.00 64.33 Gamma Trial data
Moderate GHQ-30 452.06 188.14 471.43 126.69 Gamma Trial data
High GHQ-30 353.17 204.01 715.58 171.38 Gamma Trial data
6–12 months
Low GHQ-30 242.88 76.26 204.14 37.95 Gamma Trial data
Moderate GHQ-30 452.06 65.36 820.75 200.75 Gamma Trial data
High GHQ-30 353.17 108.56 547.90 237.74 Gamma Trial data
12+ months
Low GHQ-30 343.36 104.82 211.91 49.54 Gamma Trial data
Moderate GHQ-30 315.47 51.41 442.50 66.37 Gamma Trial data
High GHQ-30 694.19 286.69 561.34 324.25 Gamma Trial data
Mean utility SE Mean utility SE Distribution Source
0–6 months
Low GHQ-30 0.710 0.029 0.653 0.037 Beta Trial data
Moderate GHQ-30 0.660 0.029 0.569 0.031 Beta Trial data
High GHQ-30 0.443 0.047 0.461 0.046 Beta Trial data
6–12 months
Low GHQ-30 0.742 0.025 0.672 0.032 Beta Trial data
Moderate GHQ-30 0.626 0.017 0.559 0.027 Beta Trial data
High GHQ-30 0.428 0.076 0.410 0.059 Beta Trial data
12+ months
Low GHQ-30 0.724 0.028 0.699 0.027 Beta Trial data
Moderate GHQ-30 0.635 0.016 0.595 0.024 Beta Trial data
High GHQ-30 0.442 0.063 0.530 0.056 Beta Trial data
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Appendix 25 Costs associated with training and
delivery of the intervention
TABLE 52 Costs associated with training and delivery of the interventiona
Costs Resource
Unit cost
(£)
Resource
usage Cost (£)
Total cost
(£)
Unit cost source/
description
Training costs Training psychologist
band 8a
66 2 hours 132 PSSRU 2016,85 bands
5–8 (p. 185)
Training AP
(mid-band 5)
35 2 hours 70 PSSRU 2016,85 band 5
(p. 185)
Cost per site 202
One-off training cost
(subtotal)
1818 Based on nine sites
Delivery costs
Per-group
variable costs
Administration staff
(band 3)
25 1 hour per
group
25 PSSRU 2016,85 band 3
(pp. 188 and 199)
Cost per group 25
Total administration
cost for groups
(subtotal)
875 Based on 35 groups
Per-session
variable costs
AP (mid-band 5) 35 2 hours per
session
70 PSSRU 2016,85 band 5
(p. 185)
Total per session 70
Total cost of sessions
(subtotal)
24,500 Based on 350 sessions
Per-participant
variable costs
Cost per manual 2.20 One manual
per participant
2.20 As advised by trial
team
Refreshments 0.50 £0.50 per
participant per
session
5.00 As advised by trial
team
Stationery costs (e.g.
pens, miscellaneous)
1.00 Estimated
total £1 per
participant for
all sessions
1.00 As advised by trial
team
Total per participant 8.20
Per-participant costs
(subtotal)
1402 Based on 171
participants
Total cost of
intervention
Overall cost of
rehabilitation
intervention
28,595
Cost of
rehabilitation per
participant
167
PSSRU, Personal Social Services Research Unit.
Note
Based on nine sites, 35 groups, 350 sessions (10 sessions per group) and 171 participants.
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Appendix 26 Resource utilisation and service
usage costs (available cases)
DOI: 10.3310/hta23160 HEALTH TECHNOLOGY ASSESSMENT 2019 VOL. 23 NO. 16TABLE 53 Resource utilisation at baseline (available cases)©
H
j
b
PResource utilisationQueen’s Printer and Controller of HMSO 2019. This work
ealth and Social Care. This issue may be freely reproduced
ournals provided that suitable acknowledgement is made a
e addressed to: NIHR Journals Library, National Institute fo
ark, Southampton SO16 7NS, UK.Trial armwas produced by das
for the purposes of p
nd the reproduction is
r Health Research, EvanNair et a
rivate rese
not assoc
luation, TrSuml. under the
arch and s
iated with
ials and StMeanterms of a c
tudy and ext
any form of
udies CoordiSDommission
racts (or in
advertising
nating CenDifference in means
(95% CI)ing contract issued by the Secretary of
deed, the full report) may be included in
. Applications for commercial reproduct
tre, Alpha House, University of Southamp-valueNumber of GP consultations (linked
to memory problems) per patientUsual care 130 19 0.12 0.44 0.056 (–0.024 to 0.137) 0.168Memory
rehabilitation137 11 0.06 0.29Number of GP consultations (for other
reasons) per patientUsual care 151 283 1.80 2.05 0.311 (–0.168 to 0.790) 0.202Memory
rehabilitation157 255 1.49 2.33Number of practice nurse consultations
(linked to memory problems) per patientUsual care 129 5 0.03 0.29 0.008 (–0.056 to 0.073) 0.797Memory
rehabilitation134 4 0.02 0.31Number of practice nurse
consultations (for other reasons)
per patientUsual care 137 68 0.43 1.01 –0.456 (–0.954 to 0.042) 0.073Memory
rehabilitation147 152 0.89 3.02Number of consultations with other
health-care professionals (linked to
memory problems) per patientUsual care 131 66 0.42 2.22 0.046 (–0.346 to 0.434) 0.817Memory
rehabilitation139 64 0.37 1.31Number of consultations with other
health-care professionals (for other
reasons) per patientUsual care 144 349 2.22 5.23 0.0241 (–1.035 to 1.083) 0.964Memory
rehabilitation156 376 2.20 4.52Number of times an inpatient because
of memory problemsUsual care 157 0 0 0 – –Memory
rehabilitation171 0 0 0Number of days an inpatient because
of memory problemsUsual care 157 0 0 0 – –Memory
rehabilitation171 0 0 0Number of times an inpatient for
other reasonsUsual care 134 11 0.07 0.28 –0.006 (–0.070 to 0.058) 0.855Memory
rehabilitation139 13 0.08 0.31Number of days an inpatient for other
reasonsUsual care 24 33 0.21 0.99 –0.094 (–0.447 to 0.259) 0.601Memory
rehabilitation27 52 0.30 2.04Number of GP home consultations
(linked to memory problems)
per patientUsual care 157 0 0 0 – –Memory
rehabilitation171 0 0 0Number of GP home consultations
(for other reasons) per patientUsual care 129 5 0.03 0.21 –0.003 (–0.063 to 0.057) 0.915Memory
rehabilitation136 6 0.04 0.32continuedState for
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168TABLE 53 Resource utilisation at baseline (available cases) (continued )T
T
NResource utilisationABLE 54 Service usage costs associate
Service usage M
Primary care visits
Usual care (n = 155) 2
Memory rehabilitation (n = 170) 2
Primary care home visits
Usual care (n = 155) 7
Memory rehabilitation (n = 170) 7
Inpatient
Usual care (n = 155) 1
Memory rehabilitation (n = 170) 2
Medication
Usual care (n = 155) 1
Memory rehabilitation (n = 170) 1
a Adjusted for baseline differences.
ABLE 55 Resource utilisation at 6 mo
Resource utilisation
Number of GP consultations (linked
to memory problems) per patient at
6 months
Number of GP consultations
(for other reasons) per patient
at 6 months
IHR Journals Library www.journalslibrary.nihr.ac.uTrial armd with resourc
ean (SE) (£)
06.06 (28.20)
02.52 (22.19)
4.172 (17.55)
1.33 (18.38)
56.85 (56.10)
11.75 (76.54)
6.24 (2.04)
3.72 (1.98)
nths (available
Trial arm
Usual care
Memory
rehabilitation
Usual care
Memory
rehabilitation
kne utilis
95%
150
158
39.4
35.0
46.0
60.6
12.2
9.81
cases)
n
84
102
85
101Sumation a
CI (£)
.346 to
.71 to 2
94 to 1
5 to 10
23 to 2
4 to 36
1 to 20
to 17.
Sum
44
35
132
121Meant baselin
261.780
46.33
08.850
7.60
67.668
2.85
.28
63
Mean
0.28
0.20
0.84
0.71SDe
Dif
(95
–3.
–2.
54.
–2.
SD
0.75
0.77
1.55
1.12Difference in means
(95% CI)ference in means
% CI) (£)a
54 (–73.53 to 66.44)
84 (–53.05 to 47.37)
90 (–134.78 to 244.59)
52 (–8.13 to 3.08)
Difference in means
(95% CI)
0.076 (–0.089 to 0.240)
0.133 (–0.159 to 0.426)p-valueNumber of practice nurse home
consultations (linked to memory
problems) per patientUsual care 128 0 0.00 0.00 –0.006 (–0.018 to 0.006) 0.339Memory
rehabilitation134 1 0.01 0.08Number of practice nurse home
consultations (for other reasons)
per patientUsual care 130 73 0.46 3.35 0.436 (–0.070 to 0.941) 0.091Memory
rehabilitation137 5 0.03 0.23Number of home consultations with
other health-care professionals (linked
to memory problems) per patientUsual care 128 26 0.17 0.72 –0.829 (–2.059 to 0.402) 0.186Memory
rehabilitation136 170 0.99 7.81Number of home consultations with
other health-care professionals
(for other reasons) per patientUsual care 132 169 1.08 3.61 –0.198 (–1.072 to 0.675) 0.655Memory
rehabilitation143 218 1.27 4.35p-value
0.921
0.911
0.570
0.376
p-value
0.368
0.371
TABLE 55 Resource utilisation at 6 months (available cases) (continued )
Resource utilisation Trial arm n Sum Mean SD
Difference in means
(95% CI) p-value
Number of practice nurse
consultations (linked to memory
problems) per patient at 6 months
Usual care 83 19 0.12 0.57 0.033 (–0.076 to 0.143) 0.549
Memory
rehabilitation
97 15 0.09 0.43
Number of practice nurse
consultations (for other reasons)
per patient at 6 months
Usual care 74 47 0.30 1.06 –0.011 (–0.249 to 0.228) 0.931
Memory
rehabilitation
88 53 0.31 1.13
Number of consultations with other
health-care professionals (linked to
memory problems) per patient at
6 months
Usual care 86 83 0.53 1.76 0.218 (–0.099 to 0.537) 0.177
Memory
rehabilitation
101 53 0.31 1.13
Number of consultations with other
health-care professionals (for other
reasons) per patient at 6 months
Usual care 79 84 0.54 1.72 –0.395 (–0.857 to 0.067) 0.094
Memory
rehabilitation
87 159 0.93 2.44
Number of times an inpatient because
of memory problems at 6 months
Usual care 80 4 0.03 0.19 0.008 (–0.032 to 0.048) 0.694
Memory
rehabilitation
97 3 0.02 0.17
Number of days an inpatient because
of memory problems at 6 months
Usual care 33 9.5 0.61 0.64 0.043 (–0.058 to 0.143) 0.401
Memory
rehabilitation
32 3 0.18 0.17
Number of times an inpatient for
other reasons at 6 months
Usual care 77 14 0.09 0.41 0.025 (–0.050 to 0.100) 0.516
Memory
rehabilitation
85 11 0.06 0.27
Number of days an inpatient for other
reasons at 6 months
Usual care 13 27 0.17 1.06 –0.027 (–0.251 to 0.197) 0.814
Memory
rehabilitation
12 34 0.20 1.00
Number of GP home consultations
(linked to memory problems)
per patient at 6 months
Usual care 81 7 0.04 0.36 0.009 (–0.065 to 0.084) 0.803
Memory
rehabilitation
104 6 0.04 0.32
Number of GP home consultations
(for other reasons) per patient at
6 months
Usual care 75 11 0.07 0.54 0.017 (–0.079 to 0.114) 0.724
Memory
rehabilitation
86 9 0.05 0.33
Number of practice nurse home
consultations (linked to memory
problems) per patient at 6 months
Usual care 83 3 0.02 0.24 0.019 (–0.017 to 0.055) 0.297
Memory
rehabilitation
102 0 0.00 0.00
Number of practice nurse home
consultations (for other reasons) per
patient at 6 months
Usual care 76 99 0.63 5.57 0.607 (–0.231 to 1.445) 0.155
Memory
rehabilitation
87 4 0.02 0.19
Number of home consultations with
other health-care professionals (linked
to memory problems) per patient at
6 months
Usual care 84 52 0.33 1.61 0.214 (–0.042 to 0.471) 0.102
Memory
rehabilitation
100 20 0.12 0.55
Number of home consultations
with other health-care professionals
(for other reasons) per patient at
6 months
Usual care 74 43 0.27 1.65 –0.036 (–0.365 to 0.292) 0.829
Memory
rehabilitation
84 53 0.31 1.37
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TABLE 56 Service usage costs associated with resource utilisation at 6 months (available cases)
Service usage Mean (SE) (£) 95% CI (£)
Difference in means
(95% CI) (£)a p-value
Primary care visits
Usual care (n = 112) 127.88 (17.30) (93.61 to 162.16) –23.83 (–64.05 to 16.39) 0.244
Memory rehabilitation (n = 121) 104.05 (11.38) (81.52 to 126.58)
Primary care home visits
Usual care (n = 112) 85.27 (29.26) (27.28 to 143.26) –47.20 (–106.70 to 12.30) 0.119
Memory rehabilitation (n = 121) 38.07 (10.51) (17.26 to 58.89)
Inpatient
Usual care (n = 112) 356.47 (130.23) (98.41 to 279.26) –189.00 (–461.57 to 83.57) 0.173
Memory rehabilitation (n = 121) 167.46 (56.47) (55.67 to 279.26)
Medication
Usual care (n = 112) 13.76 (2.21) (9.37 to 18.15) 3.41 (–3.82 to 10.63) 0.353
Memory rehabilitation (n = 121) 17.17 (2.87) (11.48 to 22.85)
a Adjusted for baseline differences.
TABLE 57 Resource utilisation at 12 months (available cases)
Resource utilisation Trial arm n Sum Mean SD
Difference in means
(95% CI) p-value
Number of GP consultations
(linked to memory problems)
per patient at 12 months
Usual care 75 39 0.25 1.01 0.044 (–0.147 to 0.235) 0.652
Memory
rehabilitation
101 35 0.20 0.73
Number of GP consultations (for other
reasons) per patient at 12 months
Usual care 88 105 0.67 1.23 –0.138 (–0.424 to 0.147) 0.341
Memory
rehabilitation
101 138 0.81 1.38
Number of practice nurse
consultations (linked to memory
problems) per patient at 12 months
Usual care 81 12 0.08 0.40 0.018 (–0.066 to 0.102) 0.674
Memory
rehabilitation
98 10 0.06 0.37
Number of practice nurse
consultations (for other reasons)
per patient at 12 months
Usual care 82 66 0.42 1.86 –0.012 (–0.440 to 0.415) 0.955
Memory
rehabilitation
97 74 0.43 2.06
Number of consultations with other
health-care professionals (linked to
memory problems) per patient at
12 months
Usual care 83 58 0.37 1.40 0.019 (–0.281 to 0.318) 0.903
Memory
rehabilitation
95 60 0.35 1.36
Number of consultations with other
health-care professionals (for other
reasons) per patient at 12 months
Usual care 77 92 0.59 1.82 –0.209 (–0.664 to 0.246) 0.366
Memory
rehabilitation
91 136 0.80 2.32
Number of times an inpatient because
of memory problems at 12 months
Usual care 79 5 0.03 0.21 –0.003 (–0.055 to 0.049) 0.902
Memory
rehabilitation
99 6 0.04 0.26
Number of days an inpatient because
of memory problems at 12 months
Usual care 33 11 0.70 0.61 –0.012 (–0.203 to 0.180) 0.904
Memory
rehabilitation
32 14 0.08 1.07
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TABLE 57 Resource utilisation at 12 months (available cases) (continued )
Resource utilisation Trial arm n Sum Mean SD
Difference in means
(95% CI) p-value
Number of times an inpatient for
other reasons at 12 months
Usual care 70 4 0.03 0.16 –0.027 (–0.076 to 0.022) 0.275
Memory
rehabilitation
87 9 0.05 0.27
Number of days an inpatient for other
reasons at 12 months
Usual care 12 7 0.04 0.29 –0.037 (–0.138 to 0.063) 0.466
Memory
rehabilitation
14 14 0.08 0.58
Number of GP home consultations
(linked to memory problems) per
patient at 12 months
Usual care 74 3 0.02 0.24 0.019 (–0.017 to 0.055) 0.297
Memory
rehabilitation
102 0 0.00 0.00
Number of GP home consultations
(for other reasons) per patient at
12 months
Usual care 73 11 0.07 0.43 –0.000 (–0.088 to 0.089) 0.998
Memory
rehabilitation
96 12 0.07 0.38
Number of practice nurse home
consultations (linked to memory
problems) per patient at 12 months
Usual care 77 4 0.03 0.32 –0.507 (–1.600 to 0.587) 0.363
Memory
rehabilitation
103 91 0.53 6.96
Number of practice nurse home
consultations (for other reasons)
per patient at 12 months
Usual care 71 44 0.28 2.91 0.269 (–0.170 to 0.707) 0.229
Memory
rehabilitation
94 2 0.01 0.11
Number of home consultations with
other health-care professionals (linked
to memory problems) per patient at
12 months
Usual care 73 24 0.15 1.25 –0.017 (–0.278 to 0.245) 0.900
Memory
rehabilitation
99 29 0.17 1.16
Number of home consultations with
other health-care professionals
(for other reasons) per patient at
12 months
Usual care 71 46 0.29 2.06 0.024 (–0.343 to 0.392) 0.898
Memory
rehabilitation
93 46 0.27 1.26
TABLE 58 Service usage costs associated with resource utilisation at 12 months (available cases)
Service usage Mean (SE) (£) 95% CI (£)
Difference in means
(95% CI) (£)a p-value
Primary care visits
Usual care (n= 105) 127.87 (19.06) (90.08 to 165.67) –0.31 (–53.10 to 52.49) 0.991
Memory rehabilitation (n = 122) 127.56 (18.67) (90.60 to 164.53)
Primary care home visits
Usual care (n= 105) 49.30 (19.83) (9.98 to 88.62) 7.65 (–70.70 to 86.00) 0.848
Memory rehabilitation (n = 122) 56.95 (32.70) (–7.78 to 121.67)
Inpatient
Usual care (n= 105) 162.77 (72.56) (18.89 to 306.66) 6.46 (–196.61 to 209.53) 0.950
Memory rehabilitation (n = 122) 169.23 (72.38) (25.93 to 312.54)
Medication
Usual care (n= 105) 15.09 (2.94) (9.26 to 20.91) 3.26 (–5.56 to 12.08) 0.467
Memory rehabilitation (n = 122) 18.35 (3.29) (11.83 to 24.87)
a Adjusted for baseline differences.
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Appendix 27 Service use questionnaire completion
TABLE 59 Completeness of the SUQ
SUQ completeness
Time point, n (%)
Baseline 6 months 12 months
Usual care
(N= 157)
Memory
rehabilitation
(N= 171)
Usual care
(N= 157)
Memory
rehabilitation
(N= 171)
Usual care
(N= 157)
Memory
rehabilitation
(N= 171)
Complete 154 (98.09) 170 (99.42) 111 (70.70) 120 (70.18) 101 (64.33) 121 (70.76)
Missing (assumed
zero)
2 (1.27) 1 (0.64) 1 (0.64) 2 (1.17) 0 (0.00) 1 (0.58)
Missing 1 (0.64) 0 (0.00) 45 (28.66) 49 (28.65) 56 (35.67) 49 (28.65)
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Appendix 28 EuroQol-5 Dimensions, five-level
version, missing data
TABLE 60 Missing EQ-5D-5L data at the 6- and 12-month follow-ups
EQ-5D-5L 6-month questionnaire
EQ-5D-5L 12-month questionnaire, n (%)
Usual care (N= 157) Memory rehabilitation (N= 171)
Complete Missing Total Complete Missing Total
Complete 99 (63.1) 20 (12.7) 119 (75.8) 110 (64.3) 18 (10.5) 128 (74.9)
Missing 7 (4.5) 31 (19.7) 38 (24.2) 13 (7.6) 30 (17.5) 43 (25.1)
Total 106 (67.5) 51 (32.5) 157 (100.0) 123 (71.9) 48 (28.1) 171 (100.0)
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Appendix 29 EuroQol-5 Dimensions, five-level
version, utilities and quality-adjusted life-years gained
over time (mean imputed data)
TABLE 61 EuroQol-5 Dimensions, five-level version, utilities and QALYs gained over time (mean imputed data)
Time point
Trial arm
Difference in
means (95% CI) p-value
Usual care (n= 157)
Memory rehabilitation
(n= 171)
Mean
EQ-5D-5L
score
Change over
time (95% CI)
Mean
EQ-5D-5L
score
Change over
time (95% CI)
Baseline 0.581 0.637
6 months 0.581 0.000
(–0.041 to 0.040)
0.639 0.002
(–0.036 to 0.039)
0.002
(–0.052 to 0.057)
0.935
12 months 0.628 0.047
(0.004 to 0.090)
0.644 0.007
(–0.027 to 0.041)
–0.040
(–0.093 to 0.014)
0.148
QALY gain at
6 months (95% CI)
0.000 (–0.020 to 0.020) 0.001 (–0.018 to 0.020) 0.001
(–0.026 to 0.028)
0.935
QALY gain at
12 months
(95% CI)
0.023 (0.002 to 0.045) 0.004 (–0.013 to 0.020) –0.020
(–0.047 to 0.007)
0.148
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Appendix 30 Change in EMQ-p score over time
(mean imputed data)
TABLE 62 Change in EMQ-p score over time (mean imputed data)
Time
point
Trial arm
Difference in
means (95% CI) p-value
Usual care (n= 157) Memory rehabilitation (n= 171)
Mean EMQ-p
score
Change over
time (95% CI)
Mean EMQ-p
score
Change over
time (95% CI)
Baseline 50.075 (1.953) 47.363 (1.606)
6 months 43.679 (1.749) –6.397
(–9.681 to –3.112)
39.572 (1.800) –7.791
(–10.678 to –4.903)
–1.394
(5.735 to 2.946)
0.528
12 months 43.268 (1.774) –6.807
(–10.119 to –3.495)
38.323 (1.707) –9.049
(–12.081 to –6.015)
–2.242
(–6.707 to 2.224)
0.324
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Appendix 31 Change in GHQ-30 score over time
(mean imputed data)
TABLE 63 Change in GHQ-30 score over time (mean imputed data)
Time
point
Trial arm
Difference in
means (95% CI) p-value
Usual care (n= 157) Memory rehabilitation (n= 171)
Mean
GHQ-30 score
Change over
time (95% CI)
Mean
GHQ-30 score
Change over
time (95% CI)
Baseline 9.601 9.670
6 months 8.811 –0.790
(–2.003 to 0.422)
8.693 –0.976
(–2.177 to 0.224)
–0.186
(–1.889 to 1.517)
0.830
12 months 8.089 –1.512
(–2.867 to –0.158)
8.492 –1.179
(–2.494 to 0.135)
0.373
(–1.549 to 2.215)
0.728
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Appendix 32 One-way sensitivity analyses of
cost-effectiveness (multiply imputed data)
TABLE 64 One-way sensitivity analysis of the incremental cost per QALY analysis (multiply imputed data)
Cost (£)
Time point, analysis
Incremental
cost (£) (memory
rehabilitation –
usual care)
Incremental
effect (memory
rehabilitation –
usual care) ICER (£)
6 months
Base case –35.612 0.004 –8903 (intervention dominant)
Upper 95% bound net cost 57.519 0.005 11,504 (north-east quadrant)
Upper 95% bound QALYs
Lower 95% bound net cost –128.744 0.003 –42,915 (intervention dominant)
Lower 95% bound QALYs
Upper 95% bound net cost 57.519 0.003 57.519 (north-east quadrant)
Lower 95% bound QALYs
Lower 95% bound net cost –128.744 0.005 –25,749 (intervention dominant)
Upper 95% bound QALYs
12 months
Base case –26.895 –0.011 2445 (south-west quadrant)
Upper 95% bound net cost 59.94 –0.008 –7493 (usual care dominant)
Upper 95% bound QALYs
Lower 95% bound net cost –280.73 –0.013 21,595 (south-west quadrant)
Lower 95% bound QALYs
Upper 95% bound net cost 59.94 –0.013 –4611 (usual care dominant)
Lower 95% bound QALYs
Lower 95% bound net cost –280.73 –0.008 35,091 (south-west quadrant)
Upper 95% bound QALYs
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TABLE 65 One-way sensitivity analysis of the incremental cost per 1-point improvement EMQ-p (multiply imputed
data)
Cost (£)
Time point, analysis
Incremental
cost (£) (memory
rehabilitation –
usual care)
Incremental
effect (memory
rehabilitation –
usual care) ICER (£)
6 months
Base case –35.612 –2.322 –15.34 (intervention dominant)
Upper 95% bound net cost 57.519 –2.667 21.56 (north-east quadrant)
Upper 95% bound EMQ-p score
Lower 95% bound net cost –128.744 –1.976 –65.16 (intervention dominant)
Lower 95% bound EMQ-p score
Upper 95% bound net cost 57.519 –1.976 29.11 (north-east quadrant)
Lower 95% bound EMQ-p score
Lower 95% bound net cost –128.744 –2.667 –48.26 (intervention dominant)
Upper 95% bound EMQ-p score
12 months
Base case –26.895 –1.410 –19.07 (intervention dominant)
Upper 95% bound net cost 59.94 –1.496 40.07 (north-east quadrant)
Upper 95% bound EMQ-p score
Lower 95% bound net cost –280.73 –1.325 –211.93 (intervention dominant)
Lower 95% bound EMQ-p score
Upper 95% bound net cost 59.94 –1.325 45.25 (north-east quadrant)
Lower 95% bound EMQ-p score
Lower 95% bound net cost –280.73 –1.496 187.68 (intervention dominant)
Upper 95% bound EMQ-p score
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TABLE 66 One-way sensitivity analysis of the incremental cost per 1-point improvement GHQ-30 (multiply imputed
data)
Cost (£)
Time point, analysis
Incremental
cost (£) (memory
rehabilitation –
usual care)
Incremental
effect (memory
rehabilitation –
usual care) ICER (£)
6 months
Base case –35.612 –0.998 –35.70 (intervention dominant)
Upper 95% bound net cost 57.519 –1.058 54.37 (north-east quadrant)
Upper 95% bound GHQ-30 score
Lower 95% bound net cost –128.744 –0.937 –137.35 (intervention dominant)
Lower 95% bound GHQ-30 score
Upper 95% bound net cost 57.519 –0.937 61.36 (north-east quadrant)
Lower 95% bound GHQ-30 score
Lower 95% bound net cost –128.744 –1.058 –121.71 (intervention dominant)
Upper 95% bound GHQ-30 score
12 months
Base case –26.895 –0.737 –36.49 (intervention dominant)
Upper 95% bound net cost 59.94 –0.439 136.54 (north-east quadrant)
Upper 95% bound GHQ-30 score
Lower 95% bound net cost –280.73 –1.037 –270.71 (intervention dominant)
Lower 95% bound GHQ-30 score
Upper 95% bound net cost 59.94 –1.037 57.80 (north-east quadrant)
Lower 95% bound GHQ-30 score
Lower 95% bound net cost –280.73 –0.439 –639.48 (intervention dominant)
Upper 95% bound GHQ-30 score
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Appendix 33 One-way sensitivity analysis of
longer-term cost-effectiveness: 5-year horizon
TABLE 67 One-way sensitivity analysis of longer-term cost-effectiveness: 5-year horizon
Time point, analysis
Trial arm
Incremental
ICER (£)
Memory
rehabilitation Usual care
Cost (£) QALY Cost (£) QALY Cost (£) QALY
Base-case analysis 3599.08 2.952 3404.27 2.651 194.81 0.301 646.36
One-way sensitivity analysis
Age 30 years 3644.67 2.990 3442.43 2.681 202.24 0.309 655.35
Age 65 years 3422.51 2.848 3280.97 2.552 141.54 0.296 477.62
Discount rate 1.5% 3770.16 3.096 3561.15 2.780 209.01 0.316 661.17
Discount rate 5.0% 3479.91 2.852 3294.90 2.561 185.01 0.291 635.50
+30% intervention cost 3649.18 2.952 3404.27 2.651 244.91 0.301 812.59
–30% intervention cost 3548.98 2.952 3404.27 2.651 144.71 0.301 480.13
+30% cost per cycle in GHQ state 4628.70 2.952 3404.27 2.651 1224.43 0.301 4062.58
–30% cost per cycle in GHQ state 2569.45 2.952 3404.27 2.651 –834.82 0.301 –2769.87
+30% utility per cycle in GHQ state 3599.08 3.838 3404.27 3.446 194.81 0.392 497.20
–30% utility per cycle in GHQ state 3599.08 2.067 3404.27 1.856 194.81 0.211 923.37
+20% transition probability higher
GHQ state
3674.46 2.904 3526.14 2.612 148.31 0.292 507.06
+20% transition probability lower
GHQ state
3526.03 3.001 3277.91 2.690 248.12 0.311 797.73
–20% transition probability higher
GHQ state
3521.44 3.004 3263.71 2.695 257.73 0.309 834.92
–20% transition probability lower
GHQ state
3697.16 2.891 3553.60 2.603 143.56 0.288 498.47
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Appendix 34 One-way sensitivity analysis of
longer-term cost-effectiveness: 10-year horizon
TABLE 68 One-way sensitivity analysis of longer-term cost-effectiveness: 10-year horizon
Time point, analysis
Trial arm
Incremental
ICER (£)
Memory
rehabilitation Usual care
Cost (£) QALY Cost (£) QALY Cost (£) QALY
Base-case analysis 6451.25 5.340 5976.51 4.806 474.73 0.535 887.76
One-way sensitivity analysis
Age 30 years 6627.24 5.486 6120.75 4.924 506.49 0.562 900.57
Age 65 years 5905.55 4.931 5503.20 4.417 402.35 0.514 782.30
Discount rate 1.5% 7066.71 5.856 6534.38 5.271 532.33 0.586 908.93
Discount rate 5.0% 6044.64 4.999 5607.79 4.498 436.86 0.501 871.83
+30% intervention cost 6501.35 5.340 5,976.51 4.806 524.83 0.535 981.44
–30% intervention cost 6401.15 5.340 5,976.51 4.806 424.63 0.535 794.07
+30% cost per cycle in GHQ state 8336.52 5.340 5976.51 4.806 2,360.01 0.535 4413.23
–30% cost per cycle in GHQ state 4565.97 5.340 5976.51 4.806 –1410.54 0.535 –2637.72
+30% utility per cycle in GHQ state 6451.25 6.942 5976.51 6.247 474.73 0.695 682.89
–30% utility per cycle in GHQ state 6451.25 3.738 5976.51 3.364 474.73 0.374 1268.22
+20% transition probability higher
GHQ state
6596.52 5.248 6196.88 4.732 399.64 0.516 774.87
+20% transition probability lower
GHQ state
6318.55 5.430 5753.57 4.878 564.99 0.552 1023.36
–20% transition probability higher
GHQ state
6301.55 5.442 5717.64 4.891 583.91 0.551 1059.79
–20% transition probability lower
GHQ state
6635.93 5.224 6246.03 4.716 389.90 0.509 766.74
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Appendix 35 Semistructured interview schedule
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Appendix 36 Interview recruitment
TABLE 69 Recruitment sites of participants for the qualitative interviews
Study site
Trial arm, n
Total, nUsual care Memory rehabilitation
1 4 3 7
2 0 0 0
3 3 4 7
4 4 2 6
5 1 2 3
6 1 1 2
7 1 1 2
8 1 1 2
9 1 2 3
Total 16 16 32
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